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Background: Close contact casting (CCC) may offer an alternative to open reduction and internal fixation
(ORIF) surgery for unstable ankle fractures in older adults.
Objectives: We aimed to (1) determine if CCC for unstable ankle fractures in adults aged over 60 years
resulted in equivalent clinical outcome compared with ORIF, (2) estimate cost-effectiveness to the NHS and
society and (3) explore participant experiences.
Design: A pragmatic, multicentre, equivalence randomised controlled trial incorporating health economic
evaluation and qualitative study.
Setting: Trauma and orthopaedic departments of 24 NHS hospitals.
Participants: Adults aged over 60 years with unstable ankle fracture. Those with serious limb or
concomitant disease or substantial cognitive impairment were excluded.
Interventions: CCC was conducted under anaesthetic in theatre by surgeons who attended training.
ORIF was as per local practice. Participants were randomised in 1 : 1 allocation via remote telephone
randomisation. Sequence generation was by random block size, with stratification by centre and
fracture pattern.
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Main outcome measures: Follow-up was conducted at 6 weeks and, by blinded outcome assessors,
at 6 months after randomisation. The primary outcome was the Olerud–Molander Ankle Score (OMAS),
a patient-reported assessment of ankle function, at 6 months. Secondary outcomes were quality of life
(as measured by the European Quality of Life 5-Dimensions, Short Form questionnaire-12 items), pain,
ankle range of motion and mobility (as measured by the timed up and go test), patient satisfaction and
radiological measures. In accordance with equivalence trial US Food and Drug Administration guidance,
primary analysis was per protocol.
Results: We recruited 620 participants, 95 from the pilot and 525 from the multicentre phase, between
June 2010 and November 2013. The majority of participants, 579 out of 620 (93%), received the allocated
treatment; 52 out of 275 (19%) who received CCC later converted to ORIF because of loss of fracture
reduction. CCC resulted in equivalent ankle function compared with ORIF at 6 months {OMAS 64.5 points
[standard deviation (SD) 22.4 points] vs. OMAS 66.0 points (SD 21.1 points); mean difference –0.65 points,
95% confidence interval (CI) –3.98 to 2.68 points; standardised effect size –0.04, 95% CI –0.23 to 0.15}.
There were no differences in quality of life, ankle motion, pain, mobility and patient satisfaction. Infection
and/or wound problems were more common with ORIF [29/298 (10%) vs. 4/275 (1%)], as were additional
operating theatre procedures [17/298 (6%) vs. 3/275 (1%)]. Malunion was more common with CCC
[38/249 (15%) vs. 8/274 (3%); p < 0.001]. Malleolar non-union was lower in the ORIF group [lateral: 0/
274 (0%) vs. 8/248 (3%); p = 0.002; medial: 3/274 (1%) vs. 18/248 (7%); p < 0.001]. During the trial,
CCC showed modest mean cost savings [NHS mean difference –£644 (95% CI –£1390 to £76); society
mean difference –£683 (95% CI –£1851 to £536)]. Estimates showed some imprecision. Incremental
quality-adjusted life-years following CCC were no different from ORIF. Over common willingness-to-pay
thresholds, the probability that CCC was cost-effective was very high (> 95% from NHS perspective and
85% from societal perspective). Experiences of treatments were similar; both groups endured the impact
of fracture, uncertainty regarding future function and the need for further interventions.
Limitations: Assessors at 6 weeks were necessarily not blinded. The learning-effect analysis was
inconclusive because of limited CCC applications per surgeon.
Conclusions: CCC provides a clinically equivalent outcome to ORIF at reduced cost to the NHS and to
society at 6 months.
Future work: Longer-term follow-up of trial participants is under way to address concerns over potential
later complications or additional procedures and their potential to impact on ankle function. Further study
of the patient factors, radiological fracture patterns and outcomes, treatment responses and prognosis
would also contribute to understanding the treatment pathway.
Trial registration: Current Controlled Trials ISRCTN04180738.
Funding: The National Institute for Health Research Health Technology Assessment programme and will
be published in full in Health Technology Assessment; Vol. 20, No. 75. See the NIHR Journals Library
website for further project information. This report was developed in association with the National Institute
for Health Research Oxford Biomedical Research Unit funding scheme. The pilot phase was funded by the
AO Research Foundation.
ABSTRACT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
viii
Contents
List of tables xiii
List of figures xvii
List of abbreviations xxi
Plain English summary xxiii
Scientific summary xxv
Chapter 1 Introduction 1
Background 1
Management of ankle fractures 1
Issues with surgery in older adults after ankle fracture 2
Operative versus casting treatment of unstable and/or displaced ankle fractures 3
Current management of ankle fractures in older adults 3
Rationale for the Ankle Injury Management trial 3
Research objectives 4
Chapter 2 Methods 5
Summary of study design 5
Settings and locations 5
Participants 5
Inclusion criteria 5
Exclusion criteria 6
Participant approach and recruitment 6
Interventions 6
Standard care: open surgical reduction and internal fixation 6
Intervention: manipulation under anaesthetic in theatre and application of a close
contact casting 6
Standardisation of other treatments 8
Monitoring intervention delivery 8
Learning and expertise effects 8
Baseline assessments 9
Outcome measures 9
Radiological outcomes 12
Complications and further surgery 12
Randomisation 12
Blinding 12
Sample size 12
Pilot study 13
Statistical methods 13
Economic analyses 14
Data 15
Analysis methods 17
Database and data processing 21
Qualitative study 21
Patient and public involvement 21
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
ix
Ethical approval and monitoring 21
Trial Steering Committee 22
Data Monitoring and Ethics Committee 22
Trial Management Group 22
Reporting 22
Summary of changes to the project protocol 22
Chapter 3 Clinical results 23
Participant flow 23
Screening for eligibility 25
Randomisation 25
Treatments received 25
Withdrawals 27
Follow-up 27
Baseline data 30
Numbers analysed 30
Per-protocol analyses results 37
Primary outcome measure (per protocol) 37
Secondary outcome measures (per protocol) 41
Short Form questionnaire-12 items mental component summary subscale
(per protocol) 41
Short Form questionnaire-12 items physical component summary subscale
(per protocol) 41
European Quality of Life 5-Dimensions score (per protocol) 45
European Quality of Life 5-Dimensions visual analogue scale (per protocol) 45
Timed up and go test (per protocol) 46
Range of ankle motion (per protocol) 46
Pain (per protocol) 49
Patient satisfaction (per protocol) 49
Radiological malunion and non-union (per protocol) 49
Ancillary analyses (per protocol) 52
Olerud–Molander Ankle Score as an ordinal outcome (per protocol) 52
Blinded assessments (per protocol) 52
Time-to-event analysis (per protocol) 53
Process variables (per protocol) 53
Experience and treatment preferences of surgeons (per protocol) 53
Surgeon learning effects (per protocol) 59
Adverse events (per protocol) 60
Additional procedures in theatre (per protocol) 60
Summary of key findings 62
Chapter 4 Health economic evaluation 63
Introduction 63
Results 63
Participant flow 63
Per-protocol analysis 64
Missing data (per protocol) 64
Baseline characteristics (per protocol) 64
Resource use (per protocol) 64
Health outcomes (per protocol) 67
Costs (per protocol) 68
Regression models (per protocol) 68
Cost-effectiveness: 6 months (per protocol) 72
CONTENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
x
Lifetime (per protocol) 74
Sensitivity 75
Imputing completely missing cases 75
Ordinary least squares models in place of best-fit generalised linear model models 75
Discussion 75
Summary of key findings 77
Chapter 5 Qualitative study findings 79
Introduction 79
Background 79
Methodology 80
Methods 81
Sample 81
Analysis 81
Rigour 82
Findings 82
Theme 1: suffering 82
Theme 2: getting on with daily life 84
Theme 3: struggling to move 85
Theme 4: treatment and being in the trial 87
Discussion 90
Suffering 90
Conclusions 93
Summary of key findings 93
Chapter 6 Discussion 95
Aim and overview of study findings 95
Internal validity and methodology 96
External validity and generalisability 96
Interpretation and implications for clinical practice and policy 97
Implications for training and implementation 98
Comparison with other literature 99
Further research 99
Acknowledgements 101
References 105
Appendix 1 Trial management 113
Appendix 2 Clinical results: intention-to-treat analysis 119
Appendix 3 Health economic evaluation 135
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xi

List of tables
TABLE 1 Outcome measures by time point 9
TABLE 2 Unit cost parameters 16
TABLE 3 Changes to the protocol during the study by version number 22
TABLE 4 Flow of participants in the AIM trial 24
TABLE 5 Randomised participants summarised by treatment group and centre 25
TABLE 6 Randomised participants summarised by randomisation strata
(recruiting site and fracture pattern) 26
TABLE 7 Participants who did not receive allocated treatment summarised by
treatment group 27
TABLE 8 Reasons participants did not receive allocated treatment summarised by
treatment group 28
TABLE 9 Timing of withdrawal summarised by treatment group 28
TABLE 10 Withdrawal details summarised by treatment group 29
TABLE 11 Follow-up rates summarised by treatment group 29
TABLE 12 Location follow-up was completed by time point 29
TABLE 13 Baseline demographic and clinical characteristics of all randomised
participants summarised by treatment group 30
TABLE 14 General health summarised by treatment group 34
TABLE 15 Comorbidities reported by the recruited sample summarised by
treatment group 35
TABLE 16 Social circumstances of all randomised participants summarised by
treatment group 36
TABLE 17 Summary of the number (%) of participants with complete data for
the per-protocol analyses 38
TABLE 18 Summary of the number (%) of participants with complete data for
the ITT analyses 38
TABLE 19 Primary outcome (OMAS) at 6 weeks and 6 months, summarised by
treatment group (per protocol) 39
TABLE 20 Primary outcome (OMAS) at 6 weeks and 6 months, summarised by
treatment group (ITT) 40
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xiii
TABLE 21 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month
assessments (per protocol) 41
TABLE 22 Timed up and go walking test at the 6-month follow-up, summarised
by treatment group (per protocol) 46
TABLE 23 Additional information from timed up and go walking test at the
6-month follow-up, summarised by treatment group (per protocol) 47
TABLE 24 Range of injured ankle motion at the 6-week and 6-month follow-up
(per protocol) 47
TABLE 25 Summary of the EQ-5D pain item and OMAS pain item at the 6-week
and 6-month follow-up (per protocol) 50
TABLE 26 Patient satisfaction at the 6-week and 6-month follow-up
(per protocol) 50
TABLE 27 Summary of radiological malunion at the 6-month follow-up (per
protocol) 51
TABLE 28 Summary of radiological malunion and no malunion at the 6-month
follow-up (per protocol) 51
TABLE 29 Summary of radiological non-union at the 6-month follow-up
(per protocol) 51
TABLE 30 Olerud–Molander Ankle Scores analysed as an ordinal outcome at
6 weeks and 6 months (per protocol) 52
TABLE 31 Assessment of the blinding strategy at the 6-month follow-up
(per protocol) 53
TABLE 32 Summary of unadjusted and adjusted time-to-event analyses looking
at time to discharge and time to first readmission (per protocol) 53
TABLE 33 Process variables summarised by treatment group (per protocol) 54
TABLE 34 Summary of the duration from randomisation and injury to the date
allocated treatment received (per protocol) 56
TABLE 35 Summary of when allocated treatment was received by participants,
with a summary of the experience of surgeon if the participant received
allocated treatment at the primary theatre procedure (per protocol) 57
TABLE 36 Preferred treatment for the primary theatre procedure, summarised
by treatment group (per protocol) 59
TABLE 37 Summary of the grade of surgeons who conducted CCC procedures in
the study (per protocol) 59
TABLE 38 Summary of reported adverse events (per protocol) 60
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xiv
TABLE 39 Summary of the additional procedures in theatre (per protocol) 61
TABLE 40 Per-protocol average resource use over the index procedure,
readmission and the 6 months’ follow-up period. Mean and SD are shown except
where indicated 65
TABLE 41 Per-protocol raw, unadjusted utility and QALYs over the 6-month
follow-up. 95% CIs obtained using the bootstrap method 67
TABLE 42 Per-protocol raw, unadjusted costs using mean unit costs over the
6-month trial period. 95% CIs obtained using the bootstrap method 69
TABLE 43 Regression coefficients for per-protocol total NHS costs 70
TABLE 44 Regression coefficients for per-protocol total societal cost 71
TABLE 45 Regression coefficients for per-protocol QALYs 71
TABLE 46 Cost-effectiveness results: 6 months (per-protocol) 72
TABLE 47 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month
assessments (ITT) 120
TABLE 48 Timed up and go walking test at the 6-month follow-up, summarised
by treatment group (ITT) 124
TABLE 49 Additional timed up and go test at details the 6-month follow-up,
summarised by treatment group (ITT) 124
TABLE 50 Range of injured ankle motion at the 6-week and 6-month follow-up
(ITT) 124
TABLE 51 Summary of the EQ-5D pain item and OMAS pain item at the 6-week
and 6-month follow-up (ITT) 126
TABLE 52 Patient satisfaction at the 6-week and 6-month follow-up (ITT) 127
TABLE 53 Summary of radiological malunion at the 6-month follow-up (ITT) 127
TABLE 54 Summary of radiological malunion and no malunion at the 6-month
follow-up (ITT) 128
TABLE 55 Summary of radiological non-union at the 6-month follow-up (ITT) 128
TABLE 56 Olerud–Molander Ankle Scores analysed as an ordinal outcome at
6 weeks and 6 months (ITT) 128
TABLE 57 Assessment of the blinding strategy at the 6-month follow-up (ITT) 129
TABLE 58 Summary of unadjusted and adjusted time-to-event analyses looking
at time to discharge and time to first readmission (ITT) 129
TABLE 59 Process variables summarised by treatment group (ITT) 129
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xv
TABLE 60 Summary of the duration from randomisation and injury to the date
allocated treatment received (ITT) 132
TABLE 61 Summary of reported adverse events (ITT) 133
TABLE 62 Summary of the additional procedures in theatre (ITT) 134
TABLE 63 Sensitivity: with completely missing cases via imputation.
Cost-effectiveness results using the best-fit and OLS models. Per-protocol population 135
TABLE 64 Baseline characteristics of per-protocol participants with complete
6-week and 6-month utility information vs. those missing either utility. Counts
and percentages are shown unless otherwise indicated 135
TABLE 65 Mean values of complete information as well as magnitude of
incomplete information for relevant outcomes and resource use items for
per-protocol patients 136
TABLE 66 Intention-to-treat average resource use over the index procedure,
readmission and the 6-month follow-up period. Means and SDs are shown except
where indicated 140
TABLE 67 Intention-to-treat raw, unadjusted utility and QALYs over the 6-month
follow-up. 95% CIs obtained using the bootstrap method 143
TABLE 68 Intention-to-treat raw, unadjusted costs using mean unit costs over
the 6-month trial period. 95% CIs obtained using the bootstrap method 144
TABLE 69 Regression coefficients for ITT total NHS costs 146
TABLE 70 Regression coefficients for ITT total societal costs 146
TABLE 71 Regression coefficients for ITT total QALYs 147
TABLE 72 Cost-effectiveness results of the ITT population 147
TABLE 73 Sensitivity: with completely missing cases via imputation.
Cost-effectiveness results using the best-fit and OLS models. ITT population 150
TABLE 74 Baseline characteristics of ITT participants with complete 6-week and
6-month utility information vs. those missing either utility. Counts and
percentages are shown unless otherwise indicated 150
TABLE 75 Mean values of complete information as well as magnitude of
incomplete information for relevant outcomes and resource use items for
ITT patients 151
LIST OF TABLES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xvi
List of figures
FIGURE 1 Comparison of the Lauge-Hansen (left column) and the AO Foundation
and Orthopaedic Trauma Association (AO/OTA) (right column) systems of ankle
fracture classification 2
FIGURE 2 Outline of the shapes and locations of the foam pads used in the CCC 7
FIGURE 3 Lateral aspect of the lower leg with a line indicating plantargrade at
the ankle 10
FIGURE 4 Positioning of the goniometer for the assessment of ankle dorsiflexion
and plantar flexion range of motion 11
FIGURE 5 Positioning of the goniometer for the assessment of ankle inversion
and eversion range of motion 11
FIGURE 6 Conceptual diagram of relevant economic inputs and their relationship
to intermediate and final economic outcomes 18
FIGURE 7 The CONSORT diagram for the AIM trial 23
FIGURE 8 Observed treatment difference plot at 6 months with 95% CIs
(per protocol) 39
FIGURE 9 Observed treatment difference plot at 6 months with 95% CIs (ITT) 40
FIGURE 10 Plot of mean scores and 95% CIs for the OMASs over time
(per protocol) 41
FIGURE 11 Plot of mean scores and 95% CIs for the SF-12 mental component
summary score over time (per protocol) 45
FIGURE 12 Plot of mean scores and 95% CIs for the SF-12 physical component
summary score over time (per protocol) 45
FIGURE 13 Plot of mean scores and 95% CIs for the EQ-5D over time
(per protocol) 46
FIGURE 14 Flow diagram of per-protocol and ITT population: withdrawals, with
exclusions because of insufficient information and final analysis populations 63
FIGURE 15 Graph showing per-protocol utility (quality of life) over time
(length of life) 68
FIGURE 16 Pie chart of per-protocol NHS costs for (a) ORIF and (b) CCC, grouped
by primary procedure, health services/medications, care homes, readmission,
additional procedure and casts 70
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xvii
FIGURE 17 Per-protocol cost-effectiveness plane showing 6-month incremental
total NHS costs along y-space and incremental QALYs along x-space for 10,000
bootstrap replicates 73
FIGURE 18 Per-protocol 6-month cost-effectiveness acceptability curve
displaying the probability of cost-effectiveness (y-axis) as a function of the
willingness-to-pay threshold (x-axis) under the NHS perspective 73
FIGURE 19 Per-protocol cost-effectiveness plane showing incremental total
societal costs along y-space and incremental QALYs along x-space for 10,000
bootstrap replicates 74
FIGURE 20 Per-protocol cost-effectiveness acceptability curve displaying the
probability of cost-effectiveness (y-axis) as a function of the willingness-to-pay
threshold (x-axis) under the societal perspective 74
FIGURE 21 Recruitment graph for the AIM trial 114
FIGURE 22 Site recruitment and management process for the AIM trial 115
FIGURE 23 Plot of mean scores and 95% CIs for the OMASs over time (ITT) 119
FIGURE 24 Plot of mean scores and 95% CIs for the SF-12 mental component
summary score over time (ITT) 119
FIGURE 25 Plot of means and 95% CIs for the SF-12 physical component
summary score over time (ITT) 120
FIGURE 26 Plot of means and 95% CIs for the EQ-5D score over time (ITT) 120
FIGURE 27 Sensitivity: with completely missing cases via imputation 138
FIGURE 28 Sensitivity: with completely missing cases via imputation 138
FIGURE 29 Sensitivity: with completely missing cases via imputation 139
FIGURE 30 Sensitivity: with completely missing cases via imputation 139
FIGURE 31 Graph showing ITT utility (quality of life) over time (length of life) 144
FIGURE 32 Pie chart of ITT NHS costs for (a) ORIF and (b) CCC, grouped by
primary procedure, health services/medications, care homes, readmission,
additional procedure and casts 145
FIGURE 33 Intention-to-treat cost-effectiveness plane showing incremental total
NHS costs along y-space and incremental QALYs along x-space for 10,000
bootstrap replicates 148
FIGURE 34 Intention-to-treat cost-effectiveness acceptability curve displaying the
probability of cost-effectiveness (y-axis) as a function of the willingness-to-pay
threshold (x-axis) under the NHS perspective 148
LIST OF FIGURES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xviii
FIGURE 35 Intention-to-treat cost-effectiveness plane showing incremental total
societal costs along y-space and incremental QALYs along x-space for 10,000
bootstrap replicates 149
FIGURE 36 Intention-to-treat cost-effectiveness acceptability curve displaying the
probability of cost-effectiveness (y-axis) as a function of the willingness-to-pay
threshold (x-axis) under the societal perspective 149
FIGURE 37 Sensitivity with completely missing cases via imputation 153
FIGURE 38 Sensitivity with completely missing cases via imputation 153
FIGURE 39 Sensitivity with completely missing cases via imputation 154
FIGURE 40 Sensitivity with completely missing cases via imputation 154
FIGURE 41 Healthy convergence of the Gibbs sampler for the major health
economic variables of per-protocol utilities 155
FIGURE 42 Density plots for selected variables showing comparable distributions
for the observed data and imputed data sets 155
FIGURE 43 Healthy convergence of the Gibbs sampler for the major health
economic variables of ITT utilities 156
FIGURE 44 Density plots for selected variables showing comparable distributions
for the observed data and imputed data sets for the ITT population 157
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xix

List of abbreviations
AIM Ankle Injury Management trial
CCC close contact casting
CI confidence interval
CONSORT Consolidated Standards of
Reporting Trials
CRF case report form
DMEC Data Monitoring and Ethics
Committee
DVT deep-vein thrombosis
EQ-5D European Quality of Life
5-Dimensions
GLM generalised linear model
GP general practitioner
ICER incremental cost-effectiveness ratio
ITT intention to treat
NICE National Institute for Health and
Care Excellence
OLS ordinary least squares
OMAS Olerud–Molander Ankle Score
ORIF open reduction and internal
fixation
PE pulmonary embolism
QALY quality-adjusted life-year
SD standard deviation
SF-12 Short Form questionnaire-12 items
TSC Trial Steering Committee
VAS visual analogue scale
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi

Plain English summary
An ankle fracture is an injury to bones of the ankle joint. If severe, the ankle joint may become unstable.Unstable ankle injuries are usually treated with surgery. The operation aligns and holds the bones in
position with metal screws and/or plates during healing. In older adults surgery outcomes are uncertain
because of bone and skin frailty. We developed a lower-leg cast called close contact casting (CCC) with
the aim of offering an alternative to surgery.
We randomly allocated 620 participants from 24 NHS hospitals to either surgery or CCC. A researcher
assessed participants before treatment and at 6 weeks and 6 months after randomisation. The assessments
collected information on ankle function, quality of life, pain, joint flexibility, mobility, complications, patient
satisfaction and NHS and personal health-care use. We also interviewed 36 participants.
Participants with CCC had very similar outcomes to surgical patients, but at reduced NHS and society
costs. Wound problems or infections occurred in around 1 in 10 participants in the surgery group. Within
6 months, around 1 in 20 participants who initially received surgery required an additional surgical
procedure. One in five participants who initially had CCC later had surgery because the cast could not
always maintain good ankle alignment. Both groups struggled to live with the fracture and with the
uncertainty about further treatment.
We are conducting follow-up of participants for at least 2 years to see if higher rates of poor ankle
alignment and bone healing observed in the CCC group affect the overall outcome in the longer term.
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Scientific summary
Background
Ankle fractures account for 9–17% of all fractures treated by orthopaedic surgeons in acute care hospitals
in the UK. The decision to treat an unstable or displaced ankle fracture by surgery in older adults,
compared with younger adults, is complicated by a higher prevalence of comorbidities, increased risk of
infection and surgical wound problems, and inadequate fixation because of poor bone quality. The
alternatives to surgery, traditional casting techniques, are associated with poorer alignment and healing of
the fracture, which are thought to result in a worse patient outcome. A modified casting technique, close
contact casting (CCC), has been developed to overcome some of the challenges of conservative ankle
fracture management. CCC may offer an alternative to open reduction and internal fixation (ORIF) in
older adults.
Objectives
1. To determine if the application of CCC for unstable and/or displaced ankle fractures in adults aged over
60 years results in an equivalent clinical outcome compared with the standard care of ORIF.
2. To estimate the cost-effectiveness of the two treatments to the NHS, and the broader societal
perspective, including to the individual and their family.
3. To explore the experiences of the participants of the interventions and the impact of taking part in
the trial.
Methods
Design
This was a pragmatic, multicentre, equivalence randomised controlled trial. The study incorporated
evaluation of clinical effectiveness and cost-effectiveness, with an embedded qualitative study.
Setting
The study was conducted in the trauma and orthopaedic departments of 24 hospitals from 22 NHS trusts.
Participants
Adults aged over 60 years with an unstable and/or displaced ankle fracture. Those with critical limb
ischaemia, insulin-dependent diabetes mellitus, active leg ulceration, open fractures, serious concomitant
disease (i.e. metastatic disease or terminal illness), substantial degenerative or inflammatory arthritis in the
ankle, unfit for general anaesthetic, or substantial cognitive impairment (Mini Mental State Examination
scores of < 16 out of 30) were excluded.
Interventions
Participants were individually randomised to receive either ORIF or CCC in a 1 : 1 allocation ratio. We used
the remote 24-hour telephone randomisation service available from the University of Aberdeen, Aberdeen,
UK. Sequence generation was by random block size and stratification by centre and fracture pattern,
using trans-/infrasyndesmotic and suprasyndesmotic categories. ORIF was conducted as per local hospital
practice. As a new casting technique, we aimed to standardise CCC application, which was conducted in
theatre under anaesthetic. CCC was applied by surgeons who had attended study-specific training and all
procedures were required to have direct consultant supervision.
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Follow-up
Follow-up was conducted at 6 weeks and 6 months after randomisation. Participants attended the clinic to
complete follow-up questionnaires and clinical assessments. The 6-month follow-up was conducted by a
blinded assessor. If participants were unable to be followed up in the clinic, then a telephone or postal
follow-up was attempted.
Clinical outcomes and analysis
The primary outcome measure was a patient-reported outcome of ankle function, the Olerud–Molander
Ankle Score (OMAS), at 6 months. The OMAS is a 0–100 scale, with higher scores indicating better ankle
function. The secondary outcomes were quality of life (as measured by the European Quality of Life
5-Dimensions and Short Form questionnaire-12 items), pain, physical impairments (as measured by ankle
range of motion and the timed up and go test), patient satisfaction and radiological outcomes (malunion
and non-union).
The target sample size was 620 and the margin of equivalence was ± 6 points on the OMAS. The primary
analysis was per protocol, with an intention-to-treat (ITT) analysis as a sensitivity analysis, in accordance
with guidance regarding equivalence trial analysis. The primary analysis was a linear regression model
adjusted for age, sex, centre, fracture pattern and baseline score.
Economic analysis
An evaluation of cost-effectiveness of CCC compared with ORIF was conducted as part of the trial.
The economic evaluation was conducted for both the UK NHS and societal perspectives. We conducted
analyses for both the per-protocol and ITT populations. Consistent with the evaluation of clinical
effectiveness, the primary analysis was per protocol. We collected NHS and private health-care resource
used over 6 months from self-reported questionnaires. We used multiple imputation, with chained
equations in which data were missing at random.
Qualitative study
A purposive sample of 36 participants undertook unstructured interviews in the clinic environment
at 6–10 weeks after treatment. Interviews were transcribed verbatim and analysed using a
phenomenological approach.
Results
We recruited 620 participants, 95 during a pilot phase in one centre and 525 from the multicentre phase
of the Ankle Injury Management (AIM) trial, between June 2010 and November 2013. Participants were
aged, on average, 71 years, and 74% were female. Ankle fracture types included were trans-/
infrasyndesmotic [542 out of 620 (87%)], and suprasyndesmotic [78 out of 620 (13%)]. The baseline
characteristics of the participants in the intervention groups were well matched. At the 6-month primary
end point, 90% (558/620) of participants were analysed for the primary outcome in the per-protocol
analysis and 96% (593/620) in the ITT analysis.
Clinical results
The majority of participants [579 out of 620 (93%)] received their allocated treatment; 52 out of 275
(19%) who received CCC per protocol had a later conversion to ORIF because of loss of fracture reduction.
In both per-protocol and ITT analyses, there was no evidence of difference between CCC and ORIF at
6 months after randomisation. In the per-protocol analysis, OMASs were 66.0 points [standard deviation (SD)
21.1 points] for ORIF vs. 64.5 points (SD 22.4 points) for CCC [mean difference –0.65 points, confidence
interval (CI) –3.98 to 2.68 points; standardised effect size –0.04, 95% CI –0.23 to 0.15]. There were no
differences between the secondary outcomes of quality of life (SF-12 mental and physical component
summary scores), range of ankle motion, ankle pain, mobility and patient satisfaction. Infection and/or
wound problems were more common with ORIF [29/298 (10%) vs. 4/275 (1%)], as were additional
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operating theatre procedures relating to surgical wounds or implants [17/298 (6%) in the ORIF group
and 3/275 (1%) in the CCC group]. The number of plaster sores and pain from casts was similar between
groups, but there were more plaster saw lacerations in the CCC group [5/275 (2%) vs. 1/298 (0.3%)].
Less common but serious complications such as deep-vein thrombosis, pulmonary embolism and wound
infections occurred in both treatment groups, but were infrequent overall. Malunion occurred in 38 out
of 249 (15%) participants in the CCC group compared with 8 out of 274 (3%) in the surgery group
(p < 0.001). Fracture non-union was lower in the surgery group than in the CCC group for the lateral
malleolus [0/274 (0%) vs. 8/248 (3%); p = 0.002] and the medial malleolus [3/274 (1%) vs. 18/248 (7%);
p < 0.001]. There was no evidence of a learning effect.
Economic results
Over the trial period, CCC showed evidence of a modest mean cost savings to both the NHS (mean
difference –£644, 95% CI –1390 to 76)] and society (mean difference –£683, 95% CI –1851 to 536)],
albeit estimates showed some imprecision. The cost savings were driven largely by savings in index
procedure theatre time, but were partially eroded over time as a result of increased readmission and health
services costs. Incremental quality-adjusted life-years were not different following CCC or ORIF. Over
common willingness-to-pay thresholds, the probability that CCC was cost-effective was very high (> 95%
for NHS and 85% for societal perspective). Results were consistent between the per-protocol and
ITT populations.
Qualitative study
The lived experience of patients were similar regardless of treatment, as both groups suffered and endured
the impact of ankle fracture and lived non-weight-bearing with a cast, and both lived with uncertainty
regarding future function and the need for further interventions. Participants with CCC were pleased
to avoid surgery but lived with concerns around swelling, healing and further damage to their ankle;
participants with ORIF were pleased that their ankle was fixed, but lived with concerns around metalwork
and infection.
Participants took part in the trial for altruistic reasons, for personal benefit and because they trusted the
clinicians. Preferences were expressed for particular treatments and there was some evidence of therapeutic
misconception. The themes were suffering, getting on with daily life, struggling to move, and treatment
and being in the trial. Suffering reflected the emotional work participants undertook in relation to feeling
vulnerable and being old, but also in order to maintain relationships for the future. Getting on with daily
life demonstrated how participants proactively recreated meaningful lives within the limitations they faced
because of the impact of injury. Struggling to move conveyed the work participants undertook to move
their fragile bodies around a confined life space. Participants also moved forward with a heightened
sense of emotional fragility. Treatment and being in the trial identified the different experiences of the
two treatments, how participants actively managed their symptoms and how they made sense of the trial.
Conclusions
Implications for health care
We conclude that, at 6 months, the two treatments result in equivalent ankle function at reduced mean
cost to health services and society. The clinical equivalence and cost-effectiveness of CCC as an alternative
to ORIF surgery should be of interest to patients, clinicians and commissioners/payers. In this trial, reflecting
current surgical opinion, approximately one in five patients who received CCC later needed to return to
theatre for ORIF surgery because of unacceptable fracture position (loss of fracture reduction). Therefore,
CCC substantially reduces the number of patients requiring surgery and the exposure to the risks of
surgical complications that, although somewhat infrequent, can be clinically serious. CCC should be
deliverable in the NHS, as it was introduced into practice as a modification of existing casting methods
with limited training requirements.
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Recommendations for research
We are currently conducting extended follow-up of the AIM trial cohort to investigate if the clinical
effectiveness and cost-effectiveness outcomes are maintained at least 2 years after randomisation. This
longer-term follow-up aims to address concerns from clinicians over potential later complications or
additional procedures (e.g. intolerance of metalwork resulting in removal, post-traumatic osteoarthritis and
possible ankle joint fusion or replacement) and their potential to impact on ankle function. It should also
identify if the higher rates of radiological malunion and non-union associated with CCC affect overall
outcome over a time period in which we would expect delayed clinical issues to manifest. In addition, we
have identified that there is substantial loss of ankle function and quality of life after ankle fracture in older
adults with either treatment, indicating the need to develop interventions that optimise recovery. Further
study of the relationships between patient factors, radiological fracture patterns and outcomes, treatment
responses and prognosis would also contribute to understanding the roles of key injury and patient
characteristics in the treatment pathway.
Trial registration
This trial is registered as ISRCTN04180738.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. This report was developed in association with the National Institute for
Health Research Oxford Biomedical Research Unit funding scheme. The pilot phase was funded by the AO
Research Foundation.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxviii
Chapter 1 Introduction
Background
Ankle fractures are a common injury in the adult population. In high-income countries, the burden from
ankle fractures placed on health-care services is substantial, as 9–17% of all fractures seen in acute care
hospitals are ankle fractures.1,2 A Scottish study reported an incidence of 132 fractures per 100,000 in men
and of 112 fractures per 100,000 in women per year, with the highest incidence of 248 per 100,000 per
year occurring in women between the ages of 75 and 84 years.3 A threefold increase in the number of
ankle fractures per year is predicted from 2000 to 2030 as the population ages.4
Ankle fractures often result in ankle pain, limitation in joint range of motion,5 muscle weakness6,7 and
difficulties with weight-bearing tasks such as walking and climbing stairs.5,8 Limitations in ankle-related
function are especially pronounced in the 6 months after injury, but can persist for several years.9
Physical function outcomes after ankle fracture are generally worse when the injury occurs in older age.9,10
The injury may contribute to a loss of independence, have a substantial impact on quality of life and have
higher health and social care costs.11–13
In this introduction chapter, we provide a background to the current management of ankle fractures,
explore the issues with existing treatment options in older-aged adults, summarise the existing evidence
base and outline the rationale for the Ankle Injury Management (AIM) trial and the novel close contact
casting (CCC) intervention.
Management of ankle fractures
Ankle fractures can be managed conservatively or surgically, depending on the extent and pattern of bone
and ligament injury. The extent/pattern of injury is determined by direction and magnitude of traumatic
forces on the ankle and resilience of the musculoskeletal tissues. Ankle fractures are usually graded on
radiographs using the Lauge-Hansen classification based on mechanism of injury or the Danis–Weber
classification extensions developed by the AO Foundation, which are based on anatomical injury
characteristics (Figure 1).14
Stable and undisplaced fractures are typically treated conservatively in an ankle splint or cast. Displaced
ankle fractures resulting in anatomical misalignment are initially managed by manipulation of the limb to
restore anatomical congruence. This is termed ‘fracture reduction’, as in reduction of the deformity. The
limb is then held in a cast or splint until definitive management is implemented. Usually displaced and/or
unstable ankle fractures are managed with open reduction and internal fixation (ORIF) surgery to both
restore and maintain congruence of the ankle mortise.14 During ORIF, bone fragments are repositioned and
held in place by plates and/or screws until healing (union) occurs.
The rationale for ORIF surgery is to improve outcomes by reducing complications from malunion such as
post-traumatic osteoarthritis.15,16 Malunion of weight-bearing joints is postulated to lead to increased
contact stresses on the articular surfaces,17,18 precipitating osteoarthritis that can result in persistent
symptoms and disability and potentially the need for further surgery.19,20 However, the aetiology of
post-traumatic osteoarthritis may also be a result of genetic factors and direct damage caused by the
initial trauma.21
Non-union (incomplete healing) of the fracture can be considered to be less likely when electing to treat
an ankle fracture with ORIF surgery than with conservative treatment.22 However, there are limited
randomised controlled trial comparisons on whether or not non-union is more likely with conservative
casting or ORIF.23
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Issues with surgery in older adults after ankle fracture
For older adults, there is greater controversy in the management of displaced and/or unstable ankle
fractures. The benefits of surgery are less clear because of the substantially increased risk of complications
such as infection, wound breakdown and fixation failure.24 It is more difficult to achieve successful surgical
outcomes in older people because of a higher prevalence of comorbidities resulting in lower bone density
(osteoporosis), frail skin and impaired wound healing. Poor bone quality directly affects the efficacy of
implant stabilisation treatment methods for the bone fracture fragments.25 In addition, such fractures,
because of the greater fragmentation and poor bone strength, tend to be less stable after repositioning, and
Supination adduction (a) Malleolus, lateral infrasyndesmotic lesion
(b) Malleolus, lateral trans-syndesmotic fibula fracture
(c) Malleolus, lateral suprasyndesmotic lesion
Supination eversion
Pronation abduction
Pronation eversion
A1 A2 A3
B1 B2 B3
C1 C2 C3
(a1)  Isolated
(a2)  With a fracture of the medial malleolus
(a3)  With a posteromedial fracture
(b1)  Isolated
(b2)  With a medial lesion
(b3)  With a medial lesion and a Volkmann
         (fracture of the posterolateral rim)
(c1)  Diaphyseal fracture of the fibula, simple
(c2)  Diaphyseal fracture of the fibula, complex
(c3)  Fibula proximal
I
I
III
IV
(either)
II
II
II
III I
(either)
I
(either)
IV
II
III
FIGURE 1 Comparison of the Lauge-Hansen (left column) and the AO Foundation and Orthopaedic Trauma
Association (AO/OTA) (right column) systems of ankle fracture classification.© From Oxford Textbook of Trauma
and Orthopaedics edited by Bulstrode (2011) Figure 12.59.4. By permission of Oxford University Press
(www.oup.com).
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the holding strength of fixation screws can be diminished up to 10-fold.26 These can render fixations
incompetent and prevent early joint movement and weight-bearing, the accepted advantages of the surgical
fixation approach in the younger patient. Other common comorbidities in the older patient (peripheral
vascular disease, chronic venous insufficiency, late-onset diabetes mellitus and/or oedema from heart failure)
directly affect the lower limb skin and soft tissue tolerance of surgical wounds or traditional casts.
There are higher rates of complications in older adults after ankle ORIF.27 In 2014, a case review of 186
patients (132 females, 71%) after ankle ORIF, which was based in the UK, found high complication rates
in persons aged over 60 years. The complications included superficial surgical site infection and delayed
wound healing (17/186, 9%), deep surgical site infection (13/186, 7%), failure of fixation (6/186, 3%),
non-union or malunion (20/186, 11%) and additional surgery for wound debridement, removal of
metalwork or revision of the fixation (20/186, 11%).24
Operative versus casting treatment of unstable and/or displaced
ankle fractures
The uncertainty in the evidence for clinical outcomes comparing surgical with non-operative treatment for
ankle fractures was highlighted in a 2012 Cochrane review,23 which included 292 participants in three
randomised controlled trials28–30 and one quasi-randomised controlled trial.31 The authors concluded that
there is currently insufficient evidence of the effects of surgical versus conservative treatment on outcome
after ankle fracture and confirmed the need for an adequately powered clinical trial.
Current management of ankle fractures in older adults
Published research, albeit of poor quality, indicates higher rates of loss of fracture reduction or malunion
(poor position at healing) and non-union (failure to heal) with traditional casting.23 Only one previously
published randomised controlled trial has studied older adults. Makwana et al.29 randomised 43 participants
aged 66 years to ORIF or a moulded below-knee plaster cast. The results of the trial indicated that
participants undergoing casting were more likely to have an early loss of reduction of the fracture (8/21
casting group and 0/22 ORIF group) and lower patient-reported ankle function. Two cases of malunion and
two of non-union were reported, all in the conservative treatment group, with only one of these participants
reporting pain and functional limitations. The ORIF group experienced other adverse clinical events such
as superficial surgical site infection and complex regional pain syndrome type 1. The results should be
interpreted with caution because of the limited sample size and high risk of bias, as there was no blinding
of outcome assessors, incomplete outcome data and unclear precautions regarding allocation concealment.
Many surgeons make a clinical judgement based on (1) the likely tolerance of a patient’s skin for surgical
incisions and (2) the bone quality and chance of achieving implant fixation. For patients judged as higher
risk for open surgery, some surgeons may select manipulation and traditional casting, assuming fewer
complications but with a higher risk of malunion. As a result, ORIF is more commonly used than
non-operative treatment for ankle fracture in older people.
Rationale for the Ankle Injury Management trial
A modification of the traditional casting treatment has been developed, CCC. This new casting technique
has the potential of improved fracture stabilisation and lower skin damage risk compared with traditional
casting. Traditional casting methods (an external support formed by an under layer of stockinette, layers
of wool roll and felt, and a rigid outer layer made of plaster of Paris and/or synthetic material) can result
in pressure sores on the skin. CCC is a plaster of Paris cast applied over a minimal lining and padding
thickness compared with traditional casts. The cast is moulded firmly to maintain reduction of the fracture
and is then reinforced with a topcoat of synthetic casting bandage. CCC can be considered a modification
of ‘total-contact casting’, which has been used extensively and successfully for more than 20 years in
treating leg ulcers in diabetic patients who have frail skin.32–34
There were key stages in the development of CCC as an intervention in orthopaedic surgery. Vascular
laboratory investigations as part of the single-centre pilot study for the AIM trial confirmed the potential
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for improved skin viability outcomes with CCC.35 The extension of the study to a pragmatic, multicentre
randomised controlled trial to assess the introduction of CCC, compared with the standard care of ORIF, in
the NHS is consistent with stages of evaluation in the IDEAL (Idea, Development, Exploration, Assessment,
Long-term) study recommendations for evaluation of surgical innovations.36
The purpose of the AIM trial was to compare ORIF with CCC in the management of ankle fractures in
older adults within the UK NHS. We carried out a pragmatic, equivalence randomised controlled
trial with parallel economic and qualitative studies to provide an evaluation of clinical effectiveness and
cost-effectiveness. The study was identified as a research priority by the orthopaedic trauma surgeon
members of the UK Association for Osteosynthesis.37
Research objectives
1. To determine if the application of CCC for unstable ankle fractures in older adults resulted in an
equivalent clinical outcome compared with the standard care of open surgical reduction and internal
fixation (ORIF).
2. To estimate the cost-effectiveness of the two treatments to the NHS, and the broader societal
perspective, including to the individual and their family.
3. To explore the experiences of participants of the interventions and the impact of taking part in the trial.
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Chapter 2 Methods
Summary of study design
This study was a pragmatic, multicentre, equivalence randomised controlled trial with parallel prospective
economic evaluation. Participants were randomised to receive ORIF or CCC after admission for surgery
for displaced and/or unstable ankle fractures in the trauma and orthopaedic surgery departments of
24 hospitals from 22 NHS trusts. The final study protocol has been published.38
Settings and locations
The trial was run in the following hospitals in England and Wales:
l Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust
l Darlington Memorial Hospital, County Durham and Darlington NHS Foundation Trust
l Derriford Hospital, Plymouth Hospitals NHS Trust
l Frenchay Hospital, North Bristol NHS Trust
l Great Western Hospital, Great Western Hospitals NHS Foundation Trust, Swindon
l Ipswich Hospital, Ipswich Hospital NHS Trust
l John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust
l Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust
l Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust
l Morriston Hospital, Abertawe Bro Morgannwg University Health Board, Swansea
l Musgrove Park Hospital, Taunton and Somerset NHS Foundation Trust
l Newham University Hospital, Barts Health NHS Trust, London
l Norfolk and Norwich University Hospital, Norfolk and Norwich University Hospitals NHS
Foundation Trust
l North Staffordshire Royal Infirmary, University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent
l North Tyneside General Hospital, Northumbria Healthcare NHS Foundation Trust
l Poole Hospital, Poole Hospital NHS Foundation Trust
l Royal Berkshire Hospital, Royal Berkshire NHS Foundation Trust, Reading
l Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust
l Southport and Ormskirk Hospitals, Southport & Ormskirk Hospital NHS Trust
l Torbay Hospital, South Devon Healthcare NHS Foundation Trust
l University Hospital Coventry, University Hospitals Coventry and Warwickshire NHS Trust
l University Hospital of North Durham, County Durham and Darlington NHS Foundation Trust
l Wansbeck General Hospital, Northumbria Healthcare NHS Foundation Trust
l Yeovil District Hospital, Yeovil District Hospital NHS Foundation Trust.
Participants
Men or women aged over 60 years with an isolated displaced and/or unstable ankle fracture who met the
following eligibility criteria.
Inclusion criteria
l Ambulatory prior to the injury – in any capacity.
l Capable of giving informed consent.
l Capable of adhering to postoperative instructions.
l Resident within the catchment area of a recruiting hospital.
l Could attend for 6 months’ follow-up.
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Exclusion criteria
l Established critical limb ischaemia.
l Insulin-dependent diabetes mellitus.
l Active leg ulceration.
l Open fractures.
l Serious concomitant disease (i.e. metastatic disease or terminal illness).
l Clinically substantial degenerative or inflammatory arthritis in the ankle.
l Unfit for general anaesthetic.
l Substantial cognitive impairment (defined as a Mini Mental State Examination score of less than 16 out
of 30).39
l Patient unwilling to give informed consent.
Participant approach and recruitment
The treating surgical team undertook the initial approach to participants. If the participant was willing, a
member of the research team explained the study in more detail and checked the eligibility criteria. A Mini
Mental State Examination to assess cognitive function was undertaken prior to randomisation. Potential
participants were given as long a time as possible to consider participation.
Interventions
All interventions were undertaken within a hospital and conformed to the NHS standard of being
performed under consultant supervision. Both study interventions were applied in theatre under general or
regional anaesthesia. We recorded time to treatment and the type of anaesthesia (regional, general or
both). Surgeons were advised that talar tilt or shift resulting in significant joint incongruence would be
considered unacceptable.
Standard care: open surgical reduction and internal fixation
Surgeons were permitted to choose from the range of implants that are used in the UK, and complied
with internationally recognised AO principles of fracture management.40 After surgery the selection of
splinting, weight-bearing and clinic follow-up was as per local practice.
Intervention: manipulation under anaesthetic in theatre and application of a
close contact casting
Standardisation of the casting materials, cast design and application, and moulding technique was achieved
by surgeon instruction (training session and access to training videos and documentation). The training video
was available to view prior to any application if a prompt was desired, which could be accessed online
(www.youtube.com/playlist?list=PL2Gg_an4nwPfIUC9RQV54Y2lbD76HiWcV). The method of closed-fracture
manipulative reduction of deformity was at the discretion of individual surgeons and this falls within the
common contemporary skills set of senior surgical trainees and consultants. We advised that CCC should be
applied once major swelling had subsided, at a similar time to when open surgery would be considered. We
also issued guidance that a consultant grade surgeon who had attended a CCC training session was required
to be involved, or at least directly observe, CCC because this was a new technique being introduced into
clinical practice. The use of specific moulding points and correspondingly sited pressure pads within the cast
(Figure 2) aimed to prevent fracture displacement while also minimising the risk of skin damage. The
locations of the moulding points were specific to the participants fracture pattern, so the points of application
required to hold the fracture were the decision of the treating surgeon.
Fracture position was checked by monitoring radiographs in the weeks following initial CCC application,
and after any reapplication of the CCC in the clinic if the cast had loosened. Such cast changes did not
require anaesthesia. The protocol specified that, if during clinical follow-up there was an unacceptable loss
of fracture position prior to clinical union, it was the treating surgeon’s decision whether to reapply a CCC
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
6
in the outpatient clinic, remanipulate and apply CCC in the operating theatre or convert to ORIF. It was
advised that participants undergoing CCC should not do more than touch weight-bearing in the initial
4 weeks after application but then build up to full weight-bearing by 6–8 weeks, but as a pragmatic trial
this progression was at the surgeon’s discretion.
A member of the trial team provided training on CCC for surgeons. The training involved a presentation
on the AIM trial and the rationale and guidance related to CCC. A training video was then viewed,
followed by a live interactive demonstration of the cast application.
The CCC construct was formed by (1) an underlayer of bandage stockinette (e.g. bandage stockinette
jersey; BSN Medical GmbH, Hamburg, Germany), (2) small self-adhesive foam pads (e.g. fleecy foam 5mm;
Hapla, Oldbury, UK) over bony prominences (tibial crest, fibular head, calcaneum and metatarsal heads)
and over the moulding points on the lower leg medially and laterally, (3) two self-adhesive strips running
the full length of the cast (e.g. fleecy web roll 5 cm; Hapla, Oldbury, UK) where the plaster saw would be
Fibula
neck pad
Heel and
Achilles
cup
Lateral
malleolar
pad
Medial
malleolar
pad
Metatarsal
head
circular strip
To protect
peroneal
nerve
Apply
circumferentially
with no overlap
Tibial
shin strip
FIGURE 2 Outline of the shapes and locations of the foam pads used in the CCC.
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placed to aid safe removal of the cast, (4) a single non-overlapping layer of synthetic wool roll (e.g.
Soffban® Plus; BSN Medical GmbH, Hamburg, Germany), (5) plaster of Paris (e.g. Gypsona®; BSN Medical
GmbH, Hamburg, Germany) and (6) a topcoat over reinforcing synthetic casting material (e.g. 3M™Soft
Cast Casting Tape; 3M Health Care Ltd, Loughborough, UK).
It was possible that in some cases, after randomisation, the intervention delivered would necessarily be
changed. CCC was excluded as an option outside the group randomised to CCC. However, the study
protocol expected and gave instruction on the following scenarios.
l After randomisation and allocation to ORIF, at the point of intervention with anaesthesia commenced,
the temporary cast was removed and the ankle skin condition was such that the surgeon considered
one or all of the necessary surgical incisions to be unsafe. An alternative treatment would be given
(1) traditional plaster cast or (2) external fixation.
l After randomisation and allocated to CCC, at the point of intervention with anaesthesia commenced,
a fracture may have proved irreducible by closed manipulation. The surgeon would necessarily have
proceeded to ORIF.
l If there was an unacceptable loss of position by either treatment method prior to fracture healing,
the surgeon was advised to adopt an alternative treatment approach best judged to achieve a
favourable outcome.
l A combination of bone and skin fragility and gross joint instability may have excluded either
intervention. The surgeon would then apply a temporising external fixator, and definitive treatment
was at the surgeon’s discretion.
l After randomisation, there may have been a requirement to have a temporising treatment applied in
theatre (manipulation and back slab cast or external fixator) until it is clinically appropriate to return to
theatre to receive the allocated treatment.
Standardisation of other treatments
Each hospital followed its own antibiotic prophylaxis protocol for the type of implant insertion procedure
for the ORIF group. No antibiotics were routinely administered to CCC patients in theatre. Sites were
advised to follow their own local hospital policy regarding thromboprophylaxis. The postoperative
management plan, including the progression of weight-bearing, was at the discretion of the individual
surgeon. As a pragmatic trial, rehabilitation was not standardised for either group.
Monitoring intervention delivery
Routine data checks on theatre procedure forms facilitated monitoring of the intervention delivery as per
the protocol. All sites were visited for delivery of training in the CCC intervention, as this was not part of
standard care. All attending surgeons completed forms to provide details on their grade and experience of
the interventions. The surgeon was then allocated a code which was required on the theatre procedure
forms to monitor that the CCC interventions were being applied by those who had attended training and
that a trial-trained consultant grade surgeon was involved or directly supervising. Any discrepancies in the
grade of surgeon recorded at CCC training compared with their grade at primary theatre were because
they had moved up a grade. Discrepancies were identified during routine data checks and sites were
contacted if any occurred. Additional training was offered when there were issues regarding availability of
trained surgeons.
Learning and expertise effects
It is common practice that surgeons have particular expertise in selected techniques, and for surgical teams
to organise their workloads so that expertise is utilised to best effect. For each surgeon participating in the
study, we collected the following information: historical experience and preferences for ORIF and casting,
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grade of surgeon and time since first operation on the study. Surgeon codes allocated at training were
used to trace the surgeons’ activity during the trial in order to inform the learning effects analysis.
However, some of the trained surgeons involved in the pilot study did not have an allocated code and
were thus known exclusions at the outset.
Baseline assessments
Baseline assessments were undertaken by one of the research team following consent and prior to
randomisation. None of the participants would have been ambulatory at the baseline phase, but we collected
information about pre-injury mobility status using a retrospective report from the Olerud–Molander Ankle
Score (OMAS)41 as well as health-related quality of life using the European Quality of Life 5-Dimensions
(EQ-5D)42 and the Short Form questionnaire-12 items (SF-12).43 Although not ideal, recall was the only
method that we had for assessing pre-fracture abilities. As the recall period was relatively short (maximum of
2 weeks from injury), we did not expect problems. The type of residence in the month prior to admission was
recorded, as was the level of support provided and whether or not the participants lived alone prior to the
injury. Information on pre-injury mobility, medical history, smoking, alcohol intake, allergies, medication and
care requirements were collected.
Outcome measures
Participants were asked to attend study assessments at 6 weeks and 6 months; those unable to were
offered telephone or postal follow-up. The outcomes and time points for the study are outlined in Table 1.
The primary outcome measure was the OMAS, an ankle function outcome questionnaire, at 6 months.41
The OMAS is a rating scale from 0 (totally impaired) to 100 (completely unimpaired) based on nine items. The
response to each of the nine items is assigned a score and the summation of these scores makes up the
overall score. The items include pain, stiffness, swelling, stair climbing, running, jumping, squatting, supports
and work/activities of daily living.
TABLE 1 Outcome measures by time point
Domain Outcome measure
Time point
Baseline Theatre 6 weeks 6 monthsa
Ankle function OMAS ✓b ✓ ✓
Quality of life EQ-5D ✓c ✓ ✓
SF-12 ✓b ✓ ✓
Pain Pain items from OMAS and EQ-5D ✓ ✓ ✓
Physical impairment Ankle range of motion by goniometry (degrees) ✓ ✓
Timed up and go test (seconds) ✓
Radiological fracture
outcomes
Ankle joint congruence and fracture healing ✓ ✓ ✓
Health economics Theatre procedure data ✓
Resource use questionnaire ✓ ✓
Patient satisfaction Two questions (Likert-type scale) ✓ ✓
✓, measure recorded.
a Outcome assessor blinded.
b Prior to injury status.
c Day before injury status and on the day of assessment.
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Secondary outcomes included health-related quality of life measured by the EQ-5D (three levels) and SF-12
(version 1). The EQ-5D questionnaire is used to compute a health utility score that typically ranges from 0
(death) to 1 (perfect health). Negative scores can also be obtained that are reflective of a patient’s quality
of life being worse than death. The SF-12 questionnaire is used to compute a mental component summary
score and physical component summary score. These scores are measured on a scale of 0–100, with a
lower score indicating poorer physical or mental functioning. Pain outcomes were reported and analysed
using the pain subscales of the OMAS and the EQ-5D separately.
Physical impairment of ankle joint range of motion and mobility were measured. The range of joint motion
was assessed at 6 weeks, when clinically appropriate, and at 6 months after randomisation. Range of
motion assessments were conducted using a goniometer.44,45 The standardised technique for the trial was
outlined in an illustrated guide issued to sites. Additional training was provided when requested.
Participants were positioned on a plinth in long sitting, reclined to about 45°. A support was placed under
the upper part of the lower legs to flex the knee to 20–30°, to reduce tension in the triceps surae muscle
complex and to lift the heels off the surface of the plinth. Ankle dorsiflexion and plantar flexion range of
motion were measured in degrees from the anatomical neutral position, otherwise known as plantar grade
(Figure 3). Participants with insufficient dorsiflexion to move the ankle beyond neutral were recorded as
having a negative score (e.g. if the participant was 5° from reaching neutral his or her score was –5°).
For dorsiflexion and plantar flexion the goniometer was placed on the lateral aspect of the ankle; the axis
of the goniometer was placed approximately 1.5 cm inferior to the lateral malleolus; the stationary arm
was placed parallel to the longitudinal axis of the fibula, lining up with the fibula head; and the moveable
arm was placed parallel to the longitudinal axis of the fifth metatarsal (Figure 4). For inversion and
eversion, the goniometer was placed on the anterior aspect of the ankle; the axis of the goniometer was
placed over the middle of the ankle joint line, the stationary arm was placed along the longitudinal axis of
the tibia lining up with the tibial tuberosity; and the movable arm was placed along the second metatarsal
in line with the base of the second toe (Figure 5).
Mobility, assessed using the timed up and go test,46 was included as an outcome at 6 months. The timed
up and go test is a test specifically designed for frail older people. The test recorded the time taken to get
up from a chair with armrests, walk 8.6 m (standardised distance for the AIM trial), turn at a mark on the
FIGURE 3 Lateral aspect of the lower leg with a line indicating plantargrade at the ankle.
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floor, then walk back to the chair and sit down again. Participants were asked to walk safely as fast as
possible and used a walking aid if they normally did so. Performance tests are a recognised standard for
measuring mobility and associations with important end points including risk of falling, functional decline
and institutionalisation.47 We also noted the date that participants commenced partial weight-bearing.
Patient satisfaction was measured on an ordered categorical scale.
Outcomes for the economic evaluation were the incremental quality-adjusted life-years (QALYs) and the
incremental costs of CCC over ORIF. Incremental differences were the differences in totals. Total costs were
the sum product of resource use with unit resource cost. Total QALYs were the integration of utility over time.
FIGURE 4 Positioning of the goniometer for the assessment of ankle dorsiflexion and plantar flexion range of motion.
FIGURE 5 Positioning of the goniometer for the assessment of ankle inversion and eversion range of motion.
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Radiological outcomes
Radiographs were taken for both groups postoperatively at 6 weeks and at 6 months. Fracture union and
joint position were assessed on standard anteroposterior, ankle mortise view and lateral view radiographs
using standard measures of joint congruence, fracture angulation, fibular shortening and subluxation.48
Radiographs were assessed within a purpose built software using Matlab (The MathWorks, Natick, MA,
USA). The radiographs were reviewed centrally by a trained independent assessor. Measurements and
decisions regarding non-union and malunion at 6 months were also verified by two independent surgeons.
Malunions were defined as a radiograph demonstrating any one or combination of showing talar
subluxation > 2 mm (talar shift), excessive talar tilt (> 2°) or a diastasis (tibiofibular clear space ≥ 5 mm).
Any disagreement was resolved by a radiologist.
Complications and further surgery
Expected recognised complications or harms related to the study treatments were recorded as adverse
events only. Adverse events attributed to medical comorbidities or anaesthesia (part of normal care) were
only recorded as adverse events and were not reported as serious adverse events. Medical problems or
surgery not associated with the study interventions were not systematically collected or reported. Other
fractures sustained, further ankle surgery or major illness due to the interventions were recorded. A serious
adverse event was any untoward medical occurrence that was both unexpected and related to the study
treatments: (1) death within 30 days of surgery, (2) death related directly to the surgical intervention at any
time, (3) life- or limb-threatening complication or (4) rehospitalisation (except a hospital stay for removal of
syndesmotic screws which was recorded as an adverse event).
Randomisation
Randomisation took place following screening and baseline assessments. The unit of randomisation was
the individual and assignment was in a 1 : 1 allocation ratio. We used the remote 24-hour telephone
randomisation service available from the University of Aberdeen.
Allocation concealment was ensured by registering participants before computer generation of the allocation
code. Sequence generation was by random block size and stratified by centre and fracture pattern, using
trans-/infrasyndesmotic (type A/B) and suprasyndesmotic categories (type C) as stratification factors.
Blinding
At 6 months a health professional, who was blind to treatment assignment, completed the clinical
measurements and ensured completion of the study questionnaires. The presence or absence of surgical
incision(s) was obscured by opaque bandage(s) applied by a research nurse/therapist prior to the
participant meeting the blinded assessor. Patients unable to attend were contacted by telephone or visited
at home. We undertook an analysis of the success of the blinding strategy using outcomes from questions
asking blinded assessors to indicate if they believe they knew the intervention allocated and/or received.
It was not possible to blind the surgeons or participants because of the nature of the interventions. It was
also not possible to blind radiograph assessors or treating surgeons as the implants, or their absence,
would be apparent on the radiographs, as would the surgical scars on examination. The 6-week follow-up
was conducted in the clinic by researcher, who was not blinded to treatment allocation. At 6 weeks, the
researcher needed to be aware of relevant precautions and contraindications to the clinical assessment of
range of ankle motion (i.e. discuss this with the surgeon to ensure fracture was stable).
Sample size
Given the paucity of data in the published literature, pilot trial data were used as a primary source to inform
estimates of variance and treatment effects measured using the OMAS, and a range of secondary outcomes.
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Although the original sample size estimate was based on a difference in proportions, this was modified
following advice from the Data Monitoring and Ethics Committee (DMEC), as data from the pilot study
showed the data to be normally distributed and that analysis based on a continuous score would be more
efficient and meaningful. Parameters for the sample size were informed by data from the pilot study,
known only to the study statisticians and the DMEC. We utilised a sample size calculation with one-sided
testing (p = 0.05), as we were not trying to prove that the new treatment was better than the standard
and, therefore, gained considerable statistical efficiency.49,50 The power of the study was set at 80% as is
conventional in clinical trials.50
Data from the pilot study informed the sample size; the standard deviation (SD) on the operative arm was
16.2 OMAS points. An equivallence margin of ± 6 points on the OMAS yielded the final sample size of
560 in total.49 We inflated for loss to follow-up of nearly 10%, yielding a total sample size of 620.
Published estimates to inform the selection of equivalence margins using the OMAS were non-existent.
Using the pilot data to calculate standardised effects sizes, the equivalence margin included small
differences (< 0.37), but excluded moderate or large treatment differences. This was consistent with
clinical opinion supporting a 6-point margin excluding clinically important differences in this condition
gathered in an informal survey of orthopaedic surgeons. It was also consistent with published data on
the minimally clinically important differences for similar scores (Foot and Ankle Score and visual analogue
pain scores in acute injury) that reported minimally clinically important differences > 10 points on a
100-point scale.
Pilot study
A pilot study was conducted in the trauma service at the Oxford University Hospitals NHS Foundation
Trust. We recruited 95 participants and this informed the design and established the feasibility of the
multicentre phase of the study. None of the participants of the pilot study completed the full health
economic evaluation questionnaire used later in the multicentre phase of the AIM trial. The independent
DMEC agreed that the pilot trial design was sufficiently similar to the multicentre phase for the data from
these participants to be integrated.
Statistical methods
In equivalence testing, a maximum clinical difference (ΔT) is prespecified at a level within which the two
treatments can be considered not to differ in any clinically meaningful way. Therefore, the relevant null
hypothesis was that a difference of greater than ΔT exists in either direction (H0: Δ ≤ –ΔT or Δ ≥ ΔT)
and the trial was targeted at disproving this in favour of the alternative that no clinical difference existed
(HA: –ΔT < Δ < ΔT). The US Food and Drug Administration’s regulations recommend both a treatment
received (per-protocol) and an intention-to-treat (ITT) analysis, aiming to demonstrate equivalence.51 Use of
an ITT approach in a superiority trial sometimes increases the chance of falsely claiming equivalence.52,53
ITT is conservative when trying to detect a difference, and so the opposite is true when trying to show
similarity. The effect of low protocol adherence would therefore make the treatment groups appear more
similar that they actually are. Initially, a per-protocol analysis was undertaken where only the patients who
received their allocated treatment were analysed and those patients who did not were excluded from the
analysis. Following we carried out an ITT analysis was carried out in which all randomised patients were
analysed according to the treatment to which they were randomised.
Participants were excluded from the per-protocol analysis if they did not receive their allocated treatment
during either their initial inpatient stay (i.e. during their primary theatre procedure or as an additional
theatre procedure) or during a readmission. The protocol allowed for the eventuality of participants
requiring a visit to the operating theatre for a temporary intervention prior to receiving the allocated
treatment (e.g. a temporary cast, back slab or external fixation). However, if the allocated intervention was
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received after a clinically definitive intervention, then the participant was not deemed to have received the
allocated treatment.
The result of the analysis of the primary end point could be one of the following:
l The confidence interval (CI) for the difference between the two treatments lies entirely within the
equivalence range, –ΔT to ΔT, so that equivalence may be concluded with only a small probability
of error.
l The CI covers at least some points that lie outside the equivalence range, so that differences of
potential clinical importance remain a real possibility. In other words, superiority of treatment cannot be
ruled out and thus equivalence cannot safely be concluded.
l The CI is wholly outside the equivalence range (although this is likely to be rare). This is indicative of
the trial being underpowered as the CI includes non-trivial effect sizes that are in favour of both arms.
As well as assessing if equivalence was demonstrated in either case, this also formed part of an additional
sensitivity analysis to assess the range of potential biases that could have resulted from loss to follow-up,
protocol deviations, withdrawal (and mortality). Numerical and graphical summaries of all the data were
compiled, including descriptions of missing data at each level. Estimates of treatment effect were reported
with 95% CIs and a figure showing CIs and margins of equivalence were also presented. Our main
analytical methods were generalised linear models (GLMs), and all primary and secondary outcomes were
adjusted for important baseline covariants [age, sex, centre (hospital), fracture pattern (Weber A and B or C),
baseline score] to maximise precision.
The OMAS, at 6 months, was the primary outcome in this study and was compared between treatment
groups as the dependent variable in a linear regression model for the primary analysis. The treatment
difference was based on the estimates of the adjusted means and 95% CIs. The OMASs were also
presented as an ordinal outcome in a secondary analysis using ordered logistic regression (proportional odds
model). Secondary outcome measures were similarly analysed with logistic regression models being used for
categorical data and linear regression models for continuous data. The EQ-5D measure was summarised
both at an item level and an overall score as recommended by the EuroQol group. Time-to-event data
(time from randomisation to discharge and time from randomisation to readmission) were analysed using a
log-rank test. Any patients who did not experience an event at the time point of interest or who withdrew
were censored. The p-value and a hazard ratio with its 95% CI from a Cox proportional hazards model were
also presented. The proportional hazards assumption across treatment arms was checked graphically
using a log-cumulative hazard plot. Outcomes that were not normally distributed were evaluated using a
non-parametric Wilcoxon rank-sum test. A data analysis plan was agreed with the DMEC.
The success of the blinding strategy was assessed using James’ Blinding Index, which ranges from 0 (total
lack of blinding) to 1 (complete blinding).54 The learning effects were assessed by fitting a longitudinal
random model. For each surgeon, operation time was ordered sequentially by date and a time variable
was created. This time variable was fitted as a random effect into a longitudinal model, with the operation
time as the response variable. The surgeon was also included as a random effect. Another similar model
was fitted nesting surgeon within hospital and treating these as random effects. This assessed the learning
effect allowing for surgeons within their hospitals.
The clinical results were analysed using Stata version 13.1 (StataCorp, College Station, TX, USA) and SAS
version 9.3 (SAS Institute Inc., Cary, NC, USA).
Economic analyses
An evaluation of cost-effectiveness of CCC compared with ORIF was conducted as part of the AIM trial.
The economic evaluation presented in this chapter was conducted for both the NHS and societal
perspectives. We conducted analyses for both the per-protocol and ITT populations. Consistent with the
evaluation of cost-effectiveness, the primary analysis was per protocol.
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Data
Outcome data
Health outcomes were expressed as QALYs. QALYs are the length of life weighted by the health-related
quality-of-life weights. Health-related quality-of-life weights were estimated by using the EQ-5D-3L
instrument. In the EQ-5D-3L, respondents rate five dimensions of health: mobility, self-care, usual activities,
pain/discomfort and depression/anxiety. For each dimensions, respondents rate the extent of their problem
as ‘no problem’, ‘some problems’ or ‘extreme problems’. Responses are transformed into an index of
general health on the interval –0.59 to 1 using an algorithm based on UK general population valuations in
which a negative value corresponds to a state worse than death.55 The interval represents the relative value
of an individual’s current health state; the lower and upper bound of the interval represent death and full
health, respectively. A lower utility indicates a lower preference for that health state.
Resource utilisation data
Relevant resource use prospectively collected over 6 months included resource use during hospitalisations,
time spent at discharge locations, and number of health services and medications used. We collected
itemised resource use for hospitalisations from administration and visit records to microcost the entire
episode of hospitalisation. Hospitalisations included the index primary procedure as well as any additional
procedures and rehospitalisations. Resource use items measured during each hospitalisation included
implant material use (screws, plates, wires, etc.), casts, anaesthesia, theatre time and length of stay.
Time spent at discharge locations, the number of contacts with health services and the provision of
medications were collected from participant questionnaires at 6 weeks and 6 months. Participants were
asked to indicate the type and quantity of each resource item used for services provided by the NHS and
for any private service use, whether paid out of pocket or by private insurance.
Discharge locations included community hospital days, intermediate care days and nursing home days.
Health services included the number of contacts to the general practitioner (GP), nurse, physiotherapist,
hospital specialist, hospital accident and emergency, psychologist, orthopaedic trauma outpatient/fracture
clinic and community care centre. Medications included painkillers, anti-inflammatory medication, analgesic
gel, sleeping pills and antidepressants. For medications, participants were asked to indicate the number of
times the medication was prescribed.
Participants were also asked to indicate any private health-care use to inform societal resource use.
In addition to the above resource uses, societal resource uses included time spent at private nursing home;
private health service use in the same aforementioned services; out-of-pocket medications for the same
aforementioned medications; and work days taken by both the patient and their friends or family.
For out-of-pocket medications, participants indicated the number of times the medications were bought.
Unit costs
The total NHS and societal cost was calculated by multiplying resource use data by their unit costs. Unit
costs included the cost of implant materials, casts, theatre time, length of stay, time spent at discharge
locations, various health services, various medications and work days taken. All unit costs reported in this
section are in 2014 units.
NHS health-care unit costs
Unit costs for all resources consumed and contacts with NHS health services were derived from published
sources relevant to the UK. Unit costs for these items are reported in Table 2.
Unit costs for implant and cast materials were derived from NHS procurement (www.supplychain.nhs.uk).
Theatre time was derived from Information Services Division Scotland,58 whose estimate of hourly theatre
time was based on 123,976 hours in orthopaedic specialties across the 367 operating theatres in all 15
health boards; this was thought generalisable across the UK. General inpatient day cost was derived from
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TABLE 2 Unit cost parameters
Units
Mean
cost (£)
Standard
error (£) Source Distribution
Implant material costs
Screw 6 2 NHS procurementa Gamma
Tension band wire 20 3 NHS procurementa Gamma
Antigliding plate 17 3 NHS procurementa Gamma
Tubular plates 17 3 NHS procurementa Gamma
Dynamic compression plate 30 8 NHS procurementa Gamma
Reconstruction plate 67 20 NHS procurementa Gamma
Locking plate 114 29 NHS procurementa Gamma
CCC 30 3 NHS procurementa Gamma
Hospitalisation costs
Anaesthesia 313 2 NICE CG124,56 Chakladar et al.57 Gamma
Theatre time, 1 hour 975 87 Information Services Division Scotland58 Gamma
Inpatient time, 1 day 276 59 NHS Reference Costs 2011–201259 Gamma
Long-term care facilities
Community hospital time, 1 day 194 19 NHS West Sussex60 Gamma
Intermediate care time, 1 day 64 13 PSSRU61 Gamma
NHS nursing home time, 1 day 98 10 PSSRU61 Gamma
Acute health resource use
A&E visit 54 7 NHS Reference Costs 2011–201259 Gamma
Physiotherapist outpatient visit 47 9 NHS Reference Costs 2011–201259 Gamma
Hospital specialist visit 45 9 NHS Reference Costs 2011–201259 Gamma
Psychologist visit 62 12 PSSRU61 Gamma
Trauma outpatient visit 95 16 NHS Reference Costs 2011–201259 Gamma
Hospital transport 189 – National Audit Office62 Gamma
Community care visit 46 11 NHS Reference Costs 2011–201259 Gamma
Medication
Painkillers 1 – BNF63 Determ
Anti-inflammatories 3 – BNF63 Determ
Gel 6 – BNF63 Determ
Sleeping pills 21 – BNF63 Determ
Antidepressants 1 – BNF63 Determ
Productivity loss, 1 day 99 – ONS64 Determ
A&E, accident and emergency; BNF, British National Formulary; CG, clinical guideline; ONS, Office for National Statistics;
PSSRU, Personal Social Services Research Unit.
a www.supplychain.nhs.uk.
Distributions were assigned to represent potential uncertainty in unit cost estimates. ‘Gamma’ is the distribution commonly
chosen for costs as the gamma distribution cannot be negative. ‘Determ’ means that those estimates were entered
deterministically into the model as point estimates only without uncertainty.
NHS Reference Costs 2011–2012;59 we used the weighted average excess inpatient bed-day for all major,
minor and intermediate foot procedures (HA31B, HA31C, HA32Z, HA33Z, HA34Z and HA35Z). The cost of
anaesthesia was derived from a UK study measuring the anaesthesia costs in hip fracture patients,57 which
was subsequently used by the National Institute for Health and Care Excellence (NICE) in its economic
evaluation of hip fracture.56
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Unit costs of all health services use were derived from NHS Reference Costs 2011–201259 and the Personal
Social Services Research Unit (PSSRU)’s Unit Costs of Health and Social Care 2012.61 There were two
exceptions. The day cost of a community hospital stay was derived from a study of community bed service
by NHS West Sussex.60 The cost of a hospital transport was derived from the National Audit Office’s report
on NHS ambulance services.62
Unit costs of prescriptions were derived from the British National Formulary.63 A prescription of painkillers
corresponded to a 32-tablet 500-mg pack of paracetamol; anti-inflammatories, an 84-tablet 200-mg pack
of ibuprofen; gels, a 100-g tube of Ibugel™ (Dermal Laboratories, Hitchin, UK) containing 10% ibuprofen;
sleeping pills, a 28-tablet 10-mg pack of temazepam; and antidepressants, a 30-capsule 20-mg pack
of fluoxetine.
Societal unit costs
Societal costs included private health-care costs. The unit costs of private nursing home days, private health
services and private medication use were the same for both NHS and private resource use. That is because
unit costs are meant to measure not the list price but the economic cost. The economic cost is the
opportunity cost of the resource. Compared with private list prices, the NHS unit costs are likely a more
accurate estimation of the opportunity cost. Thus, societal unit costs were valued at the same levels as
their NHS counterparts.
The productivity cost of a workday was derived assuming an average workday of 7.5 hours and an average
hourly wage across all UK residents of £12.83/hour as estimated from the Office for National Statistics.64
Analysis methods
The economic evaluation was conducted for both the NHS and societal perspectives. The evaluation was
also then conducted for both the per-protocol and ITT populations. The primary analysis used the
per-protocol population. The overall flow of analysis is depicted in Figure 6.
Missing data
In the case of missing data, multiple imputation with chained equations was used, in which evidence
supported the conclusion that data were missing at random. Individuals who had zero information on all
outcomes were removed from the analysis. This applied to individuals with no utility information at
presentation, 6 weeks and 6 months.
Multiple imputation with chained equations is the dominant method for complex incomplete data across
multiple variables.65 It accounts for the process that created the missing data, preserves the relations
in the data and preserves the uncertainty about these relations.65 Potential predictors included baseline
characteristics as well as all resource use and health outcome items. Downstream variables were removed
as predictors of upstream variables. Multiple imputation was conducted using 40 iterations and five
imputations. Density and convergence plots were inspected to confirm comparable distribution shapes to
observed data and healthy convergence.
Costs and quality-adjusted life-years
Mean resource use was tabulated by category and type of health-care service for ORIF and CCC.
After consideration of normality using visual inspection and Shapiro–Wilk tests, differences in resource use
were estimated using the Wilcoxon’s signed-rank test, Fisher’s exact test or chi-squared tests, depending
on the variable. Total NHS and societal costs for each participant were calculated by adding the cost of
each resource use.
Utility weights at presentation, and at 6 weeks and 6 months after randomisation, and total QALYs are
presented for the ORIF and CCC groups. After consideration of normality using visual inspection and
Shapiro–Wilk tests, differences in utility and QALYs were estimated using the Wilcoxon’s signed-rank test.
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QALYs were estimated by integrating the length of life by the utility weights as an ‘area under the curve’.
We assumed monotonic changes in utility between any two measurement points.
We presented 95% confidence limits using a bootstrap approach. Total NHS cost, total societal cost and
total QALYs were resampled 10,000 times, stratified by treatment with ORIF or CCC to ensure equal
sample sizes to that of the original number of participants in each group.
Total NHS and societal costs, as well as total QALYs, were estimated using a regression approach.
The regression included a treatment term in addition to other relevant baseline characteristics. As total
costs and QALYs were skewed (as they generally are), we used a GLM. The appropriate family and link
functions were determined using the modified Park’s and Hosmer–Lemeshow tests, respectively. We used
the best-fitting GLM and the generic ordinary least squares (OLS) model to present results. Baseline
covariates of interest were selected by clinical reasoning, independent association with the dependent
variable at the p < 0.25 level and prevalence > 10%.
The developed statistical models were then used to estimate the mean total NHS and societal costs as well
as mean total QALYs using marginal prediction. Marginal prediction eliminates known covariate imbalance
between the intervention groups before estimating total costs and QALYs. Any observed comparison of
two groups, whether randomised or not, is likely to show imbalance in baseline covariates, regardless of
statistical significance. These imbalances should be regarded as sources of bias in the estimation of mean
costs and QALYs, and by extension, differences in costs and QALYs between the intervention groups.
Marginal prediction effectively holds all else equal, save for the predictor of interest – treatment.
To appropriately incorporate sampling uncertainty, unit cost uncertainty and statistical model uncertainty,
we conducted the entire process within a bootstrap framework. The process consisted of three steps.
First, a sample was drawn from the original trial sample, stratified by treatment group. Second, unit costs
were randomly drawn from their probability distributions and applied to the resource uses in the sample
while QALYs were estimated as the area under the curve. Third, and finally, statistical models were
assembled and marginal estimation was conducted. Thus, each of the 10,000 iterations of the bootstrap
produced a new resample, a new set of unit costs and a new statistical model for marginal estimation and
a new set of total NHS cost, total societal cost and total QALYs.
Lifetime extrapolation
Lifetime extrapolation or modelling may be warranted when there is reason to expect differences in
long-term costs or QALYs. Factors that affect either include life expectancy, quality of life or events;
however, only incremental differences in these factors would affect long-term costs or QALYs.
Life expectancy is not expected to be any different after ORIF or CCC. Quality of life and the rate of its
recovery are not expected to differ in the long term. However, if there were clear differences by the end of
the trial period, their extensions into the lifetime would be explored.
The AIM trial incorporated a 6-month follow-up. Under normal circumstances, clinical union takes 6 to
12 weeks. The 6-month follow-up of the AIM trial was well suited to capture failure of closed reduction or
loss of reduction resulting in reoperation/rehospitalisation. Beyond 6 months, reoperation/rehospitalisation
because of excess complications may be possible. However, the probability of this is likely to be very low.
In an analysis of 57,183 patients with ORIF, the 6-year reoperation rate was < 1% while complications
were < 2%.27 More specifically in elderly patients, Koval et al.66 found in 33,704 elderly patients the
incidence of complications to be ≤ 2%. Importantly, there was no difference between those treated
operatively and those treated non-operatively. These findings are supported by a Cochrane review that
compared surgical and conservative management of ankle fractures with follow-up from 20 weeks to, on
average, 7 years.23 A randomised trial in elderly patients with a mean follow-up of 27 months also found
negligible incidence beyond 3 months.29 As published evidence of the long-term complications shows low
incidence and no difference between operative and non-operative management, we did not plan to model
any long-term differences in complications between ORIF and CCC. Extended follow-up of the AIM trial
will provide an opportunity to investigate long-term complication rates following ORIF or CCC.
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Excess implant removal because of local irritation is also possible beyond 6 months. Estimates in the
literature may be biased where removal is a paid part of a surgeon’s practice. Based on the experience of
the trial group, removal for irritation was estimated to be very low, at around 2–3%. We assumed the
removal cost to include a theatre time and length of stay similar to that observed for an additional
procedure/readmission from the trial data. This was later determined to be 1.3 theatre hours and 5 days
in hospital. Thus, the total cost was £2648 per removal. After weighting by a 3% removal rate, this
amounted to £79 for the population receiving implants. We attributed this removal during the index year.
No impact on QALYs was modelled, as general health domain functioning is independent of whether or
not hardware is removed in those experiencing pain/discomfort.67
Incremental analysis
Using the estimated total NHS cost, total societal cost and total QALYs, we calculated the incremental
differences between the CCC and ORIF groups. We presented the incremental cost-effectiveness ratio
(ICER) for the NHS and societal perspectives, when appropriate. The mean ICER is the mean incremental
cost divided by the mean incremental QALYs.
There are four potential combinations of incremental costs and QALYs:
1. CCC is more effective and more costly.
2. CCC is less effective and less costly.
3. CCC is more effective and less costly.
4. CCC is less effective and more costly.
These four potential combinations of incremental costs and QALYs were visualised by a cost-effectiveness
plane, which is a scatterplot of incremental costs on the y-axis and incremental QALYs on the x-axis.
We used the net benefit statistic to estimate the probability that CCC is cost-effective. CCC is cost-
effective when the net benefit is greater than zero. The net benefit was the incremental benefit minus the
incremental cost. The incremental benefit was the incremental QALYs multiplied by the willingness to pay.
There were two incremental costs: (1) the incremental total NHS cost and (2) incremental total societal
cost. We estimated two net benefits for the NHS and societal perspectives.
The probability of cost-effectiveness changes as a function of the willingness to pay. Using all 10,000
bootstrap samples, we estimated the overall probability of cost-effectiveness for all willingness to pay over
a common range (£0/QALY to £30,000/QALY). The probability of cost-effectiveness was plotted on a
cost-effectiveness acceptability curve.
Sensitivity
The bootstrapped model already incorporates sampling uncertainty, unit cost uncertainty and statistical
model uncertainty.
We explored structural uncertainty in the statistical models by employing the second best-fitted GLM as
well as the generic OLS model (a GLM with Gaussian family and identity link). The entire economic
evaluation was repeated for the ITT population.
Pilot patients did not have any utility information at presentation, and at 6 weeks and 6 months after
randomisation. They also did not complete health economic questionnaires at 6 weeks or 6 months after
randomisation. They therefore had no information valid for an economic evaluation. Patients with no
valid information were excluded from the analysis. However, we explored including these patients with
completely missing information after imputing their values on the basis of baseline characteristics and
primary procedure resource use.
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Identification of best-fit GLMs was conducted in Stata version 12 (StataCorp, College Station, TX, USA).
All other statistical and economic analyses, as well as data handling, were conducted in R version 3.1.2
(R Foundation for Statistical Computing, Vienna, Austria).
Database and data processing
The return of case report forms (CRFs) to the study office was monitored daily to proactively request any
documentation that was expected for arrival and to track any forms that were yet to be returned. On
arrival into the study office, each CRF was checked through central monitoring systems to ensure
completeness of the data and to monitor protocol compliance. These systems facilitated immediate
identification of missing or contradictory data. Sites were contacted in a timely manner to resolve
these queries. Data queries were reviewed on a weekly basis and followed through to completion to
ensure maximum data capture. Items of missing data and the reason not obtained were logged for
reference. The statistician, prior to Trial Steering Committee (TSC) and DMEC meetings, reviewed data
completion and follow-up rates.
Data were single-entered into the database by study personnel. For data quality assurance, 10% of
baseline, 6-week and 6-month follow-up questionnaires were randomly selected for data checking. Any
discrepancies identified when checking were corrected and recorded. The data were held on Warwick
Clinical Trial Unit’s SQL Server (Microsoft, Redmond, WA, USA) system that facilitated data validation,
range checks and flagging of missing data.
Qualitative study
In order to explore patient experience of their treatment, recovery and what it was like to be in the trial, a
purposive sample of 36 patients was interviewed between 6 and 10 weeks post treatment. An estimated
sample of up to 40 patients was identified in the study protocol, but data saturation (when interviews
stop revealing new data) was achieved with a sample of 36 participants. The sample covered patients from
both treatments, two study sites, and a range of ages and sexes. Participants provided informed written
consent. The interviews were conversational in style to allow patients to identify their experiences and the
issues that concerned them. The research questions were (1) what are participants’ experiences of ankle
fracture in the first 6–10 weeks after treatment? and (2) what are participants’ experiences of being in a
trial? Further information on methodology and findings for the qualitative study is presented in Chapter 5.
Patient and public involvement
The study design, patient information sheets and consent forms for the main trial and qualitative substudy
were discussed with the Oxford Trauma User Group who provided feedback and support for the study.
The user group are former users of the Oxford Trauma Service and/or previous participants in clinical
studies conducted by the Trauma Research Group based in the Kadoorie Centre for Critical Care Research
and Education, all based at the John Radcliffe Hospital, Oxford, UK. A user representative was a member
of the TSC and as part of this role made a suggestion for the additional secondary analysis of the primary
outcome as an ordered categorical outcome, as outlined in Statistical Methods.
Ethical approval and monitoring
The Oxfordshire Research Ethics Committee A gave approval for this study (09/H0604/129). We complied
with the Medical Research Council: Guidelines for Good Clinical Practice in Clinical Trials,68 and the trial
was run using the standard operating procedures of Warwick University Clinical Trials Unit and the Oxford
Clinical Trials Research Unit.
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Trial Steering Committee
The TSC was responsible for monitoring and supervising the study. The TSC consisted of two independent
members, a lay member and key members of the trial management group, in addition to clinical and
methodological experts. Membership of the TSC is given in the Acknowledgements.
Data Monitoring and Ethics Committee
The DMEC was independent of the trial and was responsible for monitoring ethical, safety and data
integrity. The trial statistician provided data and analyses requested by the DMEC at each of the meetings.
Membership of the DMEC is given in the Acknowledgements.
Trial Management Group
A Trial Management Group was responsible for the day-to-day management of the trial, consisting
of the chief investigator, coinvestigators, research fellows, research physiotherapist, statisticians, health
economists, research nurse, trial manager and data co-ordinator. The role of the Trial Management Group
was to monitor the conduct and ensure progress of the trial according to the study protocol and to take
appropriate action to safeguard participants and the trial itself.
Reporting
The trial was reported in accordance with the Consolidated Standards of Reporting Trials (CONSORT)
statement69 and its extensions relating to non-pharmacological,70 pragmatic71 and equivalence trials.53
Reporting of the intervention was also based on the template for intervention description and replication
(TIDieR) guidance.72
Summary of changes to the project protocol
The changes to the project protocol are summarised in Table 3.
TABLE 3 Changes to the protocol during the study by version number
Protocol version
number Date issued Details of changes made
1 August 2009 Original protocol
2 18 February 2010 Minor clarifications
3 25 May 2010 Removal of 10-day ASEPSIS assessment
Addition of EQ-5D at baseline ‘with injury’
Addition of health economic questions at 6 weeks
4 11 November 2010 Minor clarifications
5 16 August 2011 Update to radiography process and also the name of service used to match,
flag and trace patients
6 10 April 2013 Change to the extended follow-up time frame; now at least 2 years
(rather than at 5 years)
7 24 January 2014 Statistical section updated to ensure it was in line with analysis plan. The
main clarification was to confirm details relating to the sample size estimate
as described in Sample size. Further clarifications to the radiograph review
process were also confirmed
ASEPSIS, Additional treatment, the presence of Serous discharge, Erythema, Purulent exudate, and Separation of the deep
tissues, the Isolation of bacteria, and the duration of inpatient Stay.
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Chapter 3 Clinical results
Participant flow
Figure 7 presents the CONSORT flow diagram summarising the different phases of the trial from the
recruitment stages up to the point of final analyses. Table 4 provides details of the study flow. In summary,
620 patients were recruited and randomised. There were 309 participants randomised to ORIF, of whom
302 received their allocated treatment. There were 311 participants randomised to CCC, of whom 277
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Randomised
(n = 620)
Assessed for eligibility
(n = 2015)
Allocated to treatment ORIF (N = 309)
• Received allocated intervention, n = 302
• Did not receive allocated intervention, n = 7
Allocated to treatment CCC (N = 311)
• Received allocated intervention, n = 277
• Did not receive allocated intervention, n = 34
Excluded (N = 1344)
• Not meeting inclusion criteria, n = 127
• Meeting exclusion criteria, n = 1217
Eligible (N = 671)
• Declined to participate, n = 51
Lost to follow-upa
• Lost to follow-up at 6 weeks, n = 0
• Lost to follow-up at 6 months, n = 1
Withdrawalsa
• Withdrew prior to 6-week follow-up, n = 3
• Withdrew prior to 6-month follow-up, n = 7
Dieda
• Died prior to 6-week follow-up, n = 1
• Died prior to 6-month follow-up, n = 3
Analysed (per protocol)
• Analysed for primary outcome at 6 weeks,
   n = 298
• Analysed for primary outcome at 6 months,
   n = 291
Analysed (ITT)
• Analysed for primary outcome at 6 weeks,
   n = 305
• Analysed for primary outcome at 6 months,
   n = 298
Analysed (per protocol)
• Analysed for primary outcome at 6 weeks,
   n = 275
• Analysed for primary outcome at 6 months,
   n = 267
Analysed (ITT)
• Analysed for primary outcome at 6 weeks,
   n = 303
• Analysed for primary outcome at 6 months,
   n = 295
Lost to follow-upa
• Lost to follow-up at 6 weeks, n = 0
• Lost to follow-up at 6 months, n = 1
Withdrawalsa
• Withdrew prior to 6-week follow-up, n = 6
• Withdrew prior to 6-month follow-up, n = 8
Dieda
• Died prior to 6-week follow-up, n = 2
• Died prior to 6-month follow-up, n = 7
FIGURE 7 The CONSORT diagram for the AIM trial. a, Number of participants (n) reported is cumulative.
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received their allocated treatment. At baseline, 618 out of 620 (99.7%) participants provided baseline data,
608 out of 620 (98.1%) participants provided data at 6 weeks and 593 out of 620 (95.6%) participants
provided data at 6 months. Baseline data for two of the participants were missing as they were randomised
in error, that is they were ineligible, and thus were withdrawn. Fifteen out of the 620 (2.4%) participants
withdrew from the trial and 10 out of the 620 (1.6%) participants had died. At the 6-month primary end
point, 558 out of 620 (90%) participants were analysed for the primary outcome in the per-protocol analysis
and 593 out of 620 (96%) participants were analysed for the primary outcome in the ITT analysis. The details
of each of the stages in the flow of the trial will now be described in more detail.
TABLE 4 Flow of participants in the AIM trial
Trial participation Participants
Recruitment All patients screened 2015
Eligible patients 671/2015 (33.3%)
Patients consented and randomised 620/671 (92.4%)
Patients declined consent 51/671 (7.6%)
Excluded patients: patients meeting inclusion criteria but also meet at least
one of the exclusion criteria. Exclusion criteria include MMSE score of < 16
1344/2015 (66.7%)
Baseline Participants with baseline data 618/620 (99.7%)
Follow-up No follow-up data at any time point 12/620 (1.9%)
Follow-up data at 6 weeks only 15/620 (2.4%)
Follow-up data at 6 months only 0
Follow-up data at all time points 593/620 (95.6%)
Died Participants died 10/620 (1.6%)
After randomisation, but before theatre for treatment 0
In theatre, but before starting any trial procedure 0
During initial treatment in theatre 0
In hospital ≤ 30 days following initial treatment in theatre 2/620 (0.3%)
In hospital > 30 days following initial treatment in theatre 0
After initial hospital discharge ≤ 30 days after initial treatment, but before
6 weeks’ follow-up
0
After initial hospital discharge > 30 days after initial treatment, but before
6 weeks’ follow-up
1/620 (0.2%)
After 6 weeks’ follow-up, but before 6 months’ follow-up 7/620 (1.1%)
Withdrawals Participants withdrawn 15/620 (2.4%)
After randomisation, but before initial hospital discharge 5/620 (0.8%)
After initial hospital discharge, but before 6 weeks’ follow-up 4/620 (0.6%)
After 6 weeks’ follow-up, but before 6 months’ follow-up 6/620 (1.0%)
Loss to follow-up At 6 weeks’ follow-up 12/620 (1.9%)
At 6 months’ follow-up 27/620 (4.4%)
MMSE, Mini-Mental State Examination.
CLINICAL RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Screening for eligibility
The trial consisted of 24 hospitals (22 NHS trusts) that recruited patients over the course of the trial.
The recruitment of patients took place over two time periods, the pilot study and the main study. The pilot
study recruited patients from 1 May 2004 to 4 June 2010, whereas the main study recruited patients from
1 July 2010 to 1 November 2013. A total of 2015 patients were assessed for eligibility on admission to
hospital. Of these patients, 1344 were excluded because they either did not meet the inclusion criteria
(n = 127) or they meet one or more of the exclusion criteria (n = 1217). The remaining 671 eligible patients
were asked to participate in the trial, of which 51 patients did not give consent. Thus, in total, 620 patients
were randomised into the trial. A summary of key trial management processes is detailed in Appendix 1.
Randomisation
From the screening process, 671 eligible patients were approached to participate in the trial of whom 620
gave their consent and were subsequently randomised to receive ORIF (n = 309) or CCC (n = 311). This
equates to an overall eligibility rate of 33.3% (671 out of 2015) and a consent rate of 92.4% (620 out of
671). Of the 620 randomised participants, 95 were from the pilot study. A summary of the recruitment
across the 24 sites has been detailed in Table 5. Randomisation was balanced across the treatment groups
and hospital sites, and within strata (Table 6).
Treatments received
Of the 620 randomised participants, 41 (6.6%) participants did not receive their allocated treatment (data
shown in Table 7). Failure to receive allocated treatment was significantly greater (p < 0.001) in the CCC
arm (34/620, 5.5%), than in the ORIF arm (7/620, 1.1%). Of the 34 participants in the CCC group who
did not receive their allocated treatment at their primary theatre procedure, five received a traditional
plaster cast, one participant received external fixation, 17 went on to have ORIF, five did not receive
treatment at all because they withdrew prior to receiving treatment and the remaining six participants had
TABLE 5 Randomised participants summarised by treatment group and centre
Hospital
Treatment group
Total (N= 620), n (%)ORIF (N= 309), n (%) CCC (N= 311), n (%)
Addenbrooke’s Hospital 6 (1.9) 8 (2.6) 14 (2.3)
Darlington Memorial Hospital 2 (0.7) 2 (0.6) 4 (0.6)
Derriford Hospital 8 (2.6) 9 (2.9) 17 (2.7)
Frenchay Hospital 21 (6.8) 20 (6.4) 41 (6.6)
Great Western Hospital 12 (3.9) 10 (3.2) 22 (3.6)
Ipswich Hospital 12 (3.9) 11 (3.5) 23 (3.7)
John Radcliffe Hospital 69 (22.3) 68 (22.0) 137 (22.1)
Leeds General Infirmary 7 (2.3) 9 (2.9) 16 (2.6)
Leicester Royal Infirmary 22 (7.1) 24 (7.7) 46 (7.4)
Morriston Hospital 11 (3.6) 11 (3.5) 22 (3.6)
Musgrove Park Hospital 15 (4.8) 14 (4.5) 29 (4.7)
Newham University Hospital 0 1 (0.3) 1 (0.2)
Norfolk and Norwich University Hospital 21 (6.8) 20 (6.4) 41 (6.6)
North Tyneside General Hospital 7 (2.3) 7 (2.3) 14 (2.3)
Poole Hospital 8 (2.6) 9 (2.9) 17 (2.7)
Royal Berkshire Hospital 16 (5.2) 16 (5.1) 32 (5.2)
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TABLE 5 Randomised participants summarised by treatment group and centre (continued )
Hospital
Treatment group
Total (N= 620), n (%)ORIF (N= 309), n (%) CCC (N= 311), n (%)
Royal Victoria Infirmary 15 (4.8) 15 (4.8) 30 (4.8)
Southport and Ormskirk Hospitals 4 (1.3) 3 (1.0) 7 (1.1)
Torbay Hospital 14 (4.5) 13 (4.2) 27 (4.4)
University Hospital, Coventry 15 (4.8) 15 (4.8) 30 (4.8)
University Hospital of North Durham 3 (1.0) 4 (1.3) 7 (1.1)
North Staffordshire Royal Infirmary 2 (0.7) 1 (0.3) 3 (0.5)
Wansbeck General Hospital 6 (1.9) 9 (2.9) 15 (2.4)
Yeovil District Hospital 13 (4.2) 12 (3.9) 25 (4.0)
TABLE 6 Randomised participants summarised by randomisation strata (recruiting site and fracture pattern)
Hospital
Fracture pattern A+ B Fracture pattern C
ORIF, n (%) CCC, n (%) ORIF, n (%) CCC, n (%)
Addenbrooke’s Hospital 6 (2.2) 7 (2.6) 0 1 (2.4)
Darlington Memorial Hospital 2 (0.7) 2 (0.7) 0 0
Derriford Hospital 8 (2.9) 8 (3.0) 0 1 (2.4)
Frenchay Hospital 20 (7.4) 19 (7.0) 1 (2.7) 1 (2.4)
Great Western Hospital 10 (3.7) 9 (3.3) 2 (5.4) 1 (2.4)
Ipswich Hospital 11 (4.1) 10 (3.7) 1 (2.7) 1 (2.4)
John Radcliffe Hospital 64 (23.5) 60 (22.3) 5 (13.6) 8 (19.5)
Leeds General Infirmary 6 (2.2) 7 (2.6) 1 (2.7) 2 (5.0)
Leicester Royal Infirmary 19 (7.0) 20 (7.4) 3 (8.1) 4 (9.8)
Morriston Hospital 9 (3.3) 10 (3.7) 2 (5.4) 1 (2.4)
Musgrove Park Hospital 12 (4.4) 12 (4.4) 3 (8.1) 2 (5.0)
Newham University Hospital 0 1 (0.4) 0 0
Norfolk and Norwich University Hospital 18 (6.6) 18 (6.7) 3 (8.1) 2 (5.0)
North Tyneside General Hospital 6 (2.2) 6 (2.2) 1 (2.7) 1 (2.4)
Poole Hospital 6 (2.2) 7 (2.6) 2 (5.4) 2 (5.0)
Royal Berkshire Hospital 15 (5.5) 15 (5.6) 1 (2.7) 1 (2.4)
Royal Victoria Infirmary 13 (4.8) 12 (4.4) 2 (5.4) 3 (7.3)
Southport and Ormskirk Hospitals 2 (0.7) 2 (0.7) 2 (5.4) 1 (2.4)
Torbay Hospital 11 (4.1) 10 (3.7) 3 (8.1) 3 (7.3)
University Hospital, Coventry 12 (4.4) 12 (4.4) 3 (8.1) 3 (7.3)
University Hospital of North Durham 3 (1.1) 3 (1.1) 0 1 (2.4)
North Staffordshire Royal Infirmary 2 (0.7) 1 (0.4) 0 0
Wansbeck General Hospital 6 (2.2) 8 (3.0) 0 1 (2.4)
Yeovil District Hospital 11 (4.1) 11 (4.1) 2 (5.4) 1 (2.4)
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‘other’ treatment. Of the seven participants in the ORIF group who did not received their allocated
treatment at their primary theatre procedure, four participants received CCC and the remaining three
received ‘other’. The reasons why participants did not receive allocated treatment are shown in Table 8.
The remainder of participants received their treatment per protocol, and this included 13 out of 298
(4.4%) participants who received a temporary treatment prior to ORIF, and 2 out of 275 (0.7%) prior to
CCC. After starting treatment with the allocated CCC intervention, later loss of fracture reduction resulted
in conversion to internal fixation in 52 out of 275 (18.9%) and remanipulation and CCC applied in theatre
10 out of 275 (3.6%), which were allowable events in the study protocol.
Withdrawals
Tables 9 and 10 provide summaries of those participants that withdrew or were withdrawn from the trial
by the surgeon caring for them. In total, 15 out of 620 (2.4%) participants withdrew from the trial: seven
from the ORIF group and eight from the CCC group. Five of the participants withdrew after randomisation
but before initial hospital discharge, four withdrew after initial discharge but before the 6-week follow-up
and six withdrew after the 6-week follow-up but before the 6-month follow-up. The majority of
withdrawals were requested by the participant themselves. There was no evidence of an association
between the withdrawal request and treatment group (p > 0.05).
Follow-up
A summary of the follow-up rates is presented in Tables 11 and 12. At 6-week follow-up, 608 out of 620
(98.1%) participants completed their assessment, and at 6-month follow-up 593 out of 620 (95.6%)
participants completed their assessment (as shown in Table 11). The majority of the assessments were
completed in hospital, with a small proportion of participants completing their assessment at home or over
the telephone (see Table 12). Data collected at each of the follow-up time points were well completed. For
participants who provided follow-up data, < 1% of the primary outcome data and secondary outcome data
were missing at the item level.
TABLE 7 Participants who did not receive allocated treatment summarised by treatment group
Treatment received if allocated
treatment not received
Treatment group
Total (N= 41),
n (%)
ORIF
(N= 7), n (%)
CCC
(N= 34), n (%)
Traditional plaster cast 0 5/34 (14.7) 5/41 (12.2)
External fixation 0 1/34 (2.9) 1/41 (2.4)
Retrograde nail 0 0 0
ORIF 0 17/34 (50.0) 17/41 (41.5)
CCC 4/7 (57.1) 0 4/41 (9.8)
Other 3/7 (42.9) 6/34 (17.7) 9/41 (21.9)
l Below-knee plaster and manipulation 1 0 1
l CCC in plaster room/clinic/warda 1 4 4
l CCC applied without anaesthetica – 1 1
l Weight-bearing cast 0 1 1
l MUA and traditional cast applied in clinic 1 0 1
Missingb 0 5/34 (14.7) 5/41 (12.2)
MUA, manipulation under anaesthetic.
a Not defined as true CCC treatment as initial application not done in theatre under anaesthetic.
b These five participants did not receive their allocated intervention because they withdrew prior to receiving their primary
theatre procedure.
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TABLE 8 Reasons participants did not receive allocated treatment summarised by treatment group
Reason did not receive
allocated treatment
ORIF, number
of reasons (%)
CCC, number
of reasons (%)
Total, number
of reasons (%)
Reason why ORIF not received if patient allocated to ORIF
Ankle too swollen for surgery 0
Poor skin condition for surgery 3/9 (33.3)
Fracture blisters 2/9 (22.2)
Poor quality or fragmented bone 0
Other 4/9 (44.5)
After allocation surgeon felt suitable
for conservative management
1
MRSA positive on routine screening 2
Patient refused to go to theatre 1
Missing 0
Reason why CCC not received if patient allocated to CCC
Ankle too swollen for surgery 5/38 (13.2)
Fracture proved irreducible by
closed manipulation
10/38 (26.3)
Unable to maintain/retain reduction 4/38 (10.5)
Other 14/38 (36.8)
Blisters 4
Concern regarding adherence to
non-weight-bearing
1
Consultant trained in CCC not
available
1
Deemed not clinically necessary to
subject patient to anaesthesia
1
Fracture did not need to be reduced 1
Fracture deemed stable 1
Not fit for anaesthetic 1
Soft-tissue damage 1
Did not follow CCC protocol 3
Missinga 5/38 (13.2)
MRSA, meticillin-resistant Staphylococcus aureus.
a These five participants did not receive their allocated intervention because they withdrew prior to receiving their primary
theatre procedure.
Note
There were multiple reasons why some participants did not receive allocated treatment and, therefore, totals in this table
are greater than the total number of participants.
TABLE 9 Timing of withdrawal summarised by treatment group
Withdrawals
Treatment group
Total, nORIF, n (%) CCC, n (%)
After randomisation, but before initial hospital discharge 0 5 (62.5) 5
After initial hospital discharge, but before 6 weeks’ follow-up 3 (42.9) 1 (12.5) 4
After 6 weeks’ follow-up, but before 6 months’ follow-up 4 (57.1) 2 (25.0) 6
Missing 0 0 0
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TABLE 10 Withdrawal details summarised by treatment group
Withdrawal details
Treatment group
Total,
n (%) p-valueORIF, n (%) CCC, n (%)
Patient asked to withdraw from trial
Yes 6 (85.7) 5 (62.5) 11 (73.3) 0.569
No 1 (14.3) 3 (37.5) 4 (26.7)
Missing 0 0 0
Surgeon caring for patient requested for patient to be withdrawn
Yes 1 (14.3) 3 (37.5) 4 (26.7) 0.569
No 6 (85.7) 5 (62.5) 11 (73.3)
Missing 0 0 0
Patient level of withdrawal
Not stated 5 (83.3) 4 (80.0) 9 (81.8) 0.569
No objection to study using data collected up to withdrawal 1 (16.7) 1 (20.0) 2 (18.2)
No objection to tracking overall health status via official databases
(no patient contact)
0 0 0
Objects to study using data collected up to withdrawal 0 0 0
Objects to study tracking health status via official databases
(no patient contact)
0 0 0
Missing 0 0 0
TABLE 11 Follow-up rates summarised by treatment group
Follow-up time point
Treatment group
Total (N= 620), n (%)
ORIF
(N= 309), n (%)
CCC
(N= 311), n (%)
Completed the 6-week follow-up assessment 305 (98.7) 303 (97.4) 608 (98.1)
Completed the 6-month follow-up assessment 298 (96.4) 295 (94.9) 593 (95.6)
TABLE 12 Location follow-up was completed by time point
Location follow-up completed 6 weeks (N= 608), n (%) 6 months (N= 593), n (%)
Completed assessment (in hospital) 588 (96.7) 572 (96.5)
Completed assessment (at home) 2 (0.3) 6 (1.0)
Completed assessment (over telephone) 18 (3.0) 15 (2.5)
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Baseline data
The baseline demographic and clinical characteristics of all randomised participants have been summarised
in Tables 13 and 14. The randomised participants were, on average, around 70 years old and nearly 74%
of them were female. Both groups reported similar OMASs (before injury), SF-12 mental component
summary scores, SF-12 physical component summary scores and EQ-5D scores at baseline. The baseline
EQ-5D score and EQ-5D visual analogue scale (VAS) score for the ‘day before injury’ and on the ‘day of
assessment’ clearly suggests that the participants’ quality of life deteriorated as a result of their ankle
fracture. Around 30% of all participants suffered from allergies. Most participants had either never smoked
(50.7%) or were ex-smokers (40.1%). The comorbidities reported by the recruited sample are presented in
Table 15. The social circumstances of all randomised participants have been summarised in Table 16.
The vast majority of patients (96.9%) were admitted from their own home, most of whom were living
either alone or with someone and did not use walking aids.
Numbers analysed
All of the results from the primary per-protocol analyses are presented from here onwards using the
per-protocol sample. The ITT analyses displayed similar results and thus are not presented in this chapter
(apart from the analysis of the primary outcome). The results of the ITT analyses can be found elsewhere
(see Appendix 2) where the tables have been assigned the same numbering as those presented in
this chapter for ease of reference. The per-protocol analyses of the 6-week data comprised data from
TABLE 13 Baseline demographic and clinical characteristics of all randomised participants summarised by
treatment group
Characteristic
Treatment group
Total (N= 620)ORIF (N= 309) CCC (N= 311)
Age (years)
Mean 69.8 71.4 70.6
n 309 311 620
SD 6.9 7.6 7.3
Median 69.0 70 70
Minimum 60 60 60
Maximum 89 96 96
Missing 0 0 0
Sex
Male, n (%) 82 (26.5) 78 (25.1) 160 (25.8)
Female, n (%) 227 (73.5) 233 (74.9) 460 (74.2)
Missing, n (%) 0 0 0
Ankle fracture classification
Trans-/infrasyndesmotic, n (%) 272 (88.0) 270 (86.8) 542 (87.4)
Infrasyndesmotic, n (%) 37 (12.0) 41 (13.2) 78 (12.6)
Missing 0 0 0
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TABLE 13 Baseline demographic and clinical characteristics of all randomised participants summarised by treatment
group (continued )
Characteristic
Treatment group
Total (N= 620)ORIF (N= 309) CCC (N= 311)
OMAS (pre injury)
Mean 89.8 87.7 88.7
n 309 309 618
SD 17.0 17.7 17.4
Median 100 95 100
Minimum 10 20 10
Maximum 100 100 100
Missing 0 0 0
SF-12 mental component summary score (pre injury)
Mean 53.7 54.5 54.1
n 307 309 616
SD 8.1 7.5 7.8
Median 56.5 56.7 56.6
Minimum 14.0 19.2 14.0
Maximum 66.3 67.7 67.7
Missing 2 0 2
SF-12 physical component summary score (pre injury)
Mean 51.2 49.6 50.4
n 307 309 616
SD 8.8 10.3 9.6
Median 54.2 53.8 54.1
Minimum 19.3 16.8 16.8
Maximum 67.6 64.7 67.6
Missing 2 0 2
OMAS pain (pre injury)
None, n (%) 258 (87.8) 234 (85.7) 492 (86.8)
While walking on uneven surface, n (%) 20 (6.8) 25 (9.1) 45 (7.9)
While walking on even surface outdoors, n (%) 9 (3.1) 4 (1.5) 13 (2.3)
While walking indoors, n (%) 3 (1.0) 4 (1.5) 7 (1.2)
Constant and severe, n (%) 4 (1.3) 6 (2.2) 10 (1.8)
Missing, n (%) 0 0 0
EQ-5D mobility score (day before injury)
Level 1, n (%) 237 (76.7) 205 (66.3) 442 (71.5)
Level 2, n (%) 41 (13.3) 74 (24.0) 115 (18.6)
Level 3, n (%) 0 0 0
Missing, n (%) 31 (10.0) 30 (9.7) 61 (9.9)
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TABLE 13 Baseline demographic and clinical characteristics of all randomised participants summarised by treatment
group (continued )
Characteristic
Treatment group
Total (N= 620)ORIF (N= 309) CCC (N= 311)
EQ-5D self-care score (day before injury)
Level 1, n (%) 264 (85.4) 260 (84.1) 524 (84.8)
Level 2, n (%) 14 (4.5) 18 (5.8) 32 (5.2)
Level 3, n (%) 0 1 (0.3) 1 (0.1)
Missing, n (%) 31 (10.1) 30 (9.7) 61 (9.9)
EQ-5D usual activities score (day before injury)
Level 1, n (%) 237 (76.7) 236 (76.4) 473 (76.5)
Level 2, n (%) 40 (12.9) 39 (12.6) 79 (12.8)
Level 3, n (%) 1 (0.3) 4 (1.3) 5 (0.8)
Missing, n (%) 31 (10.1) 30 (9.7) 61 (9.9)
EQ-5D pain/discomfort score (day before injury)
Level 1, n (%) 219 (70.9) 196 (63.4) 415 (67.1)
Level 2, n (%) 56 (18.1) 78 (25.3) 134 (21.7)
Level 3, n (%) 3 (1.0) 5 (1.6) 8 (1.3)
Missing, n (%) 31 (10.0) 30 (9.7) 61 (9.9)
EQ-5D anxiety/depression score (day before injury)
Level 1, n (%) 239 (77.4) 247 (79.9) 486 (78.6)
Level 2, n (%) 38 (12.3) 30 (9.7) 68 (11.0)
Level 3, n (%) 1 (0.3) 2 (0.7) 3 (0.5)
Missing, n (%) 31 (10.0) 30 (9.7) 61 (9.9)
EQ-5D score (day before injury)
Mean 0.91 0.87 0.89
n 278 279 557
SD 0.2 0.2 0.2
Median 1 1 1
Minimum –0.02 –0.03 –0.03
Maximum 1 1 1
Missing 31 30 61
EQ-5D VAS score (day before injury)
Mean 83.1 81.4 82.3
n 278 279 557
SD 15.1 16.3 15.7
Median 89.5 85.0 85.0
Minimum 20 20 20
Maximum 100 100 100
Missing 31 30 61
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TABLE 13 Baseline demographic and clinical characteristics of all randomised participants summarised by treatment
group (continued )
Characteristic
Treatment group
Total (N= 620)ORIF (N= 309) CCC (N= 311)
EQ-5D mobility score (on day of assessment)
Level 1, n (%) 4 (1.3) 3 (1.0) 7 (1.1)
Level 2, n (%) 47 (15.2) 60 (19.4) 107 (17.3)
Level 3, n (%) 209 (67.6) 199 (64.4) 408 (66.0)
Missing, n (%) 49 (15.9) 47 (15.2) 96 (15.6)
EQ-5D self-care score (on day of assessment)
Level 1, n (%) 56 (18.1) 53 (17.2) 109 (17.6)
Level 2, n (%) 162 (52.4) 173 (56.0) 335 (54.2)
Level 3, n (%) 42 (13.6) 36 (11.6) 78 (12.6)
Missing, n (%) 49 (15.9) 47 (15.2) 96 (15.5)
EQ-5D usual activities score (on day of assessment)
Level 1, n (%) 9 (2.9) 9 (2.9) 18 (2.9)
Level 2, n (%) 27 (8.7) 32 (10.4) 59 (9.6)
Level 3, n (%) 224 (72.5) 221 (71.5) 445 (72.0)
Missing, n (%) 49 (15.9) 47 (15.2) 96 (15.5)
EQ-5D pain/discomfort score (on day of assessment)
Level 1, n (%) 28 (9.0) 33 (10.7) 61 (9.9)
Level 2, n (%) 202 (65.4) 202 (65.4) 404 (65.4)
Level 3, n (%) 30 (9.7) 27 (8.7) 57 (9.2)
Missing, n (%) 49 (15.9) 47 (15.2) 96 (15.5)
EQ-5D anxiety/depression score (on day of assessment)
Level 1, n (%) 133 (43.0) 152 (49.2) 285 (46.1)
Level 2, n (%) 119 (38.5) 100 (32.4) 219 (35.5)
Level 3, n (%) 8 (2.6) 10 (3.2) 18 (2.9)
Missing, n (%) 49 (15.9) 47 (15.2) 96 (15.5)
EQ-5D score (on day of assessment)
Mean 0.04 0.07 0.05
n 260 262 522
SD 0.3 0.3 0.3
Median 0.02 0.02 0.02
Minimum –0.59 –0.59 –0.59
Maximum 1 1 1
Missing 49 47 96
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TABLE 13 Baseline demographic and clinical characteristics of all randomised participants summarised by treatment
group (continued )
Characteristic
Treatment group
Total (N= 620)ORIF (N= 309) CCC (N= 311)
EQ-5D VAS score (on day of assessment)
Mean 57.2 58.6 57.9
n 259 262 521
SD 23.1 22.2 22.6
Median 52.0 60.0 58.0
Minimum 0 2 0
Maximum 100 100 100
Missing 50 47 97
Mini-Mental State Examination score (on day of assessment)
Mean 28.2 27.9 28.0
n 277 280 557
SD 2.1 2.3 2.2
Median 29 29 29
Minimum 17 17 17
Maximum 30 30 30
Missing 32 31 63
TABLE 14 General health summarised by treatment group
Health status
Treatment group
TotalORIF CCC
Allergies
Yes, n (%) 88 (28.5) 90 (29.1) 178 (28.8)
No, n (%) 221 (71.5) 219 (70.9) 440 (71.2)
Missing, n (%) 0 0 0
Smoking
Yes, n (%) 25 (8.1) 32 (10.4) 57 (9.2)
Never, n (%) 151 (48.9) 162 (52.4) 313 (50.7)
Ex-smoker, n (%) 133 (43.0) 115 (37.2) 248 (40.1)
Missing, n (%) 0 0 0
If ex-smoker, how many years since stopping?
Mean 24.2 26.4 25.2
n 133 115 248
SD 14.8 15.9 15.3
Median 25.0 28.0 25.0
Minimum 0 0 0
Maximum 60 70 70
Missing 0 0 0
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TABLE 14 General health summarised by treatment group (continued )
Health status
Treatment group
TotalORIF CCC
If yes or ex-smoker, how many smoked on average per day?
Mean 16.0 14.7 15.4
n 155 146 301
SD 12.0 10.2 11.1
Median 15.0 15.0 15.0
Minimum 1 1 1
Maximum 80 60 80
Missing 3 1 4
If yes or ex-smoker, total number of years as a smoker?
Mean 25.1 25.9 25.5
n 133 129 262
SD 14.9 16.9 15.9
Median 25.0 20.0 24.0
Minimum 1 0 0
Maximum 60 65 65
Missing 25 18 43
Number of units of alcohol in an average week
Mean 7.4 6.3 6.8
n 308 306 614
SD 10.2 9.0 9.6
Median 4.0 2.0 2.0
Minimum 0 0 0
Maximum 60 50 60
Missing 1 3 4
TABLE 15 Comorbidities reported by the recruited sample summarised by treatment group
Comorbidity
Treatment group
Total, n (%)ORIF, n (%) CCC, n (%)
Heart disease 38 (12.3) 44 (14.2) 82 (13.3)
Hypertension 126 (40.8) 140 (45.3) 266 (43.0)
Asthma/COPD 46 (14.9) 39 (12.6) 85 (13.8)
Diabetes mellitus 31 (10.0) 26 (8.4) 57 (9.2)
Parkinson’s disease 0 0 0
Epilepsy 4 (1.3) 5 (1.6) 9 (1.5)
Renal disease 5 (1.6) 7 (2.3) 12 (1.9)
Liver disease 2 (0.7) 4 (1.3) 6 (1.0)
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TABLE 15 Comorbidities reported by the recruited sample summarised by treatment group (continued )
Comorbidity
Treatment group
Total, n (%)ORIF, n (%) CCC, n (%)
CVA/TIA 14 (4.5) 21 (6.8) 35 (5.7)
Peptic ulcer 5 (1.6) 13 (4.2) 18 (2.9)
Malignancy 37 (12.0) 36 (11.7) 73 (11.8)
DVT/PE 10 (3.2) 19 (6.2) 29 (4.7)
Osteoarthritis 84 (27.2) 100 (32.4) 184 (29.8)
Rheumatoid arthritis 12 (3.9) 14 (4.5) 26 (4.2)
Depression 35 (11.3) 38 (12.3) 73 (11.8)
Dementia 1 (0.3) 0 1 (0.2)
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DVT, deep-vein thrombosis; PE, pulmonary
embolism; TIA, transient ischaemic attack.
TABLE 16 Social circumstances of all randomised participants summarised by treatment group
Social circumstance
Treatment group
Total, n (%)ORIF, n (%) CCC, n (%)
Admitted from
Own home 302 (97.7) 297 (96.0) 599 (96.9)
Warden accommodation 4 (1.3) 4 (1.3) 8 (1.3)
Residential home 0 0 0
Nursing home 0 0 0
Rehabilitation 0 0 0
Acute hospital 0 2 (0.7) 2 (0.3)
Community hospital 0 2 (0.7) 2 (0.3)
Temporary residence 3 (1.0) 4 (1.3) 7 (1.1)
Missing 0 0 0
Home support
Lives alone 98 (31.7) 99 (32.0) 197 (31.9)
Lives with someone 206 (66.7) 209 (67.6) 415 (67.2)
Lives with carers 1 (0.3) 0 1 (0.2)
Home care package 4 (1.3) 1 (0.3) 5 (0.8)
Institution care 0 0 0
Missing 0 0 0
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573 participants (n = 298 for ORIF and n = 275 for CCC) and the 6-month analyses comprised data from
558 participants (n = 291 for ORIF and n = 267 for CCC). The ITT analyses included all participants that
provided follow-up assessment data. In total, 608 participants were included in the ITT analyses at the
6-week time point (n = 305 for ORIF and n = 303 for CCC) and 593 were included in the analyses at the
6-month time point (n = 298 for ORIF and n = 295 for CCC). In both the per-protocol analyses and the ITT
analyses, it was assumed that the participants received the treatment to which they were initially allocated.
The quality of the primary and secondary outcomes data for both the per-protocol analyses and ITT
analyses have been presented in Tables 17 and 18, respectively.
Per-protocol analyses results
Primary outcome measure (per protocol)
Table 19 presents the unadjusted and adjusted per-protocol analyses for the OMASs at 6 weeks and
6 months. The 95% CIs for the difference between the two treatment groups at both 6 weeks
and 6 months lie totally within the equivalence margin of ± 6 points. Therefore, there is evidence to
suggest that the two treatments are equivalent. In particular, at 6 months (the primary end point), the
mean treatment effect from the adjusted analyses was estimated to be –0.65 (95% CI –3.98 to 2.68)
which corresponds to a standardised effect size of –0.04 (95% CI –0.23 to 0.15). Figure 8 clearly illustrates
this result in which the unadjusted and adjusted 95% CIs at 6 months can be seen to lie totally within the
equivalence margin. The results of the ITT analyses of the primary outcome also provided evidence that
TABLE 16 Social circumstances of all randomised participants summarised by treatment group (continued )
Social circumstance
Treatment group
Total, n (%)ORIF, n (%) CCC, n (%)
Usual walking aids
None 271 (87.7) 258 (83.5) 529 (85.6)
One stick 28 (9.1) 36 (11.7) 64 (10.4)
Two sticks 4 (1.3) 3 (1.0) 7 (1.1)
Frame/rollator 6 (1.9) 9 (2.9) 15 (2.4)
Wheelchair 0 3 (1.0) 3 (0.5)
Missing 0 0 0
Using appropriate aid, how far can you walk?
About house 6 (1.9) 14 (4.5) 20 (3.2)
< 100m 14 (4.5) 24 (7.8) 38 (6.2)
< 0.5 mile 28 (9.1) 34 (11.0) 62 (10.0)
> 0.5 mile 261 (84.5) 237 (76.7) 498 (80.6)
Missing 0 0 0
What limits your mobility?
Nothing 200 (64.7) 175 (56.6) 375 (60.7)
Pain 28 (9.1) 40 (12.9) 68 (11.0)
Breathlessness 28 (9.1) 32 (10.4) 60 (9.7)
Other 53 (17.1) 62 (20.1) 115 (18.6)
Missing 0 0 0
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
37
TABLE 17 Summary of the number (%) of participants with complete data for the per-protocol analyses
Outcome 6 weeks (N= 573), n (%) 6 months (N= 558), n (%)
Primary outcome
OMAS 570 (99.5) 558 (100.0)
Secondary outcomes
SF-12 mental component summary score 571 (99.7) 558 (100.0)
SF-12 physical component summary score 571 (99.7) 558 (100.0)
EQ-5D score 520 (90.7) 505 (90.5)
EQ-5D VAS score 519 (90.6) 506 (90.7)
Timed up and go test (6 months) 518 (92.8)
Angle of injured ankle dorsiflexion (°) 545 (95.1) 538 (96.4)
Angle of injured ankle plantar flexion (°) 545 (95.1) 538 (96.4)
Eversion of injured ankle 529 (92.3) 533 (95.5)
Inversion of injured ankle 539 (94.1) 538 (96.4)
OMAS pain score 571 (99.7) 558 (100.0)
EQ-5D pain score 520 (90.8) 506 (90.7)
Patient satisfaction 487 (85.0) 472 (84.6)
TABLE 18 Summary of the number (%) of participants with complete data for the ITT analyses
Outcome 6 weeks (N= 608), n (%) 6 months (N= 593), n (%)
Primary outcome
OMAS 605 (99.5) 592 (99.8)
Secondary outcomes
SF-12 mental component summary score 606 (99.7) 592 (99.8)
SF-12 physical component summary score 606 (99.7) 592 (99.8)
EQ-5D score 550 (90.5) 535 (90.2)
EQ-5D VAS score 550 (90.5) 536 (90.4)
Timed up and go test (6 months) 550 (92.7)
Angle of injured ankle dorsiflexion (°) 578 (95.1) 571 (96.3)
Angle of injured ankle plantar flexion (°) 578 (95.1) 571 (96.3)
Eversion of injured ankle 562 (92.4) 566 (95.4)
Inversion of injured ankle 572 (94.1) 571 (96.3)
OMAS pain score 606 (99.7) 592 (99.8)
EQ-5D pain score 550 (90.5) 536 (90.4)
Patient satisfaction 518 (85.2) 502 (84.7)
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TABLE 19 Primary outcome (OMAS) at 6 weeks and 6 months, summarised by treatment group (per protocol)
OMAS
Treatment group
Total Unadjusted statistics (95% CI) Adjusted statistics (95% CI)aORIF CCC
6 weeks
Mean 37.9 38.1 38.0 0.20 (–2.31 to 2.71) 0.26 (–2.20 to 2.72)
n 297 273 570
SD 14.7 15.8 15.2
Median 35 40 35
Minimum 0 0 0
Maximum 95 90 95
Missing 1 2 3
6 months
Mean 66.0 64.5 65.3 –1.57 (–5.19 to 2.05) –0.65 (–3.98 to 2.68)
n 291 267 558
SD 21.1 22.4 21.8
Median 70 70 70
Minimum 0 5 0
Maximum 100 100 100
Missing 0 0 0
a Treatment effect estimate using linear regression model adjusting for age, sex, hospital, baseline OMAS and
AO classification.
Note
A negative value implies that the treatment effect is in favour of ORIF.
0–1
–1.57 (– 5.19 to 2.05)
– 0.65 (– 3.98 to 2.68)
– 2– 3– 4– 5– 6– 7
Unadjusted
Adjusted
1 2 3 4 5 6 7
Mean treatment difference (95% CI)
FIGURE 8 Observed treatment difference plot at 6 months with 95% CIs (per protocol).
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the treatments are equivalent, as shown in Table 20 and Figure 9. A plot of the OMASs over time (from
pre-injury to 6-month follow-up) has been presented in Figure 10. From this plot it is evident that the ankle
functionality of participants in both groups follows a similar pattern over time. The same pattern of
recovery was also evident in the ITT sample.
TABLE 20 Primary outcome (OMAS) at 6 weeks and 6 months, summarised by treatment group (ITT)
OMAS
Treatment group
Total Unadjusted statistics (95% CI) Adjusted statistics (95% CI)aORIF CCC
6 weeks
Mean 38.0 38.0 38.0 0.03 (–2.41 to 2.47) 0.12 (–2.56 to 2.79)
n 304 301 605
SD 14.6 16.0 15.29
Median 35.0 40.0 35.0
Minimum 0 0 0
Maximum 95 90 95
Missing 1 2 3
6 months
Mean 66.0 64.7 65.3 –1.33 (–4.85 to 2.19) –0.17 (–3.36 to 3.02)
n 298 294 592
SD 21.3 22.4 21.81
Median 70.0 70.0 70.0
Minimum 0 5 0
Maximum 100 100 100
Missing 0 1 1
a Treatment effect estimate using linear regression model adjusting for age, sex, hospital, baseline OMAS and
AO classification.
Note
A negative value implies that the treatment effect is in favour of ORIF.
0–1
–1.33 (– 4.85 to 2.19)
– 0.17 (– 3.36 to 3.02)
– 2– 3– 4– 5– 6– 7
Unadjusted
Adjusted
1 2 3 4 5 6 7
Mean treatment difference (95% CI)
FIGURE 9 Observed treatment difference plot at 6 months with 95% CIs (ITT).
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Secondary outcome measures (per protocol)
Short Form questionnaire-12 items mental component summary subscale
(per protocol)
The analyses of the SF-12 mental component summary subscale scores have been presented in Table 21.
There is no evidence of a statistically significant difference between the two treatment groups at either
6 weeks or 6 months. Overall, the improvement from 6 weeks to 6 months is small. The difference between
ORIF and CCC, on average, was estimated to be 0.06 (95% CI –1.64 to 1.75) at 6 weeks and –0.21
(95% CI –1.71 to 1.28) at 6 months. Participants in both groups followed a similar pattern of recovery over
time, with their mental function at 6 months being similar to what it was pre-injury (Figure 11).
Short Form questionnaire-12 items physical component summary subscale
(per protocol)
The analyses of the SF-12 physical subscale have been presented in Table 21. There is no evidence of a
statistically significant difference between the two arms at either 6 weeks or 6 months. Overall, the SF-12
physical score improved from a mean score of 33.4 at 6 weeks to a mean score of around 45.0 at
6 months. The difference between ORIF and CCC on average was estimated to be 0.24 (95% CI –0.82 to
1.31) at 6 weeks and –0.83 (95% CI –2.39 to 0.74) at 6 months. Participants in both groups followed a
similar pattern of recovery over time, with their physical function at 6 months being slightly less than what it
was pre-injury (Figure 12).
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FIGURE 10 Plot of mean scores and 95% CIs for the OMASs over time (per protocol).
TABLE 21 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month assessments (per protocol)
Outcome
Treatment group
Unadjusted statistics (95% CI);
p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
SF-12 mental component summary score
6 weeks
Mean 48.3 48.6 0.35 (–1.45 to 2.15); 0.700 0.06 (–1.64 to 1.75); 0.946
n 297 274
SD 11.3 10.6
Median 48.9 49.5
Minimum 16.5 19.2
Maximum 70.2 68.3
Missing 1 1
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TABLE 21 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month assessments (per protocol)
(continued )
Outcome
Treatment group
Unadjusted statistics (95% CI);
p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
6 months
Mean 52.1 52.2 0.10 (–1.57 to 1.78); 0.902 –0.21 (–1.71 to 1.28); 0.781
n 291 267
SD 10.3 9.7
Median 55.4 55.7
Minimum 18.9 19.9
Maximum 66.9 68.4
Missing 0 0
SF-12 physical component summary score
6 weeks
Mean 33.3 33.4 0.07 (–1.02 to 1.17); 0.895 0.24 (–0.82 to 1.31); 0.654
n 297 274
SD 6.9 6.5
Median 32.4 32.7
Minimum 18.4 18.3
Maximum 57.1 54.9
Missing 1 1
6 months
Mean 45.6 44.0 –1.56 (–3.28 to 0.16); 0.076 –0.83 (–2.39 to 0.74); 0.299
n 291 267
SD 10.0 10.7
Median 47.0 44.5
Minimum 22.1 15.6
Maximum 66.2 64.3
Missing 0 0
EQ-5D mobility score
6 weeks
Level 1, n (%) 10 (3.4) 5 (1.8) 0.316 –
Level 2, n (%) 245 (82.2) 221 (80.4)
Level 3, n (%) 17 (5.7) 22 (8.0)
Missing, n (%) 26 (8.7) 27 (9.8)
6 months
Level 1, n (%) 134 (46.1) 106 (39.7) 0.333 –
Level 2, n (%) 128 (44.0) 132 (49.4)
Level 3, n (%) 3 (1.0) 3 (1.1)
Missing, n (%) 26 (8.9) 26 (9.8)
EQ-5D self-care score
6 weeks
Level 1, n (%) 164 (55.1) 136 (49.5) 0.026 –
Level 2, n (%) 107 (35.9) 104 (37.8)
Level 3, n (%) 1 (0.3) 8 (2.9)
Missing, n (%) 26 (8.7) 27 (9.8)
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TABLE 21 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month assessments (per protocol)
(continued )
Outcome
Treatment group
Unadjusted statistics (95% CI);
p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
6 months
Level 1, n (%) 240 (82.5) 221 (82.8) 0.530 –
Level 2, n (%) 21 (7.2) 19 (7.1)
Level 3, n (%) 4 (1.4) 1 (0.4)
Missing, n (%) 26 (8.9) 26 (9.7)
EQ-5D usual activities score
6 weeks
Level 1, n (%) 10 (3.3) 10 (3.6) 0.037 –
Level 2, n (%) 150 (50.3) 109 (39.6)
Level 3, n (%) 112 (37.6) 129 (46.9)
Missing, n (%) 26 (8.8) 27 (9.9)
6 months
Level 1, n (%) 159 (54.6) 125 (46.8) 0.179 –
Level 2, n (%) 96 (33.0) 104 (39.0)
Level 3, n (%) 10 (3.4) 12 (4.5)
Missing, n (%) 26 (9.0) 26 (9.7)
EQ-5D pain/discomfort score
6 weeks
Level 1, n (%) 130 (43.6) 124 (45.1) 0.421 –
Level 2, n (%) 136 (45.6) 122 (44.4)
Level 3, n (%) 6 (2.0) 2 (0.7)
Missing, n (%) 26 (8.8) 27 (9.8)
6 months
Level 1, n (%) 118 (40.6) 105 (39.3) 0.589 –
Level 2, n (%) 139 (47.8) 132 (49.5)
Level 3, n (%) 8 (2.7) 4 (1.5)
Missing, n (%) 26 (8.9) 26 (9.7)
EQ-5D anxiety/depression score
6 weeks
Level 1, n (%) 183 (61.4) 162 (58.9) 0.084 –
Level 2, n (%) 84 (28.2) 86 (31.3)
Level 3, n (%) 5 (1.7) 0
Missing, n (%) 26 (8.7) 27 (9.8)
6 months
Level 1, n (%) 199 (68.4) 189 (70.8) 0.706 –
Level 2, n (%) 59 (20.3) 48 (18.0)
Level 3, n (%) 6 (2.1) 4 (1.5)
Missing, n (%) 27 (9.2) 26 (9.7)
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TABLE 21 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month assessments (per protocol)
(continued )
Outcome
Treatment group
Unadjusted statistics (95% CI);
p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
EQ-5D score
6 weeks
Mean 0.52 0.48 –0.04 (–0.08 to 0.002); 0.065 –0.04 (–0.08 to 0.007); 0.100
n 272 248
SD 0.3 0.2
Median 0.59 0.49
Minimum –0.48 –0.06
Maximum 1 1
Missing 26 27
6 months
Mean 0.76 0.76 –0.006 (–0.05 to 0.03); 0.754 –0.004 (–0.04 to 0.04); 0.861
n 264 241
SD 0.2 0.2
Median 0.80 0.78
Minimum –0.36 –0.07
Maximum 1 1
Missing 27 26
EQ-5D VAS score
6 weeks
Mean 72.8 72.1 –0.67 (–3.70 to 2.36); 0.663 –0.37 (–3.18 to 2.44); 0.796
n 272 247
SD 17.1 18.1
Median 75 75
Minimum 0 10
Maximum 100 100
Missing 26 28
6 months
Mean 77.5 77.3 –0.16 (–3.35 to 3.03); 0.923 –0.09 (–3.19 to 3.02); 0.956
n 265 241
SD 18.5 18.0
Median 81 80
Minimum 0 1
Maximum 100 100
Missing 26 26
Note
A negative value implies that the treatment effect is in favour of ORIF.
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European Quality of Life 5-Dimensions score (per protocol)
The analyses of the EQ-5D score have been presented in Table 21. There is no evidence of a statistically
significant difference between the two arms at both 6 weeks and 6 months. Overall, the EQ-5D score improved
from a mean score of around 0.51 at 6 weeks to a mean score of 0.76 at 6 months. The difference between
ORIF and CCC on average was estimated to be –0.04 (95% CI –0.08 to 0.007) at 6 weeks and –0.004 (95% CI
–0.04 to 0.04) at 6 months. Participants in both groups followed a similar pattern of recovery over time, with
their quality of life at 6 months being slightly less than what it was the day before their injury (Figure 13).
European Quality of Life 5-Dimensions visual analogue scale (per protocol)
The analyses of the EQ-5D VAS score have been presented in Table 21. There is no evidence of a
statistically significant difference between the two arms at both 6 weeks and 6 months. Overall, the EQ-5D
VAS score improved from a mean score of around 73.0 at 6 weeks to a mean score of around 77.0 at
6 months. The difference between ORIF and CCC on average was estimated to be –0.37 (95% CI –3.18 to
2.44) at 6 weeks and –0.09 (95% CI –3.19 to 3.02) at 6 months.
0
10
20
30
40
50
60
70
80
90
100
SF
-1
2 
m
en
ta
l s
co
re
Pre injury 6 weeks 6 months
ORIF
CCC
FIGURE 11 Plot of mean scores and 95% CIs for the SF-12 mental component summary score over time
(per protocol).
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FIGURE 12 Plot of mean scores and 95% CIs for the SF-12 physical component summary score over time
(per protocol).
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Timed up and go test (per protocol)
Tables 22 and 23 present the results of the timed up and go test undertaken at the 6-month assessment.
There is no evidence of a statistically significant difference in the median time between the two groups at
6 months. Most of the participants who undertook the test completed it in less than 5 minutes and did
not require the use of a walking aid.
Range of ankle motion (per protocol)
Table 24 presents the results of the range of ankle motion assessments at 6 weeks and 6 months. There is
evidence of a statistically significant difference of –1.4° (95% CI –2.75° to –0.08°) between the two
groups for the angle of injured ankle dorsiflexion at 6 weeks, in favour of the ORIF group. However, this
difference was not evident later on at 6-month follow-up, when the difference was estimated to be 0.16°
(95% CI –1.59° to 1.90°).
There was no evidence of a difference between the two groups for the angle of injured ankle plantar
flexion at 6 weeks with an estimated difference of –1.87° (95% CI –4.01° to 0.27°). However, there was
evidence of a statistically significant difference at 6 months suggesting that those in the CCC group have,
on average, a smaller range of motion of injured ankle plantar flexion of about –2.55° (95% CI –4.64° to
–0.46°) than in the ORIF group.
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
EQ
-5
D
 s
co
re
Day before injury 6 weeksBaseline 6 months
ORIF
CCC
FIGURE 13 Plot of mean scores and 95% CIs for the EQ-5D over time (per protocol).
TABLE 22 Timed up and go walking test at the 6-month follow-up, summarised by treatment group (per protocol)
Timed up and go test (seconds)
Treatment group
p-valueaORIF CCC
Mean 21.3 22.1 0.079
n 276 242
SD 19.2 13.9
Median 18.0 18.4
Minimum 6.8 7.8
Maximum 224.3 133
Missing 0 1
a Wilcoxon rank-sum test p-value.
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TABLE 23 Additional information from timed up and go walking test at the 6-month follow-up, summarised by
treatment group (per protocol)
Additional timed up and go test details
Treatment group
p-valueORIF, n (%) CCC, n (%)
Completed in under 5 minutes
Yes 275 (99.6) 241 (99.2) 0.602
No 1 (0.4) 2 (0.8)
Missing 0 0
Did patient use walking aid(s)?
Yes 26 (9.4) 28 (11.5) 0.394
No 207 (75.0) 174 (71.6)
Missing 43 (15.6) 41 (16.9)
Unable to complete test because . . .
Non-weight-bearing 0 0 0.123
Declined to complete test 1 (0.3) 2 (0.8)
Other physical limitation 1 (0.3) 0
Other 13 (4.5) 22 (8.2)
Not applicable 276 (94.9) 243 (91.0)
Missing 0 0
TABLE 24 Range of injured ankle motion at the 6-week and 6-month follow-up (per protocol)
Range of ankle
motion
Treatment group
Unadjusted statistics (95% CI);
p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
Angle of injured ankle dorsiflexion (°)
6 weeks
Mean 5.1 3.7 –1.42 (–2.94 to 0.10); 0.067 –1.42 (–2.75 to –0.08); 0.037
n 283 262
SD 8.6 9.5
Median 5 4
Missing 15 13
6 months
Mean 11.9 11.6 –0.31 (–2.18 to 1.57); 0.749 0.16 (–1.59 to 1.90); 0.861
n 282 256
SD 10.4 11.8
Median 10 10
Missing 9 11
continued
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TABLE 24 Range of injured ankle motion at the 6-week and 6-month follow-up (per protocol) (continued )
Range of ankle
motion
Treatment group
Unadjusted statistics (95% CI);
p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
Angle of injured ankle plantar flexion (°)
6 weeks
Mean 24.5 22.7 –1.81 (–4.02 to 0.40); 0.109 –1.87 (–4.01 to 0.27); 0.087
n 283 262
SD 13.0 13.2
Median 24 20
Missing 15 13
6 months
Mean 33.7 31.1 –2.54 (–4.81 to –0.28); 0.028 –2.55 (–4.64 to –0.46); 0.017
n 282 256
SD 13.7 13.0
Median 35 30
Missing 9 11
Eversion of injured ankle (%)
6 weeks
Mean 50.2 51.0 0.78 (–7.71 to 9.27); 0.857 0.56 (–7.97 to 9.10); 0.897
n 277 252
SD 40.5 58.1
Median 50 50
Missing 21 23
6 months
Mean 88.0 86.1 –1.89 (–13.90 to 10.11); 0.757 –1.97 (–13.83 to 9.90); 0.745
n 282 251
SD 83.1 52.6
Median 80 80
Missing 9 16
Inversion of injured ankle (%)
6 weeks
Mean 47.9 56.6 8.73 (0.82 to 16.64); 0.031 9.02 (0.98 to 17.05); 0.028
n 281 258
SD 36.6 55.7
Median 45.5 50
Missing 17 17
6 months
Mean 83.4 83.4 –0.05 (–9.37 to 9.27); 0.992 –0.27 (–9.62 to 9.08); 0.955
n 282 256
SD 64.7 41.7
Median 75 80
Missing 9 11
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There was no evidence of a statistically significant difference between the two groups for the eversion of the
injured ankle at 6 weeks and 6 months. The difference between ORIF and CCC, on average, was estimated
to be 0.56% (95% CI –7.97% to 9.10%) at 6 weeks and –1.97 (95% CI –13.83% to 9.90%) at 6 months.
There was evidence of a statistically significant difference at 6 weeks for the inversion of the injured ankle.
This result suggests that those in the CCC group have on average more percentage inversion of the
injured ankle at 6 weeks estimated to be 9.02% (95% CI 0.98% to 17.05%). However, by 6 months this
difference diminishes such that there is no evidence of a significant difference between the groups with an
estimated difference of –0.27% (95% CI –9.62% to 9.08%). The magnitude of the differences in ankle
range of motion is unlikely to be clinically important in terms of ankle function.
Pain (per protocol)
Pain was assessed in this trial, using the pain items from both the EQ-5D and the OMAS questionnaires,
at 6 weeks and 6 months. Table 25 presents a summary of the pain items by treatment group. For both the
pain items, there is no evidence of a difference in the levels of pain reported between the two groups. In
other words, the reported levels of pain are similar across both treatment groups at each of the time points.
Patient satisfaction (per protocol)
Table 26 summarises the patient satisfaction outcome measure by treatment group. There is no evidence
of difference in the reported levels of patient satisfaction between the two treatment groups, which
suggests that patient satisfaction is similar across both groups. At both 6 weeks and 6 months, around
63% of participants reported that they were ‘very satisfied’ with their treatment in both groups.
Radiological malunion and non-union (per protocol)
Table 27 presents a summary of the different types of malunion at the 6-month follow-up. Overall, around
91% (477 out of 523) had no malunion at 6 months, 4.4% (23 out of 523) had a talar shift and 3%
(16 out of 573) had a talar shift and talar tilt. Table 28 summarises radiological malunion versus no
malunion at the 6-month follow-up. There is evidence of a statistically significant association between
whether or not a participant has malunion and their treatment allocation at the 6-month follow-up
(p ≤ 0.001). There are a higher proportion of participants in the CCC group with malunion at 6 months
(15.3%) than in the ORIF group (2.9%).
Table 29 summarises the non-union data at the 6-month follow-up. There is evidence of a statistically
significant association between whether or not a participant has lateral and medial malleolus non-union
and their treatment allocation. For both lateral malleolus and medial malleolus, the radiological
assessments suggested that the fracture was not united for a higher proportion of participants in the CCC
group than in the ORIF group.
TABLE 24 Range of injured ankle motion at the 6-week and 6-month follow-up (per protocol) (continued )
Range of ankle
motion
Treatment group
Unadjusted statistics (95% CI);
p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
Started partial weight-bearing
6 weeks
Yes, n (%) 107 (35.9%) 111 (40.4%) 0.272
No, n (%) 191 (64.1%) 164 (59.6%)
Missing, n (%) 0 0
Note
A negative value implies that the treatment effect is in favour of ORIF.
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TABLE 25 Summary of the EQ-5D pain item and OMAS pain item at the 6-week and 6-month follow-up
(per protocol)
Pain outcomes
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio
(95% CI); p-valueORIF, n (%) CCC, n (%)
EQ-5D pain/discomfort item
6 weeks
No pain/discomfort 130 (43.6) 124 (45.1) 0.89 (0.63 to 1.26); 0.514 0.91 (0.64 to 1.29); 0.584
Moderate pain/discomfort 136 (45.6) 122 (44.4)
Extreme pain/discomfort 6 (2.0) 2 (0.7)
Missing 26 (8.8) 27 (9.8)
6 months
No pain/discomfort 118 (40.6) 105 (39.3) 1.01 (0.71 to 1.42); 0.969 1.03 (0.72 to 1.47); 0.889
Moderate pain/discomfort 139 (47.8) 132 (49.5)
Extreme pain/discomfort 8 (2.7) 4 (1.5)
Missing 26 (8.9) 26 (9.7)
OMAS pain item
6 weeks
None 215 (72.2) 197 (71.7) 1.04 (0.72 to 1.49); 0.845 1.11 (0.76 to 1.62); 0.583
While walking on uneven surface 27 (9.1) 19 (6.9)
While walking on even surface
outdoors
9 (3.0) 10 (3.6)
While walking indoors 37 (12.3) 33 (12.0)
Constant and severe 10 (3.4) 14 (5.1)
Missing 0 2 (0.7)
6 months
None 127 (43.6) 121 (45.3) 0.90 (0.66 to 1.23); 0.510 0.94 (0.69 to 1.29); 0.711
While walking on uneven surface 88 (30.2) 83 (31.1)
While walking on even surface
outdoors
36 (12.4) 35 (13.1)
While walking indoors 31 (10.7) 19 (7.1)
TABLE 26 Patient satisfaction at the 6-week and 6-month follow-up (per protocol)
Patient satisfaction
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio
(95% CI); p-valueORIF, n (%) CCC, n (%)
6 weeks
Very dissatisfied 15 (5.0) 12 (4.4) 0.97 (0.65 to 1.44); 0.862 0.98 (0.65 to 1.48); 0.934
Somewhat dissatisfied 6 (2.1) 9 (3.3)
Neither satisfied nor dissatisfied 8 (2.7) 10 (3.6)
Somewhat satisfied 37 (12.4) 30 (10.9)
Very satisfied 189 (63.4) 171 (62.2)
Missing 43 (14.4) 43 (15.6)
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TABLE 27 Summary of radiological malunion at the 6-month follow-up (per protocol)
Malunion typea
Treatment group
Total (N= 523), n (%)ORIF (N= 274), n (%) CCC (N= 249), n (%)
No malunion 266 (97.1) 211 (84.8) 477 (91.2)
Talar shift 3 (1.0) 20 (8.0) 23 (4.4)
Talar tilt 1 (0.4) 0 1 (0.2)
Diastasis 0 0 0
Talar shift and talar tilt 1 (0.4) 15 (6.0) 16 (3.0)
Talar shift and diastasis 1 (0.4) 0 1 (0.2)
Talar tilt and diastasis 0 1 (0.4) 1 (0.2)
Talar shift, talar tilt and diastasis 2 (0.7) 2 (0.8) 4 (0.8)
Missing 24 26 50
a Talar shift (talar subluxation of > 2 mm); talar tilt > 2°; and diastasis (tibiofibular clear space of ≥ 5mm).
TABLE 28 Summary of radiological malunion and no malunion at the 6-month follow-up (per protocol)
Radiological assessment
Treatment group
p-valueORIF (N= 274), n (%) CCC (N= 249), n (%)
No malunion 266 (97.1) 211 (84.7) < 0.001
Malunion 8 (2.9) 38 (15.3)
Missing 24 26
TABLE 26 Patient satisfaction at the 6-week and 6-month follow-up (per protocol) (continued )
Patient satisfaction
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio
(95% CI); p-valueORIF, n (%) CCC, n (%)
6 months
Very dissatisfied 10 (3.4) 15 (5.6) 1.03 (0.68 to 1.56); 0.884 1.05 (0.68 to 1.61); 0.830
Somewhat dissatisfied 6 (2.1) 5 (1.9)
Neither satisfied nor dissatisfied 13 (4.5) 8 (3.0)
Somewhat satisfied 35 (12.0) 27 (10.1)
Very satisfied 184 (63.2) 169 (63.3)
Missing 43 (14.8) 43 (16.1)
TABLE 29 Summary of radiological non-union at the 6-month follow-up (per protocol)
Radiological assessment
Treatment group
p-valueORIF (N= 274), n (%) CCC (N= 248), n (%)
Lateral malleolus
Radiologically fracture not united 0 8 (3.2) 0.002
Not injured/no issues with union identified 274 (100) 240 (96.8)
Missing 24 27
continued
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Ancillary analyses (per protocol)
Olerud–Molander Ankle Score as an ordinal outcome (per protocol)
Table 30 presents the results of the analysis when converting the OMASs into an ordinal outcome at the
6-week and 6-month follow-up. At the 6-week assessment, the majority of participants had either a ‘poor’
or a ‘fair’ outcome. By the 6-month assessment, most participants had either a ‘fair’ or a ‘good’ outcome.
Both the unadjusted and adjusted analyses suggest that there is no evidence that the outcomes differ
between both treatment groups; that is, both groups are equally likely to report a similar outcome.
Blinded assessments (per protocol)
Table 31 presents the analysis of the blinding strategy at the 6-month follow-up. In total, 448 of the
participants had their assessor complete the 6-month follow-up question that asked if the assessor thought
they knew what the actual intervention received was. James’ Blinding Index was used (range 0–1) to assess
the overall blinding success at the 6-month assessments, in which a higher score reflects better blinding.
TABLE 30 Olerud–Molander Ankle Scores analysed as an ordinal outcome at 6 weeks and 6 months (per protocol)
OMAS
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio
(95% CI); p-valueaORIF, n (%) CCC, n (%)
6 weeks
Poor (0–30%) 98 (32.9) 96 (34.9) 0.95 (0.68 to 1.32); 0.746 0.93 (0.66 to 1.31); 0.670
Fair (31–60%) 186 (62.4) 162 (58.9)
Good (61–90%) 12 (4.1) 15 (5.5)
Excellent (91–100%) 1 (0.3) 0
Missing 1 (0.3) 2 (0.7)
6 months
Poor (0–30%) 18 (6.2) 22 (8.2) 0.89 (0.65 to 1.22); 0.484 0.94 (0.67 to 1.30); 0.697
Fair (31–60%) 92 (31.6) 94 (35.3)
Good (61–90%) 159 (54.6) 120 (44.9)
Excellent (91–100%) 22 (7.6) 31 (11.6)
Missing 0 0
a Treatment effect estimate using ordinal logistic regression model adjusting for age, sex, hospital, baseline OMAS and
AO classification.
TABLE 29 Summary of radiological non-union at the 6-month follow-up (per protocol) (continued )
Radiological assessment
Treatment group
p-valueORIF (N= 274), n (%) CCC (N= 248), n (%)
Medial malleolus
Radiologically fracture not united 3 (1.1) 18 (7.3) < 0.001
Not injured/no issues with union identified 271 (98.9) 230 (92.7)
Missing 24 27
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The James’ Blinding Index was estimated to be 0.81 (95% CI 0.78 to 0.84), which suggests that there is
evidence of adequate overall blinding at 6 months.
Time-to-event analysis (per protocol)
There is no evidence of a difference in the time from randomisation to discharge between the two
treatment arms (Table 32). However, there is evidence of a statistically significant difference in the time
from randomisation to readmission between the two groups. The results of adjusted analyses suggest that
those participants in receipt of CCC had a higher hazard (risk) of being readmitted than those in receipt of
the ORIF treatment. The estimated hazard ratio was 2.17 (95% CI 1.16 to 4.04).
Process variables (per protocol)
The process data collected during the trial are summarised in Tables 33 and 34. In both treatment groups,
the average time from injury to randomisation was 2.8 days, the time from randomisation to the primary
theatre procedure was around 2.1 days and the time from injury to primary theatre procedure was around
4.9 days. There is evidence of a statistically significant difference in the time from entry into anaesthetic
room to the start time in theatre, with surgery taking around 11 minutes longer in participants undergoing
ORIF. Moreover, there is also evidence of a difference in the time from start to end of the primary theatre
procedure, with the procedure taking around 54 minutes longer on average for ORIF. Of the additional
procedures in theatre, there is significant evidence to suggest that those undergoing CCC lasted longer
(10.7 days) before requiring an additional procedure than participants undergoing ORIF (4.9 days). There is
evidence of a difference in the time from the primary theatre procedure to hospital discharge, with those
in the CCC treatment group, on average, being discharged later. Furthermore, the mean time from
hospital discharge to readmission is significantly shorter in the CCC group (45.4 days) than in the ORIF
group (63.8 days), suggesting that undergoing CCC are readmitted much sooner than those undergoing
ORIF. There is no evidence of a difference in the duration from randomisation and injury to the date the
allocated treatment was actually received.
Experience and treatment preferences of surgeons (per protocol)
In total, 558 (97.4%) participants received their allocated treatment at their primary theatre procedure
after randomisation. There were differences in experience level of the operating and supervising surgeon at
TABLE 32 Summary of unadjusted and adjusted time-to-event analyses looking at time to discharge and time to
first readmission (per protocol)
Event
Number of participants
experiencing an event,
n (%)
Unadjusted analysis Adjusted analysis
Hazard ratio
(95% CI) p-value
Hazard ratio
(95% CI) p-value
Time to discharge (days) 573 (100.0) 0.99 (0.84 to 1.17) 0.884 1.11 (0.94 to 1.32) 0.216
Time to readmission (days) 83 (14.5) 1.44 (0.88 to 2.34) 0.139 2.17 (1.16 to 4.04) 0.015
TABLE 31 Assessment of the blinding strategy at the 6-month follow-up (per protocol)
Treatment received
Blinded assessors guess
Total James’ Blinding Index (95% CI)CCC ORIF Don’t know
CCC 36 22 153 211 0.81 (0.78 to 0.84)
ORIF 11 50 176 237
Total 47 72 329 448
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TABLE 33 Process variables summarised by treatment group (per protocol)
Process variable
Treatment group
Total p-valueORIF CCC
Randomisation
Time from injury to randomisation (days)
Mean 2.8 2.8 2.8 0.978
n 298 275 573
SD 2.7 2.7 2.7
Median 2 2 2
IQR 1–3.4 1–4 1–3.4
Minimum 0 0 0
Maximum 15 17 17
Missing 0 0 0
Randomisation/theatre
Time from randomisation to theatre procedure (days)
Mean 2.2 2.0 2.1 0.455
n 298 275 573
SD 2.5 2.1 2.3
Median 1 1 1
IQR 0–3.4 0–3 0–3
Minimum 0 0 0
Maximum 17 9.4 17
Missing 0 0 0
Treatment
Time from injury to primary treatment (days)
Mean 5.0 4.8 4.9 0.436
n 298 275 573
SD 3.5 3.2 3.4
Median 4.7 4.4 4.4
IQR 2–7 2–7 2–7
Minimum 0 0 0
Maximum 19 18 19
Missing 0 0 0
Theatre
Time from entry into anaesthetic room to start time in theatre (minutes)
Mean 29.5 18.6 24.2 < 0.001
n 295 275 570
SD 14.3 10.4 13.7
Median 28 17 22
IQR 19–37 11–24 15–30
Minimum 5 0 0
Maximum 90 100 100
Missing 3 0 3
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TABLE 33 Process variables summarised by treatment group (per protocol) (continued )
Process variable
Treatment group
Total p-valueORIF CCC
Time from start to end of procedure in theatre (minutes)
Mean 80.2 25.8 54.1 < 0.001
n 296 274 570
SD 29.0 11.9 35.1
Median 79 24 44.5
IQR 63–96 20–30 24–80
Minimum 11 8 8
Maximum 211 83 211
Missing 2 1 3
Additional theatrea procedure
Time from primary procedure to additional procedure in theatre (days)
Mean 4.9 10.7 8.2 0.008
n 14 19 33
SD 2.1 11.9 9.5
Median 5 7 6
IQR 3–6 6–12.4 4–8.4
Minimum 2 1 1
Maximum 8.4 56.9 56.9
Missing 0 0 0
Time from entry into anaesthetic room to start time in theatre (minutes)
Mean 34.3 27.9 30.6 0.284
n 14 19 33
SD 12.1 19.3 16.7
Median 35.5 22 27
IQR 18 34 29
Minimum 27–45 13–47 16–45
Maximum 50 62 62
Missing 0 0 0
Time from start to end of procedure in theatre (minutes)
Mean 83.9 70.5 76.2 0.353
n 14 19 33
SD 33.8 37.3 35.9
Median 80 77 80
IQR 76–94 34–90 50–90
Minimum 36 18 18
Maximum 180 130 180
Missing 0 0 0
continued
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TABLE 33 Process variables summarised by treatment group (per protocol) (continued )
Process variable
Treatment group
Total p-valueORIF CCC
Theatre/hospital discharge
Time from theatre to hospital discharge (days)
Mean 5.2 5.7 5.4 0.032
n 298 275 573
SD 5.8 8.4 7.2
Median 3 3 3
IQR 2–6.4 1–7 1–6.4
Minimum 0 0 0
Maximum 39.9 69.9 69.9
Missing 0 0 0
Hospital discharge/hospital readmissiona
Time from hospital discharge to readmission (days)
Mean 63.8 45.4 51.3 0.036
n 31 65 96
SD 54.5 50.9 52.5
Median 48.9 14 23.7
IQR 17–105.3 9–62.9 10–92.8
Minimum 1 4 1
Maximum 161.2 174.6 174.6
Missing 0 0 0
IQR, interquartile ratio.
a Here ‘n’ is the number of additional theatre procedures/readmissions where a patient can have more than one additional
procedure/readmission.
TABLE 34 Summary of the duration from randomisation and injury to the date allocated treatment received
(per protocol)
Time between events
Treatment group
p-valueORIF CCC
Time from injury to allocated treatment received (days)
Mean 5.3 4.8 0.164
n 298 275
SD 3.7 3.3
Median 5 4
IQR 2–7 2–7
Minimum 0 0
Maximum 27 18
Missing 0 0
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the primary theatre procedure after randomisation in the ORIF and CCC groups (Table 35). The operating
surgeon for CCC was consultant grade for approximately 85% of CCC applications. CCC was supervised
by at least a consultant 97% of the time. For ORIF, approximately 39% of operating surgeons were
consultants. Direct consultant supervision was in place for 76% of ORIF procedures.
On the day of the primary theatre procedure, with treatment allocation known, the ORIF procedure was
the preferred primary treatment for most surgeons in both the ORIF group (84.6%) and the CCC group
(56.7%) (Table 36). In the CCC group, the CCC treatment was the preferred treatment for 27.6% of the
procedures undertaken.
TABLE 34 Summary of the duration from randomisation and injury to the date allocated treatment received (per
protocol) (continued )
Time between events
Treatment group
p-valueORIF CCC
Time from randomisation to allocated treatment received (days)
Mean 2.4 2.0 0.264
n 298 275
SD 3.0 2.1
Median 1.5 2
IQR 0–4 0–3
Minimum 0 0
Maximum 26 10
Missing 0 0
IQR, interquartile ratio.
TABLE 35 Summary of when allocated treatment was received by participants, with a summary of the experience
of surgeon if the participant received allocated treatment at the primary theatre procedure (per protocol)
Treatment delivery information
Treatment group
Total, n (%)ORIF, n (%) CCC, n (%)
Time point when allocated treatment received
Primary theatre 285 (95.6) 273 (99.3) 558 (97.4)
First additional theatre procedure 12 (4.1) 2 (0.7) 14 (2.4)
Second additional theatre procedure 0 0 0
First readmission 1 (0.3) 0 1 (0.2)
Second readmission 0 0 0
Missing 0 0 0
continued
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
TABLE 35 Summary of when allocated treatment was received by participants, with a summary of the experience
of surgeon if the participant received allocated treatment at the primary theatre procedure (per protocol)
(continued )
Treatment delivery information
Treatment group
Total, n (%)ORIF, n (%) CCC, n (%)
Grade of operating surgeon at primary theatre procedure if allocated treatment receiveda
FY2b 1 (0.4) 0 1 (0.2)
ST1c 3 (1.0) 0 3 (0.5)
ST2c 5 (1.8) 0 5 (0.9)
ST3c 33 (11.6) 4 (1.5) 37 (6.7)
ST4c 17 (6.0) 4 (1.5) 21 (3.8)
ST5c 20 (7.0) 2 (0.7) 22 (3.9)
ST6c 22 (7.7) 2 (0.7) 24 (4.3)
ST7c 18 (6.3) 4 (1.5) 22 (3.9)
ST8c 10 (3.5) 1 (0.4) 11 (2.0)
Staff grade 16 (5.6) 6 (2.2) 22 (3.9)
Trust grade 4 (1.4) 2 (0.7) 6 (1.1)
Fellow 12 (4.2) 6 (2.2) 18 (3.2)
Consultant 110 (38.6) 232 (85.0) 342 (61.3)
Other 14 (4.9) 10 (3.6) 24 (4.3)
Missing 0 0 0
Grade of the most senior surgeon present at the primary theatre procedure if allocated treatment received
FY2b 0 0 0
ST1c 0 0 0
ST2c 0 0 0
ST3c 3 (1.0) 1 (0.4) 4 (0.7)
ST4c 6 (2.1) 0 6 (1.1)
ST5c 9 (3.2) 0 9 (1.6)
ST6c 6 (2.1) 0 6 (1.1)
ST7c 7 (2.5) 2 (0.7) 9 (1.6)
ST8c 10 (3.5) 0 10 (1.8)
Staff grade 11 (3.9) 1 (0.4) 12 (2.2)
Trust grade 2 (0.7) 0 2 (0.4)
Fellow 3 (1.0) 0 3 (0.5)
Consultant 218 (76.5) 267 (97.8) 485 (86.9)
Other 10 (3.5) 2 (0.7) 12 (2.1)
Missing 0 0 0
FY, foundation year; ST, specialist trainee.
a Grade of surgeon collected only at primary theatre, not if done as an additional theatre or during readmission.
b Foundation year doctor (followed by year).
c Specialist trainee/registrar (followed by year).
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Surgeon learning effects (per protocol)
We provided CCC training to 317 orthopaedic surgeons during the course of the study, of whom 154
were consultant grade (49%). Of the 275 patients randomised to the CCC intervention, details of the
operating surgeon’s experience were unavailable for 20 patients, as no allocated surgeon code was
reported. The allocated code was not reported for these patients because either the surgeon was from the
pilot study or the procedure was conducted by a non-trained surgeon. The learning effects were therefore
assessed using data from 255 patients. The number of days between CCC procedures performed by
individual surgeons was very variable [mean 161 days (SD 153 days); range 0–725 days]. In total,
100 surgeons from 23 different hospitals applied a CCC during the trial. The grade of these surgeons, as
reported at the CCC training, is summarised in Table 37. The number of surgeons across all the sites
ranged from 1 to 9, with an average 4.7 (SD 2.3) surgeons per site. Forty-five (45%) surgeons carried out
two CCC procedures, 22 (22%) surgeons carried out three CCC procedures, 19 (19%) surgeons carried
out four CCC procedures, 13 (13%) surgeons carried out five or more CCC procedures and the remainder
performed one CCC procedure. There was no evidence of a learning effect within the surgeons
(f-test = 1.45; p = 0.087). In addition, there was no evidence of a learning effect when surgeons were
assessed within hospitals (f-test = 1.44; p = 0.123). The ITT analyses gave similar results.
TABLE 36 Preferred treatment for the primary theatre procedure, summarised by treatment group (per protocol)
Preferred treatment for patient on day of assessment
Treatment group
Total, n (%)ORIF, n (%) CCC, n (%)
Traditional plaster cast 8 (2.7) 31 (11.3) 39 (6.8)
External fixation 3 (1.0) 0 3 (0.5)
Retrograde nail 0 1 (0.4) 1 (0.2)
ORIF 252 (84.6) 156 (56.7) 408 (71.2)
CCC 24 (8.0) 76 (27.6) 100 (17.5)
Other 11 (3.7) 11 (4.0) 22 (3.8)
Missing 0 0 0
TABLE 37 Summary of the grade of surgeons who conducted CCC procedures in the study (per protocol)
Type of surgeon Number (%)
ST2a 1 (1.0)
ST3a 4 (4.0)
ST4a 1 (1.0)
ST5a 1 (1.0)
ST6a 3 (3.0)
ST7a 1 (1.0)
ST8a 1 (1.0)
Staff grade 2 (2.0)
Trust grade 1 (1.0)
Fellow 3 (3.0)
Consultant 77 (77.0)
Other 5 (5.0)
Total 100
ST, specialist trainee.
a Specialist trainee/registrar (followed by year).
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Adverse events (per protocol)
No serious adverse events were reporting during the trial. A breakdown of the adverse event complications
reported is shown in Table 38. The number of participants who experienced an infection and/or wound
problem for the surgery group was 29/298 (10%) compared with 4/275 (1%) for CCC. The participants with
wound breakdown or infection in the CCC arm initially received CCC as their primary theatre procedure but
later converted to ORIF either as an additional procedure in theatre or during a readmission. The number of
plaster sores and pain from casts was similar between groups, but there were more plaster saw lacerations
in the CCC group [5/275 (1.8%) vs. 1/298 (0.3%)]. Less common but serious complications, such as
deep-vein thrombosis (DVT), pulmonary embolism (PE) and wound infections, occurred in both treatment
groups but were infrequent overall.
Additional procedures in theatre (per protocol)
A detailed breakdown of the additional procedures in theatre has been detailed in Table 39. The number
of participants requiring one or more additional operating theatre procedures, for surgery-related
complications, was 17 out of 298 (5.7%) in the ORIF group and 3 out of 275 (1.1%) in the CCC group.
TABLE 38 Summary of reported adverse events (per protocol)
Complication type
Treatment group
ORIF (n= 298) CCC (n= 275)
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Intraoperative fracture 1 (0.3) 0 1 0 0 0
Imperfect reduction
reported
0 0 0 3 (1.1) 0 3
Compartment syndrome 0 0 0 0 0 0
Vascular injury 1 (0.3) 0 1 1 (0.4) 0 1
Nerve palsy 2 (0.7) 0 2 2 (0.7) 0 2
Wound breakdown 20 (6.7) 1 (0.3) 22 2 (0.7) 0 2
Infection 7 (2.4) 1 (0.3) 9 2 (0.7) 0 2
Septicaemia 0 0 0 0 0 0
Other clinical issue with
wound (not breakdown
or infection)
6 (2.0) 0 6 1 (0.4) 0 1
Clinical issue with
metalwork
4 (1.3) 0 4 0 0 0
Implant failure 5 (1.7) 0 5 0 0 0
Non-wound skin problem 11 (3.7) 0 11 9 (3.3) 0 9
Pain from cast 12 (4.0) 0 12 16 (5.8) 0 16
Plaster sore 13 (4.4) 0 13 18 (6.6) 0 18
Plaster saw laceration 1 (0.3) 0 1 5 (1.8) 0 5
DVT 3 (1.0) 0 3 6 (2.2) 0 6
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TABLE 38 Summary of reported adverse events (per protocol) (continued )
Complication type
Treatment group
ORIF (n= 298) CCC (n= 275)
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
PE 1 (0.3) 0 1 6 (2.2) 0 6
Refracture of ankle 0 0 0 0 0 0
Fall postoperatively 3 (1.0) 0 3 4 (1.5) 0 4
Other fracture sustained 1 (0.3) 0 1 0 0 0
TABLE 39 Summary of the additional procedures in theatre (per protocol)
Complication type
Treatment group
ORIF (n= 298) CCC (n= 275)
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Remanipulation and
traditional cast
0 0 0 0 0 0
Convert to external
fixation
0 0 0 0 0 0
Convert to retrograde nail 0 0 0 0 0 0
Revision of ORIF 3 (1.0) 0 3 1 (0.4) 0 1
Wound washout 2 (0.7) 0 2 0 0 0
Delayed wound closure 0 0 0 0 0 0
Wound debridement 1 (0.3) 0 1 0 0 0
Incision and drainage
of haematoma
1 (0.3) 0 1 0 0 0
Amputation 0 0 0 0 0 0
Removal of syndesmotic
screws
6 (2.0) 0 6 1 (0.4) 0 1
Removal of other metalwork
Because of infection 1 (0.3) 1 (0.3) 3 0 0 0
With washout 0 0 0 1 (0.4) 0 1
Because of pain 0 0 0 0 0 0
Because of poor position
of implant
1 (0.3) 0 1 0 0 0
Other reason 1 (0.3) 0 1 0 0 0
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Summary of key findings
l The results from the analyses of the primary end point allow us to conclude that the ORIF and CCC
treatments are equivalent for the treatment of unstable ankle fracture in patients over 60 years.
l The functionality of the injury ankle in terms of the range of movement was similar in both groups at
6 months.
l The mental functioning, physical functioning and quality of life of participants in both groups follow
a similar pattern of recovery up to 6 months, with their scores at 6 months being similar to their
pre-injury scores.
l Malunion and non-union of the ankle were more likely after CCC than ORIF.
l Participants receiving CCC were more likely to be readmitted post hospital discharge; one in five had a
later loss of fracture reduction resulting in conversion to ORIF or remanipulation and CCC applied
in theatre.
l Complications directly relating to ORIF, wound problems or infections, occurred in around 1 in
10 participants. Within 6 months about 1 in 20 participants who initially received ORIF required an
additional surgical procedure.
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Chapter 4 Health economic evaluation
Introduction
An evaluation of cost-effectiveness of CCC compared with ORIF was conducted as part of the AIM trial.
The economic evaluation presented in this chapter was conducted for both the NHS and societal perspective.
Consistent with the evaluation of cost-effectiveness in Chapter 3, the primary analysis was per protocol.
Results
Participant flow
Participant flow is shown in Figure 14. The per-protocol population included 573 participants. The number
of participants for whom information was completely missing and who thus were ineligible for inclusion in
the economic evaluation, was 53 out of 573 (9%). Therefore, there were 520 participants with valid
information for an economic evaluation. This constituted the primary analysis population.
Full trial population
(n = 620)
Baseline (ITT)
(n = 618)
(Used for sensitivity analysis)
(Used for sensitivity analysis)
No utility information at
presentation, 6 weeks or 6 months
(n = 67)
No utility information at
presentation, 6 weeks or 6 months
(n = 53)
Withdrew before receiving treatment
(n = 2)
Withdrawals
(n = 45)
Full ITT population
(n = 618)
Analysis ITT population
(n = 551)
Analysis per-protocol
 population
(n = 520)
Full per-protocol population
(n = 573)
• ORIF, n = 298
• CCC, n = 275
• ORIF, n = 272
• CCC, n = 248
• ORIF, n = 309
• CCC, n = 309
• ORIF, n = 276
• CCC, n = 275
FIGURE 14 Flow diagram of per-protocol and ITT population: withdrawals, with exclusions because of insufficient
information and final analysis populations.
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The ITT population included 618 participants. The number of participants for whom information was
completely missing and who thus were ineligible for inclusion in the economic evaluation was 67 out of
618 (10%). Therefore, there were 551 participants with valid information for an economic evaluation.
This constituted the population used for the ITT analysis.
A full trial per-protocol or ITT population included those with completely missing information
(after multiple imputation of their entire history). This corresponded to 573 and 618 participants for the
per-protocol and ITT populations, respectively. Sensitivity analyses were conducted using these populations
(see Appendix 3).
Per-protocol analysis
Missing data (per protocol)
Cases included in the economic evaluation
Complete missingness was not statistically associated with intervention (odds ratio 1.13, 95% CI 0.62 to
2.09; p = 0.67; Fisher’s exact test). Missing cases also showed comparable baseline characteristics to the
complete cases (see Appendix 3); therefore, we treated any remaining missingness as random.
The 53 participants in whom information was missing completely were removed and the economic
evaluation continued with the 520 patients with sufficient valid information. Of the remaining participants,
incomplete data remained at around 7% across most variables (see Appendix 3). Exceptions included
lower missingness of utility prior to injury (0%), at 6 weeks (0%) and at 6 months (3%). Having concluded
that missingness was random, we continued with multiple imputation with chained equations.73 Multiple
imputation showed healthy convergence and the density plots of imputed values followed closely to the
observed values (see Appendix 3).
Baseline characteristics (per protocol)
Baseline characteristics have previously been presented in Chapter 3. It should be noted that the CCC
group appeared slightly less healthy than the ORIF group. The CCC group showed lower utility prior to
injury than the ORIF group (0.83 vs. 0.85; p = 0.05; Wilcoxon rank-sum test). Otherwise, the CCC group
showed comparable baseline characteristics across age, sex, OMASs and a range of health conditions.
Resource use (per protocol)
Mean resource use following ORIF and CCC is presented in Table 40. Compared with the ORIF group, the
CCC group shows lower theatre time during the index procedure (–54 minutes), slightly higher rates of
additional procedures (+0.9%), higher rates of readmission (+14.6%) and greater cast use (+1.51).
Among readmission visits, the CCC group showed greater implant material use and theatre time. Length
of stay was comparable both during the index admission (8.99 vs. 9.70 days) and for any readmission
(5.04 vs. 5.23 days) for the CCC and ORIF groups, respectively.
Over the 6 months, most of the care time was spent at home with friends/family, at an average of just
under 12 days for both CCC and ORIF groups. Both groups spent around ≤ 2 days at a community
hospital, nursing home or intermediate-care hospital; the CCC group had slightly shorter mean stays in the
first two and slightly longer stay in the last.
Mean health service use is also presented in Table 40. Health service use was generally very low to
negligible. Exceptions include modest nurse (≥ 3 visits), physiotherapy (≥ 3 visits), trauma outpatient
(around two visits) and community care contacts (≥ 5 visits). The CCC group had slightly higher use in a
number of health services. Medication use between the two groups was low to negligible.
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TABLE 40 Per-protocol average resource use over the index procedure, readmission and the 6 months’ follow-up
period. Mean and SD are shown except where indicated
Resource
Treatment group
Difference, meanORIF, mean (SD) CCC, mean (SD)
Index procedure
Theatre time (hours) 1.32 (0.48) 0.42 (0.18) –0.90
Screws 6.65 (2.91) 0.00 (0.00) –6.65
Antigliding plates 0.10 (0.34) 0.00 (0.00) –0.10
Tubular plates 0.74 (0.60) 0.00 (0.00) –0.74
Dynamic compression plates 0.01 (0.10) 0.00 (0.00) –0.01
Reconstruction plates 0.01 (0.10) 0.00 (0.00) –0.01
Locking plates 0.12 (0.51) 0.00 (0.00) –0.12
Other plates 0.04 (0.21) 0.00 (0.00) –0.04
Tightropes 0.00 (0.00) 0.00 (0.00) 0.00
Wirings 0.08 (0.33) 0.00 (0.00) –0.08
Other implants 0.08 (0.35) 0.00 (0.00) –0.08
Additional procedure, n (%) 14 (5.1) 15 (6.0) 0.9
Theatre time (hours)a 1.40 (0.56) 1.27 (0.61) –0.12
Anaesthesia, n (%)a 14 (100) 15 (100) 0.0
Screwsa 6.50 (2.71) 4.73 (3.90) –1.77
Antigliding platesa 0.29 (0.47) 0.13 (0.35) –0.15
Tubular platesa 0.57 (0.51) 0.47 (0.52) –0.10
Dynamic compression platesa 0.07 (0.27) 0.07 (0.26) 0.00
Reconstruction platesa 0.00 (0.00) 0.00 (0.00) 0.00
Locking platesa 0.14 (0.36) 0.13 (0.35) –0.01
Other platesa 0.00 (0.00) 0.07 (0.26) 0.07
Tightropesa 0.00 (0.00) 0.00 (0.00) 0.00
Wiringsa 0.07 (0.27) 0.07 (0.26) 0.00
Other implantsa 0.14 (0.53) 0.00 (0.00) –0.14
Casts in plaster room 0.00 (0.00) 0.08 (0.34) 0.08
Casts in theatre room 0.00 (0.06) 1.00 (0.20) 1.00
LOS (days) 9.70 (23.20) 8.99 (9.55) –0.70
Readmission, n (%) 23 (8.5) 56 (22.6) 14.1
Theatre time (hours)a 0.31 (0.48) 1.03 (0.87) 0.72
Anaesthesia, n (%)a 10 (43.5) 41 (73.2) 29.7
Screwsa 0.35 (1.30) 4.59 (4.03) 4.24
Antigliding platesa 0.00 (0.00) 0.07 (0.32) 0.07
Tubular platesa 0.04 (0.21) 0.38 (0.49) 0.33
Dynamic compression platesa 0.00 (0.00) 0.05 (0.23) 0.05
Reconstruction platesa 0.00 (0.00) 0.00 (0.00) 0.00
continued
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TABLE 40 Per-protocol average resource use over the index procedure, readmission and the 6 months’ follow-up
period. Mean and SD are shown except where indicated (continued )
Resource
Treatment group
Difference, meanORIF, mean (SD) CCC, mean (SD)
Locking platesa 0.00 (0.00) 0.16 (0.60) 0.16
Other platesa 0.00 (0.00) 0.04 (0.19) 0.04
Tightropesa 0.00 (0.00) 0.04 (0.27) 0.04
Wiringsa 0.00 (0.00) 0.04 (0.19) 0.04
Other implantsa 0.00 (0.00) 0.05 (0.30) 0.05
LOSa (days) 5.23 (7.87) 5.04 (9.81) –0.19
Total inclusive of 6 months
Theatre time (hours) 1.42 (0.56) 0.73 (0.69) –0.69
Casts 0.07 (0.35) 1.57 (0.91) 1.50
Hospital LOS (days) 10.14 (23.47) 10.13 (10.91) –0.01
Follow-up inclusive of 6 months
Care homes
Friend/family at home days 11.70 (21.27) 11.69 (27.56) –0.01
Community hospital days 2.81 (14.21) 2.34 (8.36) –0.47
Intermediate care days 0.78 (8.93) 1.39 (10.66) 0.61
Nursing home (NHS) days 0.97 (7.20) 0.39 (3.45) –0.58
Nursing home (private) days 0.61 (6.14) 0.34 (3.54) –0.28
Productivity
Sick days 7.87 (24.50) 8.40 (31.64) 0.53
Friend/family stay days 2.78 (13.42) 1.77 (11.89) –1.01
Work-days off by friend/family 2.84 (9.12) 2.64 (12.46) –0.20
Health services
GP 0.69 (1.69) 0.62 (1.29) –0.07
Nurse 3.90 (11.63) 3.65 (16.22) –0.25
Physiotherapy inpatient 0.95 (4.14) 1.34 (4.79) 0.39
Physiotherapy outpatient 3.35 (4.13) 3.17 (4.05) –0.18
Physiotherapy home 0.63 (1.90) 0.68 (2.10) 0.05
Hospital A&E 0.10 (0.35) 0.09 (0.30) –0.01
Hospital specialist 0.92 (2.87) 1.20 (2.12) 0.28
Psychologist 0.01 (0.12) 0.02 (0.23) 0.01
Trauma outpatient 1.83 (2.08) 2.65 (2.49) 0.81
Hospital transports 1.23 (2.24) 2.06 (2.98) 0.82
Community care 5.85 (30.44) 8.10 (35.60) 2.25
Private physiotherapy 0.46 (2.34) 0.22 (1.37) –0.24
Private consultant 0.00 (0.06) 0.00 (0.06) 0.00
Private osteopath 0.04 (0.43) 0.09 (0.98) 0.05
Private transports 0.37 (2.12) 0.28 (1.03) –0.09
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Private health resource use was generally low to negligible and mean levels were comparable between
ORIF and CCC. On average, patients in both groups took about 8 days off work, slightly more in the CCC
group than in the ORIF group, while their family or friends took closer to 2–3 days off work, slightly less in
the CCC group than in the ORIF group.
Health outcomes (per protocol)
The raw, unadjusted utilities at presentation, 6 weeks and 6 months after randomisation are presented in
Table 41. At presentation, the utility in the CCC group trended higher than that in the ORIF group (0.07
vs. 0.04), although this difference was clinically small and not statistically significant (p = 0.11). Compared
with the ORIF group, utility in the CCC group was comparable at 6 weeks (0.36 vs. 0.37; p = 0.15) and
6 months (0.49 vs. 0.49; p = 0.56). Total QALYs over the trial period were also comparable between the
CCC and ORIF groups (0.30 vs. 0.30; p = 0.96). Figure 15 shows the mean utility scores; the QALYs are
indicated by the area under the curve. QALYs were estimated from presentation time to 6 months.
TABLE 40 Per-protocol average resource use over the index procedure, readmission and the 6 months’ follow-up
period. Mean and SD are shown except where indicated (continued )
Resource
Treatment group
Difference, meanORIF, mean (SD) CCC, mean (SD)
Prescriptions
Painkillers 2.28 (3.62) 2.47 (4.11) 0.19
Anti-inflammatory 0.43 (1.31) 0.35 (0.84) –0.08
Gel 0.14 (0.62) 0.09 (0.43) –0.05
Sleeping pills 0.05 (0.32) 0.15 (1.40) 0.10
Antidepressants 0.10 (0.64) 0.27 (2.34) 0.17
Painkillers (self-buy) 2.44 (7.05) 2.33 (9.10) –0.10
Anti-inflammatory (self-buy) 0.48 (1.85) 0.32 (1.19) –0.16
Gel (self-buy) 0.14 (0.67) 0.13 (0.52) –0.02
Sleeping pills (self-buy) 0.00 (0.06) 0.00 (0.00) 0.00
Antidepressants (self-buy) 0.00 (0.00) 0.00 (0.00) 0.00
A&E, accident and emergency; LOS, length of stay.
a Estimates use denominator restricted to those who had relevant event.
TABLE 41 Per-protocol raw, unadjusted utility and QALYs over the 6-month follow-up. 95% CIs obtained using the
bootstrap method
Health outcomes
Treatment group
Difference, mean (95% CI) p-valueORIF, mean (95% CI) CCC, mean (95% CI)
Utility (baseline) 0.04 (0.02 to 0.07) 0.07 (0.04 to 0.10) 0.03 (–0.01 to 0.07) 0.11
Utility (6 weeks) 0.37 (0.35 to 0.39) 0.36 (0.34 to 0.38) –0.01 (–0.04 to 0.01) 0.15
Utility (6 months) 0.49 (0.47 to 0.51) 0.49 (0.47 to 0.50) 0.00 (–0.03 to 0.03) 0.56
QALYs 0.30 (0.28 to 0.31) 0.30 (0.29 to 0.31) 0.00 (–0.01 to 0.02) 0.96
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Costs (per protocol)
The mean raw, unadjusted costs of the resource uses using mean unit cost parameters for each group are
presented in Table 42. Compared with the ORIF group, the CCC group had a large initial cost savings
(–£1144), driven by savings in theatre time use (–£880), as well as a modest savings in care homes
(–£137), that were eroded with costs in increased readmissions (+£448) and health services (+£435).
Mean cost differences were negligible for additional procedure (+£8), casts (+£45) and medications (+£2).
Societal cost differences between the CCC and ORIF groups were negligible across private nursing homes
(–£27), private health services (–£25), out-of-pocket medications (–£1) and work days (+£33).
Over the 6-month trial period, the CCC group had a mean cost savings to the NHS of –£316. The mean
cost saving to society was –£335. Figure 16 presents the cost burden for the CCC and ORIF groups for the
cost categories. The cost burdens, from largest to least, were the primary procedure, health services/
medications, care homes, readmission, additional procedure and then casts. The figure represents the total
cost burden; 360° represents around £6600. The cost savings in the CCC group is represented by the
white space, where a full circle fails to fill.
Regression models (per protocol)
Total societal and NHS costs, as well as QALYs, were obtained by fitting a GLM and adjusting for baseline
characteristics. This sections details the results of the models adjusted for the predictors and the resulting
estimates after marginal prediction and bootstrapping.
The GLMs dichotomised the home care support (lives alone, does not live alone), walking aids (none, one
or more) and walking distance (more than half a mile, half a mile or less) because of low counts in the
more severe categories. Using the Modified Park’s and Hosmer–Lemeshow tests, appropriate families and
links were determined for each GLM. The gamma family and identity link were identified for total costs,
whereas the Gaussian family and identity link (OLS) were identified for the total QALYs.
Regression coefficients for total NHS and societal costs are presented in Tables 43 and 44. Regression
coefficients for total QALYs are presented in Table 45.
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FIGURE 15 Graph showing per-protocol utility (quality of life) over time (length of life). Area is the QALYs.
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TABLE 42 Per-protocol raw, unadjusted costs using mean unit costs over the 6-month trial period. 95% CIs
obtained using the bootstrap method
Resource
Treatment group
Difference, mean, £ (95% CI)ORIF, mean, £ (95% CI) CCC, mean, £ (95% CI)
Index procedure
Theatre time 1602 (1547 to 1657) 722 (701 to 745) –880 (–938 to –820)
Implant 79 (72 to 87) 0 (0 to 0) –79 (–87 to –72)
LOS 2667 (2134 to 3541) 2482 (2165 to 2827) –185 (–1120 to 493)
Total 4348 (3807 to 5225) 3204 (2886 to 3552) –1144 (–2081 to –460)
Additional procedure
Theatre time 86 (43 to 136) 95 (48 to 147) 8 (–60 to 77)
Implant 4 (2 to 6) 4 (2 to 7) 0 (–3 to 4)
Total 90 (45 to 142) 99 (50 to 154) 8 (–63 to 81)
Readmission
Theatre time 37 (15 to 64) 278 (197 to 365) 241 (155 to 332)
Implant 0 (0 to 1) 14 (9 to 20) 14 (9 to 20)
LOS 122 (46 to 218) 315 (170 to 518) 193 (15 to 413)
Total 159 (70 to 272) 607 (408 to 851) 448 (219 to 713)
Casts
Number 2 (1 to 3) 47 (43 to 50) 45 (41 to 49)
Care homes
Community hospital (days) 547 (253 to 902) 455 (270 to 665) –92 (–489 to 270)
Intermediate care (days) 49 (2 to 129) 88 (19 to 184) 39 (–69 to 151)
Nursing home (NHS) (days) 96 (25 to 190) 38 (1 to 87) –57 (–160 to 27)
Nursing home (private) (days) 60 (0 to 141) 33 (0 to 82) –27 (–118 to 51)
Total 752 (401 to 1165) 615 (393 to 862) –137 (–606 to 289)
Health services 1,352 (1,075 to 1,670) 1787 (1460 to 2164) 435 (–27 to 904)
Health services (private) 94 (52 to 150) 68 (44 to 95) –25 (–87 to 27)
Medications 5 (4 to 6) 7 (4 to 12) 2 (–1 to 7)
Medications (private) 4 (3 to 6) 4 (3 to 5) –1 (–3 to 1)
Work-days 1058 (765 to 1381) 1091 (695 to 1558) 33 (–482 to 576)
Total societal cost 7864 (6926 to 9027) 7528 (6662 to 8453) –335 (–1767 to 1005)
Total NHS cost 6648 (5744 to 7777) 6,332 (5599 to 7127) –316 (–1661 to 919)
LOS, length of stay.
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FIGURE 16 Pie chart of per-protocol NHS costs for (a) ORIF and (b) CCC, grouped by primary procedure, health
services/medications, care homes, readmission, additional procedure and casts. CCC displays cost savings
represented by the white space.
TABLE 43 Regression coefficients for per-protocol total NHS costs
Variable
GLM
Estimate Standard error p-value
Intercept 4269 3532 0.23
CCC –626 364 0.09
Age 92 33 0.01
Female 618 402 0.12
Baseline utility 126 2177 0.95
Baseline OMAS –53 22 0.02
Hypertension 506 399 0.21
Asthma –863 501 0.09
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TABLE 43 Regression coefficients for per-protocol total NHS costs (continued )
Variable
GLM
Estimate Standard error p-value
Diabetes mellitus 1472 924 0.11
Ex-smoker –299 405 0.46
Smoker –667 358 0.06
Home support: does not live alone –1767 523 0.001
Walking aids: one or more 2987 1291 0.02
Walking distance: < 0.5 mile or worse 2387 903 0.01
TABLE 44 Regression coefficients for per-protocol total societal cost
Variable
GLM
Estimate Standard error p-value
Intercept 16291 4297 < 0.001
CCC –637 459 0.17
Age –16 39 0.68
Female 513 518 0.32
Baseline utility –5 2628 1.00
Baseline OMAS –80 27 0.00
Hypertension 134 488 0.78
Asthma –1319 644 0.04
Diabetes mellitus 2116 1155 0.07
Ex-smoker –408 523 0.44
Smoker –1050 463 0.02
Home support: does not live alone –2468 645 < 0.001
Walking aids: one or more 2696 1405 0.06
Walking distance: < 0.5 mile or worse 2798 1037 0.01
TABLE 45 Regression coefficients for per-protocol QALYs
Variable Estimate Standard error p-value
Intercept 0.778 0.064 < 0.001
CCC –0.011 0.009 0.22
Age 0.001 0.001 0.48
Female 0.022 0.010 0.04
Baseline utility –0.106 0.040 0.01
Baseline OMAS 0.000 0.000 0.31
Hypertension –0.019 0.009 0.04
Asthma –0.006 0.013 0.68
continued
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Cost-effectiveness: 6 months (per protocol)
NHS perspective
After resampling the trial population and unit costs, refitting the GLMs and using marginal estimation,
mean total NHS cost and total QALYs for the CCC and ORIF groups were generated. The results of the
cost-effectiveness outcomes are presented in Table 46. The mean total QALYs for CCC and ORIF were
0.30 and 0.29, respectively, while the mean total NHS costs were £6050 and £6694, respectively.
The incremental differences favoured the CCC group. The CCC group had higher mean total QALYs
(+0.01) and lower mean total NHS cost (–£644). At the mean for an ICER of £25,000/QALY, as CCC was
both more effective and less costly, it dominated ORIF.
To assess the variability of the estimates, we plotted the incremental costs and incremental QALYs on
the cost-effectiveness plane (Figure 17). The cost-effectiveness plane summarises all 10,000 bootstrap
estimates. The cost-effectiveness plane shows that the large majority of incremental costs are negative;
the incremental QALYs, however, show more uncertainty with a modest proportion being negative.
The variability across the range of willingness-to-pay thresholds was summarised with a cost-effectiveness
acceptability curve (Figure 18). Over a common willingness to pay, CCC displayed a high probability of
cost-effectiveness (> 95%).
Societal perspective
The mean total QALYs remained the same for both the NHS and societal perspectives. Costs, however,
differed. After resampling the trial population and unit costs; refitting the GLMs and using marginal
estimation, mean total societal cost for the CCC and ORIF groups was £7320 and £8003, respectively
(see Table 46).
The incremental differences favoured the CCC group. The CCC group had a lower mean total societal cost
(–£683) and unchanged higher mean total QALYs (+0.01). At the mean incremental cost and QALYs for
an ICER of £25,000/QALY, CCC dominated ORIF as it was both more effective and less costly.
TABLE 46 Cost-effectiveness results: 6 months (per-protocol)
Outcome
Treatment group
Difference, mean (95% CI)ORIF, mean (95% CI) CCC, mean (95% CI)
NHS costs (£) 6694 (5285 to 8465) 6050 (4711 to 7744) –644 (–1390 to 76)
Societal costs (£) 8003 (6483 to 9906) 7320 (5815 to 9167) –683 (–1851 to 536)
QALYs 0.2928 (0.2714 to 0.3116) 0.3034 (0.2853 to 0.3209) 0.0106 (–0.0158 to 0.0381)
TABLE 45 Regression coefficients for per-protocol QALYs (continued )
Variable Estimate Standard error p-value
Diabetes mellitus –0.003 0.016 0.86
Ex-smoker 0.023 0.011 0.04
Smoker –0.004 0.009 0.65
Home support: does not live alone 0.003 0.010 0.74
Walking aids: one or more 0.041 0.016 0.01
Walking distance: < 0.5 mile or worse 0.043 0.014 0.002
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The cost-effectiveness plane displayed modest variability in incremental costs (Figure 19). However,
the large majority of incremental costs were negative. The incremental QALYs also displayed a modest
proportion of negative estimates.
Over a common willingness to pay, CCC displayed a high probability of cost-effectiveness (around 85%)
(Figure 20).
0
0.00
0.25
0.50
0.75
1.00
10 20 30
Willingness to pay (£000/QALY)
Pr
o
b
ab
ili
ty
 o
f 
co
st
-e
ff
ec
ti
ve
n
es
s
FIGURE 18 Per-protocol 6-month cost-effectiveness acceptability curve displaying the probability of
cost-effectiveness (y-axis) as a function of the willingness-to-pay threshold (x-axis) under the NHS perspective.
The dotted line presents the asymptote where the willingness to pay is infinite.
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FIGURE 17 Per-protocol cost-effectiveness plane showing 6-month incremental total NHS costs along y-space and
incremental QALYs along x-space for 10,000 bootstrap replicates. Origin is ORIF.
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Lifetime (per protocol)
There was no difference in QALYs between ORIF and CCC by the end of the trial period. Although return
to baseline quality of life (utility) was not complete, it was nearly the same at each time point. Therefore,
the QALYs, quality of life and the rate of its recovery were the same with no evidence of divergence.
Based on this evidence, there was no justification for modelling long-term QALY differences between CCC
and ORIF.
Implant removal may have resulted in an additional £79 to the ORIF cohort. This would result in an
additional £79 in mean cost savings to the NHS and society. We did not repeat all analyses to include this
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FIGURE 19 Per-protocol cost-effectiveness plane showing incremental total societal costs along y-space and
incremental QALYs along x-space for 10,000 bootstrap replicates. Origin is ORIF.
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FIGURE 20 Per-protocol cost-effectiveness acceptability curve displaying the probability of cost-effectiveness (y-axis)
as a function of the willingness-to-pay threshold (x-axis) under the societal perspective. The dotted line presents
the asymptote where the willingness to pay is infinite.
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as it did not affect the magnitude of incremental differences. In addition, it would be applied in the same
direction (cost savings) and thus conclusions would be insensitive.
Sensitivity
Intention to treat
Results were robust to the inclusion of protocol violators. Using the ITT analysis, incremental NHS costs
(–£692), incremental societal costs (–£773) and incremental QALYs (+0.01) were virtually the same to the
per-protocol results. Decision certainty was also similar. Full results are provided in Appendix 3.
Imputing completely missing cases
Results were robust to the inclusion of completely missing cases (53 participants). These participants were
included after imputing their entire history on the basis of baseline characteristics and index procedure
resource use. Full results are provided in Appendix 3.
Ordinary least squares models in place of best-fit generalised linear
model models
Ordinary least squares models of total NHS cost, total societal cost and total QALYs had little impact on
the estimation of incremental costs (NHS –£613; societal –£420). CCC remained cost saving at a
similar magnitude.
Discussion
An economic evaluation of CCC compared with ORIF for ankle injury management was conducted.
Over the trial period, CCC showed evidence of a modest mean cost savings (around £400–700) to both
the NHS and society. The cost savings were driven largely by savings in index procedure theatre time, but
were eroded over time by increased readmission and health services costs. Incremental QALYs following
CCC were no different from those following ORIF, with evidence leaning towards a slight advantage with
CCC. Over common willingness-to-pay thresholds, the probability that CCC was cost-effective was very
high (> 95% for NHS and 85% for societal perspective). Results were robust to the use of per-protocol or
ITT populations, the use of standard OLS models instead of best-fitted GLM models and the inclusion of
completely missing cases via multiple imputation.
The AIM trial was a randomised controlled trial. Despite randomisation, there was evidence of differences
in utility prior to injury. The CCC group had a lower utility prior to injury than the ORIF group. This
suggests a lower baseline quality of life. Other differences such as utility at presentation and baseline
walking distance, albeit not statistically significant, represented imbalances that effect the estimation of
mean total and incremental costs and QALYs.
The bootstrapped, adjusted results showed greater mean cost savings than the raw, unadjusted trial
results. Without adjusting for imbalances in baseline characteristics, whether or not statistically significant,
the estimated total and incremental costs can be biased. The GLM model results show that small
differences in baseline characteristics can contribute to important differences in total cost. This was
particularly the case for baseline walking distance and walking aids statuses, among others.
The NHS and societal perspectives showed comparable incremental differences in total cost at the mean.
Uncertainty was slightly greater using the societal perspective. This led to slightly greater decision
uncertainty as visualised by the cost-effectiveness acceptability curve (see Figures 18 and 20). However,
incremental costs remained largely negative and the probability of cost-effectiveness for CCC remained
very high.
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Incremental total costs and QALYs were robust to whether the per-protocol or ITT population was used.
Results with the ITT population showed cost savings to the NHS and society at similar magnitudes to
the per-protocol population. The probability of cost-effectiveness of CCC was also similarly very high.
The best-fit models also showed comparable results to the OLS models for the ITT population, as they did
for the per-protocol population.
Incremental total costs and QALYs were also robust to whether completely missing cases were excluded or
included using multiple imputation. CCC continued to show a high probability of cost-effectiveness over
the common willingness to pay.
On average, CCC was followed by more rehospitalisation, because of loss of fracture reduction and
conversion to ORIF, as previously shown in the clinical results. Cost increases following CCC also occurred
outside hospitalisations. A substantial proportion of cost increases related to increased health services use
in the follow-up period. CCC appeared to require additional health services following discharge.
We did not find justification to extrapolate trial outcomes or incorporate modelling of new outcomes to a
lifetime. Utility was the same at each time point. This suggested that quality of life, its rate of recovery and
QALYs were the same. There was no clinical reasoning for a difference in life expectancy between CCC
and ORIF management. Implant removal because of local irritation may be an incremental cost to ORIF;
however, it did not affect conclusions of incremental costs or QALYs. Given the evidence on functional
assessments, quality of life, life expectancy and implant removal, there was not enough justification to
model long-term differences.
Radiological evidence did identify a possible signal of increased malunion associated with CCC. Malunion
has been suggested as a factor in the development of long-term osteoarthritis.74 However, there is
uncertainty regarding the rates and severity of post-traumatic osteoarthritis in relation to malunion after
fracture because of a lack of clinical data. A recent review highlights the poor quality of the available
evidence, with limited basic scientific knowledge and a dependence on retrospective case series.75 We are
conducting extended follow-up of the AIM trial cohort to address some of these uncertainties. When
completed, this additional phase of follow-up will allow us to conduct modelling for any explicit long-term
differences between ORIF and CCC regarding quality-of-life recovery, functional recovery, development of
osteoarthritis or whether increased health service use with CCC is sustained or increases.
There are two other relevant cost-effectiveness studies.76,77 Slobogean et al.76 conducted a cost-effectiveness
analysis of ORIF versus non-operative treatment for unstable ankle fractures in a Canadian setting. There are
several differences in the design. Although Slobogean et al.76 also used a trial-based evaluation, the trial
randomised far fewer patients (81 vs. 620). In addition, the non-operative intervention did not include CCC.
Slobogean et al. also considered a narrower perspective, only the procedure and rehospitalisations for
reoperation or, in the case of the non-operative arm, secondary ORIF. In contrast, the AIM trial also
included care home stay, health services, medication and productivity. Owing to their exclusion of other
important resource issues, Slobogean et al. found a much larger short-term (index year) cost savings with
non-operative treatment [CAD4512 (2014, GBP2718)]. This is still several times larger than just the
hospitalisation costs of the present analysis. This may be because of the underlying differences in unit
resource costs between Canada and the UK, as well as the use of summary unit cost estimates of different
hospitalisations in contrast to the present study, which microcosted actual resource use.
Slobogean et al.76 found mean incremental QALYs to be higher with ORIF (+0.02). They did not report
uncertainty on incremental estimates or cost-effectiveness planes. However, the SDs of the total QALYs
suggests imprecision nearly six times greater than the present study. Thus, incremental QALYs
of +0.02 were likely highly imprecise across negative and positive space. In addition, QALYs were not
similarly adjusted to baseline utility, which is important when estimating differences for cost-effectiveness
(see Chapter 2). A simple plot using their Short-Form questionnaire 36-item physical component summary
scores would show ORIF with consistently higher scores from time at presentation all the way through
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1 year, compared with non-operative treatment.78 This is, however, just one domain of health-related
quality of life. Utility at each time point was not reported and thus it is not possible to explain the nature
of the (imprecise) QALY difference in the Slobogean et al. analysis.
Slobogean et al.76 concluded that ORIF was cost-effective in the long term (lifetime). The long-term
model included only osteoarthritis and the assumed reconstruction following this event. ORIF became
cost-effective because non-operative treatment gave way to osteoarthritis on the basis of higher malunion.
However, osteoarthritis was modelled expressly on malunions not on ankles in which joint congruence
had been achieved. In this way, it was assumed osteoarthritis could only follow malunion. However,
normal anatomical alignment does not preclude osteoarthritis, neither does malunion mandate arthritis.
The evidence does not support a non-significant absolute risk difference on the order of 50% between
malunited and congruent ankles (50% vs. 0%), which Slobogean used. Moreover, the study which was
used to derive this estimate was not a comparison of malunited and congruent ankles; it used a small
sample of malunited ankles that underwent surgical reconstruction.79 Slobogean also assumed a stable
QALY benefit over the lifetime. The highly imprecise difference in QALYs at the end of the index year was
simply assumed the same for all ensuing years in those without arthritic development. It is not clear that
this is the most appropriate base case, given the difference was very imprecise and reasoning to justify
how differences are sustained was lacking.
Michelson et al.77 conducted a model-based evaluation of ORIF and traditional casting separately for
unstable and stable ankle fractures in a US setting. There were a number of limitations. The only outcomes
were infection following ORIF and osteoarthritis following either ORIF or casting; all removals, reoperations
and rehospitalisations were not considered. In addition, as infection was just 1%, the driving force in the
model was solely the development of arthritis. However, its cost was excluded from the analysis as well as
everything outside of the index ORIF/casting hospitalisation cost. Michelson et al. estimated a 25% higher
absolute risk of development of arthritis following casting than with ORIF (30% vs. 5%). However, the
reasoning for this very large difference was not provided and neither was the source for this estimate.
This contrasts to the evidence provided by Koval et al.66 in 33,704 elderly patients with ankle fracture; the
incidence of arthroplasty or arthrodesis (procedures assumed to be performed for osteoarthritis) was less
than 1% for both operative and non-operative treatment. The Michelson et al. analysis assumed that
quality of life was different in the presence of arthritis (and infection, although that branch’s effect is
negligible to begin with) but otherwise equivalent between ORIF and casting. However, it is not clear the
utilities employed were valid as they were not on the (0,1) range; no source was provided. The large
difference in arthritis gave way to a large difference in utility and quality of life. These were applied at
baseline and extended over the lifetime, this led to 0.96 greater QALYs attributed to ORIF for a 70-year-old
with unstable fracture. Incremental costs for unstable fractures were not presented. Decision uncertainty
was likewise not presented for unstable fractures. The Michelson et al. analysis presents evidence of low
comparability because of limitations in its design and evidence base.
Summary of key findings
l The primary economic analysis used the per-protocol population, excluding cases without any
valid information.
l There were no differences in QALYs between CCC and ORIF. However, management with CCC led
to a mean cost savings greater than £600 under both NHS and societal perspectives (total £1327).
The probability that CCC is cost-effective was very high (NHS > 95% and societal 85%) at common
willingness-to-pay thresholds.
l Results were robust to the use of the ITT population, OLS models in replace of best-fit GLM models and
the inclusion of completely missing cases via imputation.
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Chapter 5 Qualitative study findings
Introduction
A qualitative study was embedded into the AIM trial to investigate patients’ experiences of living with a
fractured ankle and experiences of being in a trial. This chapter outlines the background of this element of
the trial, describes the approach and methods used before presenting and discussing the findings.
Background
Researching patient experience is crucial to understanding how patients make sense of injury and recovery
and how interventions impact on their daily lives. As a form of evidence, experience has utility when
translating interventions into practice.80 For example, McInnes et al.,81 through a qualitative meta-synthesis
of older people’s experience of falls interventions, demonstrated that participants had complex and varied
stories with many factors influencing acceptance of risk status and preference for intervention along with a
strong need to maintain control and fit interventions into everyday life. Experience evidence is also valued
as an integral part of NICE guidance. Staniszewska et al.82 from development of the Warwick Patient
Experience Framework have generated quality standards around knowing the patient, tailoring care,
continuity of care, participation and essential care that require consideration alongside other sources of
evidence. Interventions for orthopaedic trauma are increasingly incorporating patient experience within
studies of clinical effectiveness and Gooberman-Hill and Fox83 suggest this will benefit both trial design and
the suitability of interventions from provider and service user perspectives.
Understanding how participants make sense of trials within their acute hospital care is important evidence
for the design of future clinical trials in trauma. A study exploring participant experiences from a range
of trials suggested that they take part in trials both for altruistic reasons and because of perceptions of
personal benefit; however, personal benefit may take precedence.84 Acceptance and understanding
of the principles underlying trials in a clinical setting can be problematic, leading to therapeutic
misconceptions.84,85 Robinson et al.86 identify the difficulty lay participants have viewing randomisation or
equipoise as acceptable in a clinical setting in which they would prefer an interaction based on what is
best for them. Other trial participants experience a sense of indifference to the interventions, particularly if
they were satisfied with their treatment, and did not perceive any active harm as a consequence of the
intervention.85 Rejection of randomisation and uncertainty over outcome were reasons for declining to
take part in a trial,85 as were perceptions of burden and concern over side effects of interventions.84
How participants are informed about trials is therefore crucial. Based on their trust in clinicians, participants
may pick up cues that subtly coerce them into consenting to take part in trials.85 In this study, participants’
experience in relation to consenting to the trial and being randomised to CCC and ORIF was explored.
Current research evidence on patients’ experience of traumatic orthopaedic injury presents a broad range
of emotional, physical, social and financial impacts on participants’ lives over prolonged periods of time.
The experience of being hospitalised as a result of a traumatic orthopaedic injury is emotionally and
physically demanding, where patients cope with feelings generated from the incident, the impact on their
bodies and live with the uncertainty of full recovery.87 Patients struggle to feel hopeful, often oscillating
between hope and hopelessness as they focus on the immediate future aiming to progress their recovery
and return home.88 Evidence from patients who have experienced a broad range of injuries, the majority of
whom had been hospitalised, reveals a range of experience that includes omissions in care, a struggle to
cope at home with little social support, continuing pain, low emotional states, a general loss of confidence
and a more cautious approach to life; physiotherapy is seen as beneficial for those who received it.89
Patients interviewed up to 2 months after lower limb injury struggled with pain, fear and anxiety with a
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feeling of loss of control over their lives but had a strong desire to return to normal.90 Trickett et al.91
demonstrated that patients with open tibial fracture interviewed at least 15 months post injury suffered
from pain, stiffness and discomfort, had not regained their normal mobility, felt fearful of many aspects of
their recovery including falling, were concerned about their appearance and were anxious about their
employment and finances as a result of being injured. Forsberg et al.92 included ankle fracture in their
sample of participants with surgery for lower limb fracture interviewed 1 month to 1 year after surgery.
The participants identified a range of strong emotions such as anger, frustration and remorse in relation to
the incident; anxiety, vulnerability and pain through the surgical period; and helplessness, fear of falling,
and insecurity with use of equipment once discharged from hospital.
McPhail et al.12 focused specifically on adults under 60 years of age from 6 to over 24 months post ankle
fracture in order to develop an outcome measure. The findings suggest that participants had or were
suffering from a range of impacts: reduced mobility, increased anxiety, a reduction in participation in
activities and social life, disruption and sometimes change of work life, loss of earnings, weight gain and
loss of ability to wear preferred shoes and some need for medication. Overall, patients experienced
traumatic orthopaedic injury as a struggle to return to normal life. Evidence pertaining directly to ankle
fracture is limited and there is a gap in relation to the older participant and different forms of treatment.
The quality of the studies regarding description of their methodology is often limited; the studies cover a
range of time frames since injury and do not take into account change in perceptions over time. This study
aimed to explore older participants’ experience of ankle fracture and the acceptability of two interventions,
CCC and ORIF.
Methodology
The lack of understanding around patients’ experiences of living with a fractured ankle and treatment led
to the research questions.
1. What are participants’ experiences of ankle fracture in the first 6–10 weeks after treatment?
2. What are participants’ experiences of being in a clinical trial?
In order to answer these two questions a naturalistic approach drawing on the principles of Heideggerian
phenomenology was utilised. Phenomenology is commonly used in health sciences to facilitate exploration
of how participants come to know and understand the world through their embodied experience of what
it is like to be in the world. It focuses on gaining ‘a deeper understanding of the nature of meaning in
our everyday experiences’ (p. 9).93 Todres and Wheeler94 suggest it grounds research in the reality of
human experience harnessing the reflective skills of the researcher. Key tenets are (1) being in the world,
(2) forestructures, (3) temporality and (4) space.
1. Being in the world is conveyed through the notion of dasein (being or presence) in which subject and
object are inseparable and human beings exist within the framework of the world. Being ‘is to be
shown as it is proximally and for the most part – in its average everydayness’ (pp. 16–17).95 Research
focuses on what it is like in the life-world of the other; or the ‘understandings, feelings and perceived
relationships i.e. all the everyday phenomena of common experience’ (p. 3).94
2. Forestructures reflect the notion that knowledge and meaning is founded on the social, cultural and
historical context of the person. The researcher through description and interpretation uncovers what is
already in existence and thus understanding leads to meaning. ‘Our investigation itself will show that
the meaning of phenomenological description lies in interpretation’ (p. 61).95 Meaning is further
enhanced by a cycle of understanding, from the part to the whole, often called the hermeneutic circle
by researchers.96
3. For Heidegger, temporality is an integral part of being human as the past, present and future are part
of the life world ‘time must be brought to light – and genuinely conceived – as the horizon for all
understanding of being and for any way of interpreting it’ (p. 39).95
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4. How people are situated in relation to space is also important; this may be spatially but also what is
brought to the fore in relation to ‘concern for’ or what merges into the background. This involves
listening to what participants say to identify what is important to them in relation to the phenomena.96
Madjar and Walton97 refer to the listening gaze as a phenomenological way of being: openness to what
is unknown or taken for granted in order to develop a better understanding of the other.
Methods
The method used was unstructured interviews, a focused conversation where the interviewer keeps the
question open yet focused on the phenomena and the interviewee becomes coinvestigator in the study.93
In this study there were two questions:
1. What has it been like for you since you fractured your ankle?
2. What was it like being part of a trial?
These were followed with prompts such as: tell me what that was like?; how did that feel?; what were
you thinking at that point?; what helped/did not help at that stage? Written and verbal information about
the study was provided to participants and they had at least 24 hours to consider their participation.
Written informed consent was obtained from the participants prior to interview.
The interviews were situated within the outpatient clinic at the 6- or 10-week clinic visit to minimise
participant burden. It was considered a good time for the interview as participants’ experiences of
treatment and the trial would be relatively fresh. In retrospect, the clinic environment was busy and
interruptions were common. For the participant the 6-week visit involved a radiograph, consultation,
plaster removal and trial questionnaires; delays to radiography, transport arriving unexpectedly and
interruptions curtailed six of the interviews. However, participants in general were keen to be interviewed
and pleased not to have to make a separate visit for the interviews and tolerated interruptions.
Sample
A purposive sample of 36 study participants from the main trial from two sites (Bristol and Oxford) that
provided a range of ages, male and female, both treatments and a breadth of experience was obtained.
From the sample 27 participants were female and nine were male; 27 were interviewed at 6 weeks
and nine at 10 weeks post intervention; 24 were interviewed at Oxford and 12 at Bristol; the age range
was 60–80 years, with an average and median age of 67 years; 21 received CCC and 15 received ORIF;
the sample were all white, British and ethnic minorities were not represented; and the interview duration
ranged from 11 to 78 minutes (average, 34 minutes; median, 33 minutes).
Analysis
The interviews were transcribed verbatim. Analysis developed an understanding of the other study
participants through reading, listening and writing, focusing on the life-world, exposing what exists in the
form of meaning, being alert to temporality and what is of concern to participants living with a fractured
ankle. Units of meaning were identified from the words and phrases participants used, units with similar
meanings were gathered together under researcher-generated categories such as ‘being vulnerable’
and then drawn together into themes such as ‘getting on with daily life’ which Van Manen93 calls the
‘structures of experience’ (p. 79). Analysis was facilitated through writing and rewriting as ‘writing teaches
us what we know and in what way we know what we know’ (p. 127).93 Constant reflection took place
on the meanings and how they were similar to, or different from the theme, and in relation to the findings
as a whole, drawing on the principles of the hermeneutic circle.96 Through this process a deeper
understanding of the phenomena was obtained while staying ‘true to text’ (p. 57) and the experience of
the participants.98 Data saturation was achieved in all themes. Help with organising the large amount of
data was provided by NVivo version 10 (QSR International, Warrington, UK).
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Rigour
Rigour in the study was demonstrated, drawing on Lincoln and Guba99 and their notion of trustworthiness.
The researcher engaged with the data over a prolonged period of time; data collection took place from
October 2012 to September 2013 and used verbatim quotes. A range of experiences was presented to
facilitate resonance with the reader and transferability of the findings. Auditability was ascertained through
clarity of the research processes. The researcher brings their own ‘being’ to the research and this influences
the process of the research and interpretation of the research data: ‘Thus to work out the question of being
adequately, we must make an entity – the enquirer – transparent in his own being’ (p. 27).95 Reflection,
field notes and use of memos through the research process provided ways in which the researcher made
these explicit. In this study, the researcher brought her own experience of other concepts such as comfort,
pain, participation and hope to the study; for example, when participants identified uncertainty in relation
to healing there was a heightened awareness of their hopes and fears for the future.
Findings
The participants’ experience was conveyed through a core theme of struggling to live with a fractured
ankle. This was further divided into four themes and nine categories:
1. Theme 1: suffering – categories (1) being vulnerable and (2) renegotiating roles and relationships.
2. Theme 2: getting on with daily life – categories (1) finding ways of doing things and (2) finding ways of
keeping busy.
3. Theme 3: struggling to move – categories (1) living with hopping and (2) moving forward.
4. Theme 4: treatment and being in a trial – categories (1) living with a CCC, (2) living with metalwork
and (3) decision-making.
Theme 1: suffering
Being vulnerable
The suddenness and unexpected nature of the fracture impacted on participants’ lives in terms of how
they felt about themselves as being vulnerable and older people, what they could do, their roles and
relationships. The experience was described as incapacitating, annoying, terribly frustrating, difficult,
terrible, a shock, soul-destroying, unbelievably miserable, aggravating, boring and hard. Normal protective
mechanisms of everyday life were removed and participants felt emotionally exposed. It was a shock for
participants as they realised that they were vulnerable and dependent, were not ‘invincible’ (participant 17)
and felt helpless which reminded them of their own parents:
I kept seeing myself as my parents.
Participant 12
Others felt worn out, extremely frustrated and angry that they had missed family events and holidays.
Normally robust participants felt emotionally fragile and little things could tip the balance:
I just burst into tears because I so wanted to get in this bath.
Participant 21
Supportive family and thinking positively helped to contain these emotions; however, there was a sense of
impending old age.
A shock. I sort of laboured under the illusion I might not be as old as I am for quite a long time and I also
don’t drive and walk everywhere and I thought I was quite fit. I didn’t expect to just slip on a patch of mud
and break my ankle nor did I expect when I got in here and they did a whole lot of tests that I wasn’t really
quite as fit as I thought. I wasn’t ill but I just wasn’t as I thought and all of a sudden it did occur to me that
I was older than I thought I was in my head, it was a bit of a surprise . . .
Participant 30
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Acceptance was considered a useful way of being in order to contain emotions, and stoically getting on
with it was helpful for some: ‘I’ve just accepted it and that’s it’ (participant 18), although processing anger
and frustration could be a slow process: ‘It does take a while to accept it’ (participant 21). It was also seen
as part of old age ‘because of being old you have to accept help in any case’ (participant 1). Ways of living
with and mitigating feelings of vulnerability were keeping positive, getting back to work, drawing on inner
spiritual resources and strong social connections with friends and family.
Renegotiating roles and relationships
The sudden reduction in mobility and ability to undertake daily activities in a normal fashion created a
dependency on others to maintain a household where routines and responsibilities had been maintained
for sometimes up to 43 years. Normal roles, sometimes related to sex, and relationships were disturbed
creating a concern that relationships might not be repairable. Participants felt strongly that support was
required particularly in the first few weeks:
Without it I would be really, really struggling.
Participant 25
None of the participants enjoyed dependency; some felt they got used to it, while others felt
increasingly frustrated:
I hated it . . . I did the caring, people didn’t have to look after me.
Participant 21
Role reversal was frustrating as they felt they had to tell their partner what to do, ‘Always telling him that,
always telling him’ (participant 8), they felt they were ‘nagging’ and had become ‘she who must be
obeyed’ (participant 7). Participants attempted to minimise their demands, demonstrating an empathetic
insight into the impact on their partner.
You have to be very careful I think to not say too many things at once, not make too many demands
at once because it’s very hard for that person looking after you anyway to know that you’re totally
dependent on them for the shopping and the cooking . . . So they’re nerve wracked I think and under
a lot of pressure.
Participant 12
Relationships could become tense and volatile as both parties were stressed and anxious about the
uncertainty of the future and the change in roles that reduced their freedom to act independently:
It does play havoc with your marriage.
Participant 13
To balance this, the participants encouraged their partner to maintain their normal outside activities;
several went on holiday, which was important for the relationship.
Regaining independence was tricky as new boundaries were renegotiated:
As I started to get back my mobility then we started to clash a bit.
Participant 36
Negotiating intimacy within the relationship was also problematic as the body was perceived as fragile
and breakable.
Yes, it’s changed his life as well as mine. And as for one’s sex life? What’s that! . . . I think he’s almost
been afraid to touch me as though I have become fragile because some bones have broken. I think
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I’m not going to break you know, it’s just my ankle everything is absolutely fine but he’s obviously
worried, he’s concerned he’s lacking in confidence about it but who knows how long it will take to
repair before it all starts to feel normal again.
Participant 7
Both partners appeared to be actively undertaking forms of emotional containment in order to maintain
daily life. Friends and family provided supportive functions, which alleviated the burden of dependency.
Theme 2: getting on with daily life
Finding ways of doing things
The participants found that once they got home nothing was as normal and they had to rethink how to
undertake the smallest activity. This involved reframing what they thought as normal and working through
activities by trial and error or by planning ahead how they could be done. Helpful equipment supplied by
friends and the NHS made life easier. Being creative and using imagination to think things through could
lead to a sense of achievement.
You have to start being imaginative and do things. You just have to learn how am I going to go to the
toilet and bathroom. How am I going to wash my hair, how am I going to shower . . . You felt like you
had achieved something if you could do it and you had thought that process through and oh I can do
this, I can do that.
Participant 22
Learning through experience was crucial, as was finding ways of achieving activities while also accepting
what was not possible; transporting cups of tea was a regular example of what could not be done while
hopping. Occasionally, some solutions did not work so well, leading to unexpected weight-bearing incidents:
I did manage to get in the bath but the stool I was using to sit on went from under me and that’s
when I put the weight on my foot.
Participant 11
If it was not straightforward some participants did not attempt to bath or shower during their 6 weeks’
non-weight-bearing. Undertaking activities in a small space where there was very little room and a walking
frame created worries about a possible fall. For many there was a sheer determination to maintain
household standards, ‘It’s a representation of me’ (participant 26), even though it was difficult to do and
took longer than usual. Finding ways of doing things was through experience and trial and error, and
creative ways were found to do what would otherwise be normal daily activities.
Finding ways of keeping busy
The participants felt that their lives had suddenly lost any sense of freedom and spontaneity. They had to
adapt to new activities or bring to the fore existing activities that could be undertaken within a confined
environment. Participants who could draw on skills such as sewing, embroidery or computer-based work
seemed to fare better in finding suitable occupation. However, planning was required even with these
activities if they were to be maintained effectively:
Really it’s things just need a little bit more thinking about, just really the lack of freedom to get in
my car.
Participant 26
However, manual-based or outdoor activities were impossible to achieve, such as woodturning, cycling,
swimming, walking or clay-pigeon shooting:
It just stops, it can’t be done, that ended until it could be started again.
Participant 27
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Creative ways of maintaining activities, such as practising the saxophone, were found using positioning
and household items. Wheelchairs were a boon and enabled participants to move around freely inside and
outside the home. However, some participants struggled to find suitable occupation and felt bored
and frustrated:
I’ve laid there waiting for something to happen and then you’re doing nothing all day and in the
evening you think I’ve got to go to bed again now.
Participant 25
Social connections were crucial:
She got me out without too much difficulty and I pruned my clematis which was getting on my nerves
and that was a very successful feeling . . . I was triumphant doing that.
Participant 32
A new way of being was required that enabled participants to adjust mentally. The participants inhabited a
smaller space both geographically and mentally, but were joyful when they found they could move out of
this space.
So you just put yourself in a completely different zone, I can’t describe it, it’s not like, I don’t mean like
meditating or something but your life becomes very small and within that you try to control it as much
as possible I think, in terms of your comfort, your entertainment, you know all that stuff . . . It is only
now that I think that yes that is what I was doing, I was in a different layer of existence – a parallel
universe almost. I had switched off from everything normal and if I did do anything normal, it was a
bonus, like wheelchair gardening . . .
Participant 12
Mental strategies were required to reframe the present and switch off from normal activities and refocus
on what was possible within a confined physical space and reduced mobility.
Theme 3: struggling to move
Living with hopping
Struggling to move was problematic for all participants. The ability to walk was taken for granted and they
felt disabled and prematurely old. Hopping was considered to be a nightmare or terrifying; no one found it
a good experience and, although some adapted well depending on their fitness and agility, some could
not adapt. Walking frames and crutches impacted on other areas of the body, upper arms, knees, palms,
the ‘good leg’, often creating more pain than the actual ankle fracture. There were many accidental
weight-bearing incidents or near falls:
I was nervous and twice I had times where my foot slipped.
Participant 36
I had trouble with both my knees, the doctor called it ‘housemaid’s knee’ . . . I had to hold on to the
[walking frame] and they knew I was doing it wrong and I was terrified of falling on it and I was
putting all my weight on it and ended up with sore arms. I was leaning right over it, I couldn’t help it
and I was going fast, I couldn’t help it. A couple of times I went to the loo and had a couple of near
misses, going over.
Participant 2
The participants found crutches were not easy to use – ‘But for about three weeks after I suppose I
couldn’t cope with the crutches because my balance was all out and I was giddy and I felt nauseous’
(participant 11) – but got used to them over time and used them successfully once they felt better.
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Frames were in general accepted as providing more security, but neither device was effective on uneven
surfaces. Participants indicated that finding appropriate footwear was a serious problem:
You move your foot back and your slipper doesn’t go with you and then you lose balance. I’ve had a
few scares with that.
Participant 10
Participants found managing stairs very difficult and many, if they could, didn’t attempt them; some were
terrified of falling down the stairs:
You look down from the top of the stairs and you think oh my God.
Participant 31
Often participants went up the stairs on their bottom and put a chair at the top of the stairs to enable
them to get from sitting to standing. Getting about the house was a struggle.
Yes that’s right. I think people have been shocked to see me and to see how I have had to cope
around the house. Well when they see my sort of ladder for getting up and down the main part of
the house it suddenly struck them that this is quite a difficult thing to negotiate you know, and then
having to go everywhere in a wheelchair.
Participant 7
Struggling to move could be seen as ‘the struggling body’ which left them tired and lacking in energy,
and they often felt low and depressed; sunshine, visitors and exercise were good for their spirits.
Moving forward
Moving forward in terms of mobility was seen as real progress, a ‘breakthrough’ (participant 7), being able
to move from the walking frame to crutches felt like freedom and they could see the future unfolding:
Yes and there you are looking at yourself 3 days ago I was in the boot and now I’m in shoes.
Participant 21
The move to weight-bearing was approached with caution; participants were weary of pain, and used the
walker boot for support or when they needed protection. They were unsure how their ankle would
function and fearful of causing damage:
I’m weary of it, I don’t want to break it or hurt it.
Participant 3
Learning occurred through experience and trial and error, with participants working out what they could
and couldn’t manage:
It did send a bit of a shooting pain up the back of my leg.
Participant 31
The Sampson boot was seen as good for support and protection but not good for stairs. The body had
come to the fore and there was a greater awareness of its fragility, the ‘fragile body’. There was a sense
of watchfulness:
I think from here on in I might be more watchful about what I do.
Participant 29
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Removal of the cast created a sense that the foot did not belong to them any more:
It doesn’t feel part of me any more . . . it feels as if it’s had bad cramp and there’s pins and needles
kicking in, it feels a bit sort of tingly.
Participant 29
There was a concern about the future outcome of the intervention in relation to their return to normal
activities and exercise.
There is worry yes of course and all the time you’re slightly worried, is it ever going to be the same
again . . . Yes and will I be able to run, I’m not a big deal runner but I go for little jogs along the canal
but not for hours on end but I want to be able to do that and I want to be able to go walking in the
mountains, how I will feel about that I don’t know but more wary I think.
Participant 36
There was a general lack of confidence, fear of falling, or ability to prevent a fall, in relation to moving
forward. Moving forward was something participants wanted to do but their bodies were fragile and they
were now more watchful and protective, not wishing to cause any further harm. There was a feeling that
confidence would slowly grow over time and physiotherapy was mentioned as helpful.
Theme 4: treatment and being in the trial
Living with a close contact casting
Living with a CCC was seen within the overall experience of struggling to live with a fractured ankle; with
personal benefits of no surgery, no scar, less risk of infection, lack of further surgery to take the metalwork
out. The cast itself was generally seen as comfortable, ‘quite comfortable and I had no pain at all’
(participant 10), with some anxiety about looseness as the swelling lessened leading to extra visits to clinic:
I thought I had better tell someone that I could move around in this.
Participant 32
Participants who experienced discomfort focused on heaviness and tightness due to swelling leading to
pain. Participants actively managed their legs with elevation during the day when they could to control
the tightness.
The first 2 weeks as soon as I put my leg over the bed I could feel the cast filling up and it felt like
something was going to explode because I had to take my foot off the ground and do it in stages but
that got better and it wasn’t too bad but I try to keep a happy medium, not being upright for too long
and not being horizontal for too long, just trying to keep the blood evenly distributed.
Participant 31
They endured discomfort on the basis that they hoped their ankle would heal; they did not question the
strength of the ankle without metalwork but wanted to walk again. They came into clinic to have
the plaster changed if the pain was overwhelming. There was uncertainty about healing; radiographs
were the only tangible evidence and there was anxiety about causing further harm. The experience of
having the ankle remanipulated at 2 weeks was unexpected, but the evident skill of the surgeon enabled
the participants to feel positive and secure about the outcome:
I was so impressed at how they did that, to get those bits back in just by feel, that’s amazing.
Participant 35
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
However, confidence was undermined for participants and they had a sense of security and protection
staying within the home environment.
One thing I have discovered, I’ve done less because I’ve just wanted to stay home and stay safe, that’s
the thing I really felt particularly when I came back the second week and it had moved so it had to be
remanipulated, which was fun . . . I couldn’t think of anything I had done to move it, it wasn’t as
though I had fallen over and that did knock my confidence and I think that’s why I tended to just stay
home and potter around the house and not go out. I did find it very restrictive and I think certainly in
the early days I got quite depressed, sometimes the thought of 6 weeks . . . it’s not something I would
ever want to do again. I think if you break your arm you can still move around. Losing the use of a leg
is really, really tough I think.
Participant 35
Crossover to metalwork was an emotional time for participants, who felt that they had endured a
treatment at considerable cost to themselves and their partner; they were angry, disappointed and sad.
They felt they had struggled enough and now had to find the energy to face surgery and another 6 weeks
of non-weight-bearing:
I’ve just got to be brave and whether you can stand up to it, can you (to husband)?
Participant 14
They questioned the trial and the care they received as they tried to make sense of what had happened:
Yes, but the point I’m trying to make here is that if the doctor said at the outset you‘ve got a 5%
chance of this working.
Participant 15
Participants endured the heaviness of the CCC and actively managed the swelling, pain and discomfort;
part of the uncertainty of living with CCC was not knowing if healing was occurring and the anxiety that
they might further damage their ‘fragile body’.
Living with metalwork
Having surgery and metalwork was accepted as normal by participants and others in their family; often
they knew someone with metalwork. Some would rather not have scars or ‘some foreign body stuck in
there’ (participant 10). Concerns were that the metalwork would go rusty, break, restrict movement, cause
allergic reactions or that the pins would require taking out. There was a sense of finality about metalwork
that enabled participants to feel that at least the ankle was fixed and had additional strength, ‘The plate
must have been better because its strengthened the bone’ (participant 3), which avoided the uncertainty
of not knowing it had healed. This was set against the background of advancing age, in which time
was precious.
It doesn’t really bother me, I mean if I was younger it might but I’m just so glad that people tell me it’s
the best way really to get you on your feet quickly because it’s so fixed and you can’t really do
damage you know following the op. Well obviously you can but you know if you follow the rules
you’re pretty safe and so I was glad about that in the end, life’s too short to spend months and
months and months around the house worrying about whether or not the bone has knitted properly
but I’ve no idea if that is the case . . . Yes, a quick fix. The way that the surgeons you know are always
saying ‘I fixed you up. You’ll be fine now. That all went very well and off you go’.
Participant 12
Both groups had pain at injury, and postsurgery pain was experienced particularly in the first 2 weeks.
There were problems with controlling the pain, although some participants were surprised to have no pain
at all: ‘No I wasn’t in any pain at all after the operation’ (participant 11). Both treatment groups had
QUALITATIVE STUDY FINDINGS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
problems with uncontrollable shooting pains that came unexpectedly and were incapacitating and could
not be controlled with medication. For some this increased in frequency on weight-bearing.
It’s not that painful when you walk on it – it’s ooh that feels a bit uncomfortable but then I’ve been
woken up typically twice a night 1.30 and 4.00 o’clock is the usual time in absolute agony and that
went on for about the first week after I was weight-bearing and I presume it’s because when sleeping
all these healing processes are taking place . . . my goodness the pain is awful and wakes you up even
though I’ve usually gone to bed with painkillers.
Participant 7
Some participants had a lot of discomfort from fracture blisters; those with a removable cast really valued
the ability to get relief from discomfort and provide attention to the skin and wound:
I thought that was good because if at least I was sitting down with my foot up I could take it off.
Participant 6
Metalwork was accepted as an expected necessity and was felt to fix the ankle and be strong, but the
group lived with the uncertainty of further complications.
Decision-making
Participants’ experience of the intervention was set within their broader experience of living with a
fractured ankle. There was a feeling of inevitability that some sort of intervention was required, ‘I just
wanted to get the whole procedure over and done with as quickly as possible . . . Just sort this ankle out
and stop the pain’ (participant 22), and they trusted that professionals had the knowledge and would
supply an appropriate intervention. Participants chose to join the study from a sense of altruism to
improve knowledge for the future, balanced with minimum effort although some couldn’t really remember
the trial:
It’s a little bit of a payback really, not much, the study doesn’t seem to have required any great effort.
Participant 24
Some were initially worried they might not get the best treatment:
I was frightened that it was something that hadn’t been tried and tested.
Participant 33
They felt that they could not really compare both arms because they had no experience of them and could
go only on what they had been told. On randomisation, however, some had decided one way or the other
which option they preferred and were disappointed with the outcome. There was a preference for CCC as
participants had thought through this option as the ‘new’ intervention and were convinced of its value.
Although they knew the intervention would be randomly assigned, the outcome did not sit well with how
they felt.
Well I didn’t mind at all actually you know. And when she said you’re going to have the plates I was
quite disappointed really, I thought I was going to try the different one, you know. But it’s been fine
and I don’t know what the other one would have been like anyway so, so what you don’t know you
can’t compare really can you? . . . No, you know when the computer decides don’t they and the
computer decided ‘no, you can’t have that’. After I came around to it and then she said, no, you can’t
have it, oh right.
Participant 11
There was a preference for the CCC because it avoided the need to have an operation or metalwork,
avoided wounds so that there were ‘no scars or cuts’ (participant 13), reduced the risk of infection with
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‘flesh-eating bugs’ (participant 33) and was better for ‘brittle bones’ (participant 35); for some it felt like a
‘lifeline’ (participant 19). ORIF was preferred because it was an intervention that participants were familiar
with and that they felt was tried and tested, and there was a concern that the cast for CCC would not be
close fitting enough. Participants could not always articulate why they preferred the metalwork but they
felt it was right for them:
I did remember feeling quite relieved when I knew I was going to have the conventional plate and pin
as opposed to the close cast and why I don’t know, I’ve got no idea why.
Participant 17
At 6 weeks, participants did not express much interest in relation to what it would be like if they had the
alternative intervention. At this stage they had endured their non-weight-bearing period and were looking
forward to regaining some form of mobility. Those few who experienced a crossover to metalwork did
question their original treatment (see Living with close contact casting).
The participants were very pleased with the trial processes and hospital contacts because they
saw the same people over time, who knew them, and they felt that they were fast tracked through
the system and rarely had to wait very long. They liked the continuity, being known and having a
contact telephone number, and they felt at times as if they had their own private nurse. It was easy to
enter the trial, participants did not feel stressed and the demands made on them for information
were minimal.
It’s been quite nice as every time I come to hospital, it’s only been four times; Kate has been there to
meet me so I’ve felt like I’m somebody special. I’ve felt like an individual rather than a long line of
people with long faces and a plaster on so I think it has been very positive.
Participant 26
Altruism therefore existed alongside feelings of personal benefit gained from being in a trial. In addition,
despite initial feelings of disappointment in relation to the treatment arm at the time of interview,
participants felt that they had had the right intervention for them.
Discussion
The findings reflect that the participants experienced the themes of suffering, getting on with daily life,
struggling to move and treatment and being in the trial. The theme of suffering reflected the emotional
work participants undertook in relation to feeling vulnerable and being old and to emotional containment
as a way of enduring but also maintaining relationships for the future. The theme of getting on with daily
life demonstrated how participants reframed their lives by being proactive, drawing on their own and
others resources to recreate meaningful lives within existing limitations. The theme of struggling to move
encompassed new ways of being, as participants worked hard to move their fragile bodies around a
confined life space and moved forward with a heightened sense of emotional fragility. The theme of
treatment and being in the trial identified the different experiences of the two treatments; how
participants actively managed their symptoms and made sense of being in a trial.
Suffering
The experience of living with ankle fracture had elements that were similar to those of younger adults12
but differed because the dependency of the participants was linked to their experiences of old age and
of caring for their parents and others in the past. The participants’ experience was similar to chronic
conditions in which changes in appearance led to feelings of old age and unattractiveness and a reduction
in capabilities led to dependency and a sense of uselessness.100 Oakley101 suggests that ‘ageing, like illness,
is primarily an experience of embodiment: a time in our lives when it’s hard to pretend that we are in any
sense separate from our bodies’ (p. 111). As a consequence, participants could feel low and depressed,
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sometimes exacerbated by lack of sleep or pain. This is similar to the studies of hope in acute trauma care
in which patients oscillate between hopefulness and hopelessness, when feeling depressed reduced their
capacity for hope.88 To mitigate these feelings participants actively focused their mind to stop worrying,
used positive thinking, determinedly found ways of doing things they felt were important, kept busy,
garnered social support or got back to work.
The participants lost their normal ways of being and relationships were disrupted. Embodied endurance,
incorporating physical, emotional and social aspects, came to the fore as participants struggled to live
within a confined geographic space, to move around and to live with pain and discomfort. Emotional
endurance was evident when emotions were put on hold and participants stoically just got on with life, as
identified by Morse and Penrod.102 Their framework linked the concepts of enduring, suffering, uncertainty
and hope leading to a reframing of self as people moved through the illness/injury experience. In this study
these concepts were present but reflected the concept of lived experience rather than a focus solely on
emotions. Acceptance as a means of enduring was a short-term strategy of being in the present in this
study rather than as a result of a deep understanding of the impact of the event and a route to hope for the
future as identified by Morse and Penrod.102 In this study, suffering and enduring were apparent throughout
the 6–10 weeks after treatment, were overlapping and were incorporated an embodied lived experience.
Participants and their carers undertook emotional work to manage their relationships with a view to the
future. A form of containment was evident:103 ‘the ways in which emotion is experienced or avoided,
managed or denied, kept in or passed on, so its effects are either mitigated or amplified’ (p. 525).
Normal patterns of intimacy were disrupted by notions of a fragile body, and feelings of helplessness
required processing. Physical support for daily life was required, which is also found in the demanding/
dependent body that is identified by Kvigne and Kirkevold.104 Normal relationships that were taken for
granted required active management through minimising needs and supporting normal leisure activities to
reduce the burden of care on the partner in order to facilitate good relationships in the long term.
Getting on with life
The participant’s sense of self in this study was disrupted by an inability to carry out normal roles and
responsibilities. They used their knowledge and experience, and that of their partner, family and local
community, to creatively problem-solve daily activities, gain social support and create opportunities for
leaving the home environment. The suddenness and impact of the injury experience had elements of
‘biographical disruption’ and a ‘critical situation’ identified in relation to chronic illness.105 Bury105 suggested
that reflection on biographical lives and self-concept occurred along with an ability to use social and
community connections to mobilise resources with a reliance on their ‘own stocks of knowledge and
biographical experience’ in the light of limited medical input (pp. 173–4). Conceptual understandings in
many areas since Bury105 have moved forward and further work on areas such as age, ethnicity, context and
norms is still required,106 but the sense of disruption and use of personal experience and social resources is
evident in this study. Being busy and sorting out new ways of being and doing was a way of getting on with
life alongside finding meaningful occupation. In other areas of injury finding meaningful occupation is
important for self-identity, which is constructed through interactions with others.107 In this study those who
lived alone or could not find meaningful activity struggled with getting on with life.
Struggling to move
Daily life was dominated by the struggle to move ‘the struggling body’, which was problematic for all
participants. This goes beyond Kvigne and Kirkevold104 and their notions of the limited body to imply action
and effort. There was a lack of skill with using walking frames and crutches, also noted by Forsberg et al.,92
and with getting up steps and stairs; participants drew on experience and trial and error to move around.
Older women who have experienced a fall note how walking aids expose their vulnerability and weakness to
others yet are essential to maintaining daily life.108 In this study, living with hopping reduced the geographical
space participants could live in, in and outside the home. Reduced life space outside the home is also
identified as the result of living more carefully after a fall.108 Any support for mobility from professionals was
gratefully received, although not consistent in its provision. Many participants’ skill improved as they felt
better and became more mobile, but many did not improve and just waited until they could weight-bear.
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Participants expressed hope as a keenness to move forward and get back to normal in a similar way to
other trauma patients;88,90 however, the participants were hampered by fear, anxiety and weariness
regarding weight-bearing. Loss of confidence, increased caution in general life and a fear of falling support
existing evidence on patient experience in relation to trauma.89–92 Participants’ bodies, which were
previously uncontested and taken for granted, were now vulnerable and fragile, requiring monitoring
and active management. This is similar to the unreliable and betraying body identified by Kvigne and
Kirkevold104 in which participants did not trust their body to work consistently; this was evident in the near
misses and falls in this study. Participants also felt emotionally vulnerable; a vulnerable body can be ‘in a
way defenceless’ (p. 1299) and open to pain and emotional fragility.104
Treatment and being in a trial
The lived experiences of the two treatments were similar as both groups suffered and endured the
impact of ankle fracture and lived with non-weight-bearing with a cast and both lived with uncertainty
regarding future function and the necessity for further interventions. The main differences were the
ways in which the treatments could be experienced: (1) CCC was heavy and tight causing discomfort and
pain, with swelling that had to be actively managed, healing progress that was unknown, the possibility
that participants may cause damage to the ankle and strong emotions if surgery was required; and
(2) ORIF was a known entity, tried and tested, which was strong and provided structural support but
there was uncertainty regarding possible infection. Participants actively managed specific symptoms based
on their experiential knowledge of what worked best for them using their own stocks of knowledge as
identified in Bury.105 A feature of CCC was living with the uncertainty of not knowing if healing was
occurring; Oakley101 notes that ‘we have no way of knowing what our bodies are silently doing to us’
(p. 65). In contrast, those with metalwork felt some security from perceptions of their ankle as fixed.
There was some concern in both groups about causing damage to their ‘fragile body’, which is also
evident in women living with osteoporosis109 and women at risk of falling who actively protect themselves
from further damage.108
Although altruistic reasons for participation in the trial were expressed, other common rationales for trial
participation included trust in the surgeon and personal benefits.84,85 However, there was concern that
personal benefits may link to misunderstandings of trial design84 and, in this study, there was evidence
that some participants did not fully understand randomisation or had little memory of the trial.
There were, at randomisation, strong feelings of preference for one treatment or the other, although,
on reflection, participants felt that they had the right treatment for them. This suggests that there may be
an element of ‘therapeutic misconception’ identified in other studies84,85 based on the interaction with
clinicians and how participants make sense of that interaction. The participants often could not
articulate a rationale for their preference or drew on experiences of family and friends, also noted by
Canvin and Jacoby.85 In order to understand this, study of the sources of knowledge that participants use
to make sense of interactions with clinicians and the process of consent is required. Participants felt they
could not compare treatments as they had experienced only one of them and they could not imagine what
the other one was like, suggesting experiential ways of knowing are important when making sense
of interventions.
Limitations
The study had four limitations:
1. One interview was undertaken at 6 weeks post injury. An interview nearer the time of consent would
provide further evidence regarding the decision to participate in a clinical trial. A longitudinal study that
followed patients throughout the year would provide understanding of the experience of ankle fracture
over time.
2. Partners and family were not interviewed. They were often present at the interview and their lived
experience would be useful additional evidence.
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3. The clinic setting was not always conducive to obtaining a good interview. Some interviews were
curtailed because of the intense nature of the clinic visit and unpredictability of hospital transport, but
data saturation was achieved. Other ways of interviewing such as home or telephone may have
been useful.
4. The sample was not ethnically diverse but reflected the population in the study. Non-western, ethnically
diverse populations may have culturally different experiences.
Conclusions
The findings of this study suggest that participants require professional support for their new way of being
to make it easier for them to endure this period of recovery. Supportive activities that focus on the
experience of injury in relation to being old, the vulnerable and fragile body, changing relationships, skills
required for mobility and support for active management of living with the prescribed treatment are
required. Supportive activities would require research evidence but could focus on co-ordinated packages
of care, accessible learning materials, specialist-based emotion-focused intervention, consistent allocation
of helpful equipment and educational materials around lived experience for patients and staff. Further
research is required to explore how this experience, in relation to biographical disruption, is processed
regarding healthy ageing and future health-care experiences. A longitudinal study would provide valuable
insights into the impact of injury over time and implications for rehabilitation. This study has clearly
identified the similarities and differences between the lived experiences of both treatments; both of which
were considered acceptable. Further exploration is required to understand how patients make decisions
about preferred treatments and process the consequences of these decisions. The experience/stocks of
knowledge participants draw on, the way they make sense of risks, the way they process changes in
treatment because of a lack of bone healing and how the treatment choice impacts on future treatment
decisions require further exploration.
Summary of key findings
l Both treatment groups, CCC and ORIF, require support to ease, when possible, the struggle to live with
a fractured ankle. Support that focuses on (1) suffering, vulnerability and challenges in relation to roles
and relationships; (2) getting on with daily life, finding ways of doing things and keeping busy; and
(3) struggling to move, living with hopping and moving forward.
l Participants with CCC require support for managing pain and discomfort caused by swelling, living
with uncertainty in relation to healing and concerns regarding further damage to their ankle. Those
requiring further surgical intervention require help that supports their ability to endure further periods
of non-weight-bearing.
l Participants with ORIF require clarity regarding aspects around the use of metalwork and support for
concerns regarding infection and further surgical interventions.
l Further research is required to examine how patients develop preferences for treatments and process
the consequences of decisions made about treatments in the light of their recovery.
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Chapter 6 Discussion
This discussion chapter reviews the aims of the study and summarises the main findings beforeconsidering the internal and external validity of the trial. The interpretations and implication for clinical
practice and policy are then considered, the findings of this study are compared with other studies and
recommendations are made for future research.
Aim and overview of study findings
The decision to treat an ankle fracture by surgery in older adults, compared with younger adults, is
complicated by a higher prevalence of comorbidities, increasing the risk of infection, surgical wound
problems and inadequate fixation as a result of poor bone quality. Existing trial data are of poor quality
but overall indicate that traditional casting methods may lead to a higher risk of malunion because of a
loss of fracture reduction. Traditional surgical teaching equates malunion (post-traumatic joint deformity)
with poor patient outcome. Therefore, surgery is usually the preferred recommended treatment, with the
aim of optimising alignment and congruence (best fit) of the ankle joint, assuming this will translate into
better ankle function for patients. In the AIM trial, we aimed to estimate the clinical effectiveness and
cost-effectiveness of a new casting intervention, CCC, compared with ORIF surgery.
Our primary objective was to estimate if there was equivalence in patient-reported ankle function outcome
between CCC and ORIF, as measured by the OMAS, at 6 months. A qualitative study of participants’
experiences of the intervention and of being in a randomised controlled trial was also embedded into the
trial in order to build the context and frame of reference for interpretation of the study findings by
clinicians and patients.
This study was a definitive large-scale equivalence randomised controlled trial; assessors were blinded and
it was undertaken in a pragmatic way across 24 hospital orthopaedic trauma departments in the UK.
The trial has demonstrated ankle function outcomes were equivalent between CCC and ORIF at 6 weeks
and at the primary end point of 6 months. There were also no differences between treatments in the
secondary outcomes of quality of life (mental and physical), range of ankle motion, ankle pain, mobility
and patient satisfaction.
The most common treatment-related issue in the CCC arm was a loss of closed reduction. As a result
about 1 in 5 patients who had CCC later returned to theatre to receive ORIF. A later conversion to ORIF
was an expected and allowable event in the study protocol. Fewer participants in the ORIF group, about
1 in 20, required additional surgery within 6 months; these surgeries were usually for surgical wound- or
implant-related complications, but some of which were clinically serious. At 6 months, CCC was associated
with higher rates of radiological malunion and non-union.
The experiences of the treatments were similar as both groups endured the impact of ankle fracture and
uncertainty regarding future function and the necessity for further interventions. However, those who had
CCC experienced concern regarding healing and the possibility of further damage to their ankle. Returning
to theatre for ORIF in the first 6 to 10 weeks after treatment impacted on how they felt and how they
made sense of their treatment. Participants who received ORIF had concerns about the use of metalwork
and the potential for infection.
Close contact casting resulted in a modest mean cost savings to the NHS and society. The cost savings
were driven largely by savings in theatre time, which were partially eroded over time because of increased
readmission and health services costs. Consistent with the clinical results, incremental QALYs following
CCC were no different from ORIF, with evidence leaning towards a slight advantage with CCC. Over
common willingness-to-pay thresholds, the probability that CCC was cost-effective was very high.
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The conclusions for the clinical and health economic evaluations were consistent for the per-protocol or
ITT analyses.
Internal validity and methodology
The study was powered to be a definitive equivalence trial and had lower than expected loss to follow-up.
Blinding of outcome assessors and very low levels of missing data across the outcome measures strengthen
the trial results. Allocation concealment was ensured through random computer allocation, stratified by
site and fracture pattern, on participant registration via a remote telephone randomisation service.
Analyses were preplanned and agreed by the DMEC. The consistency between the conclusions of the per
protocol and ITT analyses improves confidence in the findings of the AIM trial.
The OMAS is one of the most commonly used outcome measures in ankle fracture research,23,110 but has
been criticised for methodological shortcomings in its development.111 We found no published minimal
clinically important differences for the OMAS and, therefore, had to develop the sample size drawing on
wider literature and in consultation with clinical experts. The OMAS has evidence supporting its construct
validity and there are few alternative condition-specific measures.112 More recently, additional evidence
supporting the validity and reliability of the OMAS has been published.113 In the context of the AIM trial,
the conclusions drawn from the OMASs are supported by the high precision of estimates and the
consistency with the secondary outcomes [SF-12 (mental and physical), EQ-5D and EQ-5D VAS, timed up
and go test, ankle range of motion and pain].
On formal analysis the success of the outcome assessor blinding at 6 months was adequate. For the
6-week assessment the assessor was aware of relevant precautions and contraindications to the clinical
assessment and so was not blinded. The 6-week results did not have a strong influence on the analysis or
conclusions for the clinical and heath economic evaluations, so we feel this limitation does not detract
from the overall findings.
External validity and generalisability
We consider the external validity of the AIM trial to be good for several key reasons. The study was
conducted in a range of acute hospitals including major trauma centres through to smaller district general
hospitals and, therefore, is representative of the range of settings for ankle fracture interventions in the
UK. The CCC intervention was delivered by NHS surgical teams with relatively little training and the trial
was pragmatic, which allowed other aspects of care except the intervention to continue unchanged.
Based on previous studies in the UK,1,24 the demographics of the trial participants were representative of
the age and sex expected in older adults with ankle fractures, with the majority being female and
approximately 70 years of age. The exclusion of patients with insulin-dependent diabetes mellitus and
established peripheral vessel disease limits generalisability. However, the results of this study open up the
option to investigate the applicability of CCC to patients with these diseases, as there is a high risk of
harms after surgical treatment.27,114,115
The primary end point at 6 months could be criticised as being too early for definitive assessment of
outcome. A recent systematic review and meta-analysis,9 however, demonstrated that improvement of
patient outcomes from all previously published studies of ankle function outcomes after ankle fractures
showed that improvement plateaued by 6 months and, therefore, supports this as the definitive
assessment point.
There were differences in experience level of the operating surgeon for ORIF and CCC. The operating
surgeon for CCC was consultant grade for approximately 85% of procedures. For ORIF, approximately 39%
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of operating surgeons were consultants. CCC and ORIF procedures had high levels of consultant
supervision, 97% and 76%, respectively. This difference was driven by the protocol as it was felt it was
necessary to introduce the standard of direct consultant supervision for CCC because of the uncertainty of
it as a new intervention and the likelihood of clinical issues early in the introduction of the technique.
We did not identify a learning effect within the trial, although we might not expect to detect it given that
just under half of surgeons who conducted CCC in the trial performed only two applications and that these
were not necessarily conducted within a close enough time period to reinforce learning. Nevertheless, high
consultant involvement is consistent with a new intervention and contemporary NHS practice, further
supporting its applicability in practice without concern of unattributed inexperience or learning effects.
Interpretation and implications for clinical practice and policy
The implications of the results of this study to the orthopaedic trauma surgical community are significant and
challenge what has been orthopaedic surgical dogma and teaching for several decades. For patients, who
are increasingly being involved in decision-making about their treatments, these findings are an important
contribution. The qualitative study within this trial elucidated the patient view that the opportunity to avoid
undergoing surgery was appealing. The tight equivalence around the point estimate of the primary outcome
and the almost identical patient-reported secondary outcomes strongly support the validity of the conclusion
that CCC is clinically equivalent to ORIF. The previous extrapolation of witnessed outcomes for this injury in
younger patients to patients 60 years of age and above, in whom there are higher incidences of poor bone
quality, diminished circulation and skin resilience, now seems unjustified. The study protocol identified that
both CCC and ORIF would be associated with treatment-related issues and complications, but that the type
would be different for each (e.g. loss of reduction with CCC and surgical wound problems with ORIF). Such
treatment-related issues and adverse events that were known to occur and therefore ‘expected’ were
monitored for absolute numbers and as a proportion, and expected ranges were agreed with the DMEC.
This information is now important for surgeons explaining the equivalence and for patients to understand
the advantages and disadvantages of the two treatment options. In general, ORIF has the established risks of
surgery and if problems occur they are usually more serious and 6% of patients require a second surgery
within 6 months. Approximately 20% of patients who start off by receiving CCC later require an additional
visit to theatre to undergo ORIF for unacceptable loss of position, although this may be seen as a positive
outcome with 80% avoiding surgery to no detriment. Patients may value the opportunity to try to avoid
surgery, in the confidence that there will be an equivalent outcome in terms of ankle function at 6 months.
However, the qualitative study would suggest that support for the group that converted to ORIF would be
required to help them process the change in their treatment and endure another period of non-
weight-bearing.
A significant and consistent finding across the outcomes in the AIM trial was the major impairment in
function and quality of life resulting from an ankle fracture, irrespective of the treatment received. This
observation was supported by the qualitative study that identified how participants struggled to live with a
fractured ankle. They experienced feelings of vulnerability and were challenged in their roles, relationships,
daily life and in their ability to mobilise. This finding highlights the implications of ankle fracture for older
adults to stakeholders in health- and social-care and policy in the UK.
There has been a deficiency in the published literature relating to the treatment of ankle fractures in older
people. Surgeons recognise that they have their own preferences, formed over time from clinical and
training experiences, and perhaps modified by the limited published research. Those preferences were
borne out in our study by enquiry made of surgeons after randomisation. Of patients allocated ORIF,
for 85% of their surgeons that would have been preferred treatment, whereas CCC was the surgeon’s
preference in only 28% of those allocated to CCC. This has considerable implications for the difficulty in
adoption of this study’s findings and translating them into shared decision-making with patients.
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There are also implications in interpreting the results of this trial, as it can be assumed participating
surgeon preferences may have influenced perseverance with CCC and willingness to redo the
manipulation and cast in the presence of loss of fracture reduction. One key aspect of follow-up when
using CCC, as with any conservative treatment for unstable fractures, is close monitoring of the fracture
position in the first few weeks after injury with the opportunity to reapply the cast. The willingness to
reapply CCC may be important. We recently conducted a laboratory investigation of the effects of
reduction in lower leg swelling. We found that CCC was susceptible to a loss of ankle stabilisation as
swelling resolves, highlighting the importance of monitoring and reapplication of the cast as necessary in
the first few weeks after injury.116
As a pragmatic trial, the decision to reapply CCC or convert to ORIF was left to the treating surgeon’s
judgement. The decision to convert 20% of CCCs to ORIF may, we assume, have been based on the same
preconceived opinions that were responsible for the preference of surgeons for ORIF, that is that they
needed to achieve exact anatomical restoration of bony architecture of the ankle joint components and
that implants were necessary to maintain that reduction of deformity and hold fracture fragments until
healing. Those judgements have been central to surgical methods teaching for fractures involving joints for
several decades. They are now challenged by this definitive study in which we move from process
measures, complications rates and radiological outcomes to patient-reported outcomes in an arguably
well-conducted adequately powered and valid randomised blinded trial.
The higher rates of malunion/non-union associated with CCC compared with ORIF indicate that achieving
alignment may be more challenging with conservative treatment. However, the equivalence in clinical
outcome challenges the importance of restoring anatomical alignment of the joint as part of ankle fracture
management in older adults. There will be justifiable reservations of whether or not these differences in
radiological outcomes manifest as clinical issues in the longer term. Pain and disability as a result of later
post-traumatic osteoarthritis will be a concern.20 However, the aetiology of post-traumatic osteoarthritis
may also be because of genetic factors and direct damage caused by the initial trauma.21 Lateral malleolar
non-union is often thought to be more of a clinical issue than medial malleolar non-union. However, a
2012 systematic review found low-quality evidence regarding lateral malleolar non-unions, reporting these
as an uncommon complication and one that can often be asymptomatic.117 These uncertainties regarding
the longer term will be addressed by the extended follow-up of the AIM trial cohort that is under way.
We aim to establish if there are any differences in later ankle function, quality of life and resource use
[e.g. need for ankle arthrodesis (fusion) or arthroplasty (replacement)] at least 2 years after injury.
Implications for training and implementation
The novel intervention (CCC) in this trial was successfully taught to 317 orthopaedic surgeons and the
technique demonstrated to other staff (plaster nurses, technicians and operating room practitioners).
Training was achieved through a short instructional video and a face-to-face demonstration. Plaster cast
application is within the skill set of orthopaedic surgeons, although modern surgical practice has deprived
many younger surgeons of the manual skills of fracture reduction and cast-moulding techniques of
former generations. The CCC treatment method draws on elements of both the total contact cast
technique32–34 for managing diabetic leg ulcers and also those traditional three-point moulding and gravity
fracture-reduction techniques applicable to Potts (ankle) fractures.118 For the CCC intervention to be
adopted there will also need to be a change in the scrutiny of interpretation and surveillance of follow-up
radiographs in orthopaedic fracture clinics.
Cast-related complications such as plaster sores and pain from the cast were common in both treatment
arms. The most clinically serious technical casting complication was plaster saw lacerations on removal of
casts, occurring in 5 out of 275 (1.8%) participants in the CCC group compared with 1 out of 298 (0.3%)
in the ORIF group. It seems plausible that there may have been some technical challenges removing the
CCC with the plaster saw compared with traditional casts and there are several potential reasons.
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The operator of the saw may have (1) not been experienced in using the saw on a minimally padded cast,
(2) not known the cast was minimally padded or (3) been unaware of the location of the foam cutting
strips for protecting the skin, especially if not adequately marked on the exterior of the cast. In addition,
the foam cutting strips may have offered insufficient protection or were not applied during CCC
application. As a pragmatic trial we did not monitor the application and removal of CCC, therefore it is
recommended that when implemented in clinical practice that steps are taken locally to reduce the risk of
plaster saw injuries.
When the AIM study was proposed there was concern raised regarding return to weight-bearing.
The assumption was that ORIF gave patients the advantage of earlier weight-bearing compared
with conservative treatment. As identified in our qualitative study, participants found coping with
non-weight-bearing challenging and so an earlier return to weight-bearing may be advantageous during
recovery. In the AIM study, hospitals followed their own postoperative weight-bearing protocols for
ORIF and we advised no more than touch weight-bearing in the first 4 weeks after CCC. However, we
found no difference in the time to start partial weight-bearing between the two interventions and so those
concerns prior to the trial were not substantiated.
In addition to being of interest to the UK NHS, the findings of the AIM trial are also likely to be of interest
to health services in other comparable high-income countries. The finding of clinical equivalence for a
conservative treatment option for older patients with unstable ankle fracture is also important for low- and
middle-income countries,119 where availability of specialist surgeons and surgical implants can be limited.120
Comparison with other literature
A clinical trial from Canada has been published since the start of the AIM trial and subsequent to the
2012 Cochrane review, comparing ORIF with conservative treatment with a brace or cast.78 The study
included 81 participants who had an isolated, undisplaced, unstable, type B fracture of the distal fibula.
Participants were younger than those in the AIM trial, aged, on average, 41 years. There were no
differences in patient-reported ankle function or quality-of-life scores during the 1-year follow-up period.
In the conservative treatment group, 8 out of 40 (20%) developed radiographic joint misalignment. In the
operative group, 6 out of 41 (15%) experienced a surgical site infection, one of which was deep and
required an additional operation to wash out the joint. Five participants in the operative treatment group
also required an additional operation to remove the metalwork. The Canadian study included a health
economic analysis.76 The economic analysis was from a health service cost perspective, which estimated
that within 1 year operative treatment was not cost-effective. From the lifetime horizon analysis, these
conclusions were different, if it was assumed that conservative treatment results in much higher rates
of post-traumatic osteoarthritis. These health economic findings cannot be easily translated to the
UK NHS, as costs of rehabilitation were not included. There is also a lack of high-quality prospective
research to support the rationale that conservative treatment necessarily results in higher rates of
post-traumatic osteoarthritis.21
Further research
As mentioned previously, in accordance with the IDEAL (Idea, Development, Exploration, Assessment,
Long-term study) recommendations for long-term follow-up in the development of surgical innovation,36
we are conducting an extended follow-up of the AIM trial participants beyond 2 years, funded by the
National Institute for Health Research Health Technology Assessment programme. The extended follow-up
should be completed by November 2016. Longer-term follow-up was deemed important because of
concerns from clinicians over potential later complications or additional procedures (e.g. intolerance
of metalwork resulting in removal, post-traumatic osteoarthritis and possible ankle joint fusion or
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replacement) and their potential to impact on ankle function. The extended follow-up will also inform a
longer-term projection of the cost-effectiveness analysis.
As part of the implementation of CCC in NHS practice, it is also important to examine how patients
develop preferences for treatments and process the consequences of decisions made about treatments in
the light of their recovery. In addition, the need to develop support strategies for patients dealing with the
uncertainties faced when recovering after CCC and ORIF has been identified.
We plan to build on the findings from the AIM trial cohort. We will undertake predictive modelling of the
anatomical fracture patterns, variants of radiological malunion and joint incongruence that predispose to
loss of reduction with CCC (malunion or convert to ORIF). The results of the AIM trial directly challenge the
assumption that the best outcomes for unstable ankle fractures can only be achieved through surgery.
The equivalence of outcome with CCC still begs the question, given the overall significant impairment of
function at 6 months, whether or not it is possible to identify the patients who would benefit most from
one or other intervention. It is possible that certain patient or fracture injury characteristics may be
associated with better outcomes or lower complication rates with one treatment. The substantial decline
in function and quality of life after ankle fracture for those aged over 60 years also indicates a need to
further optimise the recovery and rehabilitation of older patients.
Finally, the findings of the AIM trial, and the recent trial from Canada,78 also raise questions of whether or
not CCC could provide an alternative surgery to adults under 60 years of age; further studies are
now warranted.
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Appendix 1 Trial management
Many clinical trials fail to deliver because not enough attention is paid to the practicalities of deliveringthe project. The AIM trial recruited slightly ahead of schedule, maintaining the trajectory of
recruitment (Figure 21), while also obtaining very good levels of follow-up and relatively low missing
outcome data. We believe that an experienced, dedicated, trial management team who could apply the
same depth of consideration as given to the scientific elements of the study, in addition to the dedication
of the clinicians and researchers at the recruiting hospitals, were critical to success of the AIM trial. In this
appendix we aim to provide a brief overview of the key lessons learned in the central management of the
AIM trial, with the hope that sharing this information will benefit other projects, just as we have benefited
from the experiences and expertise of others.
Overview of the Ankle Injury Management trial project milestones
Study start date was January 2010 and involved 20 recruiting sites around the UK at any one time.
The sample size was 620 participants who were recruited from orthopaedic trauma wards/clinics. The
project funding was for 5 years, with a 6-month set-up phase, 42-month recruitment phase, 6-month
follow-up phase and 6-month analysis and write-up phase. The Health Technology Assessment programme
recognises that good trial management is key to the success of a project and recommends all primary
research projects appoint a dedicated trial manager.
During the early part of the set up phase of the study, the trial manager and chief investigator worked
closely, met regularly and adopted a practical, delivery-focused approach. This emphasis on conduct
took into account the likely barriers to both clinical and participant participation and helped to avoid
unworkable systems and processes. The approach taken by the trial manager was to take the protocol and
turn it into a living project, guided by a focus on how the processes would work best in the realities of
practice. Each activity within the project was evaluated in depth by asking questions such as: ‘If I was
doing that – who I would be? What would I need? How would I do it? When would I do it? How many
times? Where would I do it? To whom?’
The pathway of the participant was tracked from first identification at screening, through to follow-up, to
ensure all decisions made centrally by the trial team took this practical process into account. The attention
to detail paid to the design of CRFs and the order of paperwork prepared for sites was always from the
users’ standpoint. The approach taken is consistent with the recommendations of Farrell et al.,121 who call
for trial management to be integral part of trial delivery.
Building a trial-specific multidisciplinary management team
A multidisciplinary team was funded for this study. The chief investigator was joined by an experienced
senior trial manager who played a lead role in developing the roles of the research physiotherapist and the
data/administrative co-ordinator based on the needs of project/protocol. The research physiotherapist role
required travel throughout the UK to deliver intervention training to surgeons at collaborating sites.
In addition, research nurses based at the Kadoorie Centre for Critical Care Research and Education, in the
John Radcliffe Hospital in Oxford, who led the pilot study phase, provided key guidance and support,
particularly during the set-up phase of the multicentre trial.
During site recruitment, staff reacted to the needs of sites as quickly as possible, discussing any concerns
raised within the team and, when necessary, held brainstorming sessions to think through all possible
approaches. Central trial management staff actively participated in the sessions, were given autonomy to
solve problems independently, and felt fully informed regarding key aspects of the study and the
current status.
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The management group, made up of coapplicants and the central trial management staff, met every
3 months to review progress. In the early stages e-mail updates were exchanged with the group and,
when necessary, specific issues were discussed with relevant members.
Recruitment targets and site selection
Our target was to establish 20 sites, the process of site recruitment and management is outlined in
Figure 22. In the predefined project management timetable, at least one patient per month, per site, was
required to achieve target. Sites approached the trial office via two routes: (1) known collaborators
(orthopaedic surgeons who were part of the Injuries and Emergencies Specialty Group or the Trauma and
Orthopaedic Research Collaboration), and (2) collaborators enquiring after searching the UK Clinical
Research Network Portfolio Database. Interested sites completed a site feasibility questionnaire.
Staff resources funded to support trial activities at sites
When the study was funded it was identified that trauma surgeons would need additional research
nurse/therapist support over that available via the UK Clinical Research Network if the study was to be
successful. This study involved a population aged ≥ 60 years, who had attended hospital after injury.
Site enquiry
Sent CS
Return CSDid not return CS
Sufficient
numbers
Insufficient
numbers
Did not respond after
multiple contacts
Preliminary site visit (optional)
• Surgeon training visits/initiation visit
• Training pack sent (sample CRFs, etc.)
• Nurse finding
• Documents/equipment provision
Approval applcations prepared and sent to principal investigator
Approvals in place/training delivered/’go live’ date set
Recruitment starts
Monitor activity: recruitment and screening figures checked
against CS
Consistent under-recruitment: investigate barriers, discuss
with local principal investigator and team, offer visit
If all avenues exhausted,
agree with local team 
to close site and 
reallocate resources to 
set up a new site
FIGURE 22 Site recruitment and management process for the AIM trial. CS, collaboration sheet.
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Research nurse/therapist time with these patients was key with regard to study tasks, as busy orthopaedic
trauma surgeons would need to be free to react to other emergency operating needs. In addition,
participants attended for 6-week and 6-month clinic appointments at which study data were collected,
one of which was a blinded assessment. The local nurse organised these visits and the relationship built
with the participant helped in achieving good follow-up rates. With the knowledge that all sites were
required to recruit at least one participant per month from the outset and that we had a resource in the
research grant that we could offer sites which equated to a 0.25 whole-time equivalent band 6 nurse cost,
close attention was paid to recruitment to ensure this resource was used wisely. The sponsors contract
with the participating trust indicated that if ‘insufficient numbers of participants are being recruited by the
participating site to the study’, there was the possibility of terminating the agreement. This allowed us to
move resources to a new site if necessary.
Monitoring recruitment
Recruitment was monitored closely. On the first of the month a review of the previous month’s activity was
carried out by the trial office team. Both recruitment and screening figures per site were investigated, and
measured against expected target and figures provided by the site on the original site feasibility
questionnaire.
The following recruitment documentation was circulated to site personnel each month:
l overall recruitment graph (actual/target)
l site-specific recruitment graphs (actual/target)
l recruitment table listing all sites by monthly recruitment and recruitment rate against target
l e-mail highlighting recruitment to date, highest recruiters overall and for the previous month.
As the study progressed, we also introduced a last 6 months-only league table and recruitment rate.
This allowed sites who had underperformed initially to be congratulated for recent successes.
If a site had under-recruited for 2 months, the office team would contact the principal investigator and research
nurse/therapist at the local site. Practicalities of recruitment were talked through in detail in an attempt to
identify where the barriers to recruitment lay. A visit would be offered and/or the opportunity for the nursing
staff to make contact with other nurses in ‘successful’ sites to see what had worked locally for them.
We held ‘collaborators meetings’ each year where the principal investigators and up to two further
surgeons, along with two research staff were invited. In addition, in 2011 we held a researcher day in
Oxford for the nursing and physiotherapy staff from our sites as a forum to share learning and
problem-solve common recruitment challenges.
When it came to under-recruiting sites, we offered support as outlined above. One issue we could not
resolve, however, was the lack of suitable patients presenting. If lower than expected recruitment took
place over a 3-month period, and despite the best efforts of all concerned then continued, resources linked
to the study were re-allocated (i.e. need to establish another site). This was the case with four of our sites:
l In one trust we established recruitment at another hospital within the same trust to allow a wider
screening pool: two geographically (approximately 20 miles) separate locations for which recruitment
figures counted as one site under their trust.
l At another trust, two hospitals who expected a large number of recruits each (geographically separate
as above), accepted that recruitment was unlikely to improve and therefore agreed for one of the two
nurse funding allocations to be removed and for the recruitment figures to be merged, representing
the sites as a trust rather than individually.
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l At one site, we investigated establishing another hospital within their trust but this was not possible
because of restructuring changes.
l At another site, the lack of a suitable trauma hospital within their trust meant that establishing
recruitment at another hospital was not possible.
For the latter two hospitals the sites were closed and new sites were established.
Screening
As mentioned, activity overall at a site was reviewed monthly which meant that screening figures were
interrogated alongside recruitment figures. Screening forms, one per patient, listed the inclusion/exclusion
criteria and allowed the person completing the form to select the reason why the patient had been
unsuitable for the study. The forms were returned to the study office. The first check was the number of
screening forms per month returned to the office, by site. Sites were contacted if no forms were returned
for 2 or more months. The second check was carried out by looking at the reasons, overall and per site,
why patients were not being recruited.
Data management
Sites returned CRFs to the study office using a Freepost account. All data queries were dealt with in a
systematic and timely fashion to ensure missing fields could be highlighted and addressed as appropriate.
Data queries related to primary outcome were dealt with within 24 hours from receipt.
Documentation and process training
Visits to sites were part of the site set-up. Practical demonstrations of the documentation pack were
provided. Owing to the relatively small numbers of patients per site, it was important that the
documentation was easy to understand and that the CRFs were designed taking into account
the infrequency of use.
Trial promotion
A range of promotional materials were also used; some examples were:
l A study logo was used on all documentation to allow easy identification of study materials.
l Pens with the study logo and office telephone number were provided.
l Removable sticky notelets were provided after a request by site research staff, so we arranged for these
to be printed with the logo and key inclusion criteria.
l Magnetic calendars were provided to act as quick tool for nurses to calculate the 6-week and 6-month
follow-up appointments.
l Newsletters were provided to sites in both hard copy and electronic formats. A large distribution list
was established that included any member of staff at a site who had a role to play.
l A website was created with the ability to update recruitment figures and the last site to recruit.
This information was also circulated to the collaborators via e-mail, and allowed for constant referral to
our website where fuller information about the trial could be found.
l New simple and quick-to-read staff packs were provided, including key eligibility information and a
one-page summary protocol. This was provided to sites to disseminate to new staff joining their team.
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l A consulting room poster designed for surgeons to quickly refer to the eligibility criteria was provided,
which also listed their local research nurse and principal investigator details (bleeper, mobile, etc.) to
allow referral if a suitable patient presented.
l Microsoft PowerPoint® presentations (Microsoft Corporation, Redmond, WA, USA) were made,
updating staff at sites with study progress.
The role of trial management
In this appendix we have highlighted some of the key trial management activities that the AIM trial team
believe facilitated successful recruitment. However, it is recognised that it was the hard work and
engagement of the surgeons and research nurses/therapists at the recruiting sites that made the study a
success. The AIM trial team aimed to support sites in their endeavours to aid their work on the study,
while also ensuring adherence with the protocol and optimising data collection and recruitment.
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Appendix 2 Clinical results: intention-to-treat
analysis
Intention-to-treat analyses results
The results from the ITT analyses of the primary and secondary outcomes are presented in this section of
the appendix. The ITT analyses displayed similar results to that of the per-protocol analyses.
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FIGURE 23 Plot of mean scores and 95% CIs for the OMASs over time (ITT).
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FIGURE 24 Plot of mean scores and 95% CIs for the SF-12 mental component summary score over time (ITT).
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TABLE 47 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month assessments (ITT)
Outcome
Treatment group
Unadjusted statistics
(95% CI); p-value
Adjusted statistics
(95% CI); p-valueORIF CCC
SF-12 mental component summary score
6 weeks
Mean 48.3 48.7 0.34 (–1.40 to 2.09); 0.700 –0.14 (–1.78, 1.50); 0.864
n 304 302
SD 11.27 10.57
Median 49.1 49.6
Minimum 16.5 19.2
Maximum 70.2 68.3
Missing 1 1
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TABLE 47 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month assessments (ITT) (continued )
Outcome
Treatment group
Unadjusted statistics
(95% CI); p-value
Adjusted statistics
(95% CI); p-valueORIF CCC
6 months
Mean 52.0 52.2 0.21 (–1.42 to 1.83); 0.805 –0.11 (–1.55, 1.33); 0.876
n 298 294
SD 10.47 9.68
Median 55.4 55.7
Minimum 18.9 19.9
Maximum 66.9 68.4
Missing 0 1
SF-12 physical component summary score
6 weeks
Mean 33.4 33.3 –0.02 (–1.10 to 1.05); 0.967 0.15 (–0.90 to 1.20); 0.783
n 304 302
SD 6.94 6.55
Median 32.5 32.7
Minimum 18.4 18.3
Maximum 57.1 54.9
Missing 1 1
6 months
Mean 45.6 44.2 –1.34 (–3.00 to 0.32); 0.113 –0.59 (–2.08 to 0.91); 0.440
n 298 294
SD 10.01 10.56
Median 46.9 45.4
Minimum 22.1 15.6
Maximum 66.2 64.3
Missing 0 1
EQ-5D mobility score
6 weeks
Level 1, n (%) 11 (3.6) 7 (2.3) 0.292
Level 2, n (%) 248 (81.3) 243 (80.2)
Level 3, n (%) 17 (5.6) 25 (8.3)
Missing, n (%) 29 (9.5) 28 (9.2)
6 months
Level 1, n (%) 135 (45.3) 120 (40.7) 0.475
Level 2, n (%) 131 (44.0) 144 (48.8)
Level 3, n (%) 3 (1.0) 3 (1.0)
Missing, n (%) 29 (9.7) 28 (9.5)
continued
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TABLE 47 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month assessments (ITT) (continued )
Outcome
Treatment group
Unadjusted statistics
(95% CI); p-value
Adjusted statistics
(95% CI); p-valueORIF CCC
EQ-5D self-care score
6 weeks
Level 1, n (%) 167 (54.8) 149 (49.1) 0.028
Level 2, n (%) 108 (35.4) 118 (38.9)
Level 3, n (%) 1 (0.3) 8 (2.6)
Missing, n (%) 29 (9.5) 28 (9.2)
6 months
Level 1, n (%) 243 (81.5) 246 (83.4) 0.642
Level 2, n (%) 22 (7.5) 19 (6.4)
Level 3, n (%) 4 (1.3) 2 (0.7)
Missing, n (%) 29 (9.7) 28 (9.5)
EQ-5D usual activities score
6 weeks
Level 1, n (%) 11 (3.6) 11 (3.6) 0.023
Level 2, n (%) 152 (49.8) 120 (39.6)
Level 3, n (%) 113 (37.1) 144 (47.5)
Missing, n (%) 29 (9.5) 28 (9.3)
6 months
Level 1, n (%) 161 (54.0) 142 (48.1) 0.265
Level 2, n (%) 98 (32.9) 111 (37.6)
Level 3, n (%) 10 (3.4) 14 (4.8)
Missing, n (%) 29 (9.7) 28 (9.5)
EQ-5D pain/discomfort score
6 weeks
Level 1, n (%) 132 (43.3) 137 (45.2) 0.375
Level 2, n (%) 137 (44.9) 136 (44.9)
Level 3, n (%) 6 (2.0) 2 (0.7)
Missing, n (%) 30 (9.8) 28 (9.2)
6 months
Level 1, n (%) 120 (40.3) 115 (39.0) 0.496
Level 2, n (%) 140 (47.0) 147 (49.8)
Level 3, n (%) 9 (3.0) 5 (1.7)
Missing, n (%) 29 (9.7) 28 (9.5)
EQ-5D anxiety/depression score
6 weeks
Level 1, n (%) 186 (61.0) 179 (59.1) 0.108
Level 2, n (%) 84 (27.5) 95 (31.4)
Level 3, n (%) 6 (2.0) 1 (0.3)
Missing, n (%) 29 (9.5) 28 (9.2)
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TABLE 47 Summary of SF-12 and EQ-5D outcomes at the 6-week and 6-month assessments (ITT) (continued )
Outcome
Treatment group
Unadjusted statistics
(95% CI); p-value
Adjusted statistics
(95% CI); p-valueORIF CCC
6 months
Level 1, n (%) 201 (67.4) 210 (71.2) 0.594
Level 2, n (%) 61 (20.5) 52 (17.6)
Level 3, n (%) 6 (2.0) 5 (1.7)
Missing, n (%) 30 (10.1) 28 (9.5)
EQ-5D score
6 weeks
Mean 0.53 0.48 –0.04 (–0.08 to –0.001); 0.047 –0.04 (–0.08 to 0.005); 0.088
n 275 275
SD 0.25 0.25
Median 0.59 0.49
Minimum –0.48 –0.06
Maximum 1 1
Missing 30 28
6 months
Mean 0.76 0.76 –0.004 (–0.04 to 0.03); 0.814 –0.001 (–0.04 to 0.04); 0.968
n 268 267
SD 0.24 0.22
Median 0.80 0.78
Minimum –0.36 –0.11
Maximum 1 1
Missing 30 28
EQ-5D VAS score
6 weeks
Mean 72.7 72.0 –0.77 (–3.73 to 2.19); 0.609 –0.39 (–3.13 to 2.36); 0.781
n 276 274
SD 17.28 18.06
Median 75.0 75.0
Minimum 0 10
Maximum 100 100
Missing 29 29
6 months
Mean 77.3 77.4 0.02 (–3.09 to 3.12); 0.991 0.10 (–2.91 to 3.11); 0.947
n 269 267
SD 18.81 17.74
Median 81.0 80.0
Minimum 0 1
Maximum 100 100
Missing 29 28
A negative value implies that the treatment effect is in favour of ORIF.
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TABLE 48 Timed up and go walking test at the 6-month follow-up, summarised by treatment group (ITT)
Timed up and go test (seconds)
Treatment group
p-valueaORIF CCC
Mean 21.4 21.9 0.095
n 283 267
SD 19.08 13.45
Median 18.0 18.3
Minimum 6.8 7.4
Maximum 224.3 133.0
Missing 0 1
a Wilcoxon rank-sum test p-value.
TABLE 49 Additional timed up and go test details at the 6-month follow-up, summarised by treatment group (ITT)
Additional timed up and go walking test details
Treatment group
p-valueORIF, n (%) CCC, n (%)
Completed in under 5 minutes
Yes 282 (99.6) 266 (99.3) 0.614
No 1 (0.4) 2 (0.7)
Missing 0 0
Did patient use walking aid(s)?
Yes 27 (9.5) 32 (11.9) 0.372
No 210 (74.2) 194 (72.4)
Missing 46 (16.3) 42 (15.7)
Unable to complete test because of . . .
Non-weight-bearing 0 1 (0.3) 0.266
Declined to complete test 1 (0.3) 3 (1.0)
Other physical limitation 1 (0.3) 1 (0.3)
Other 13 (4.4) 22 (7.5)
Not applicable 283 (95.0) 268 (90.9)
Missing 0 0
TABLE 50 Range of injured ankle motion at the 6-week and 6-month follow-up (ITT)
Range of ankle motion
Treatment group
Unadjusted statistics
(95% CI); p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
Angle of injured ankle dorsiflexion (°)
6 weeks
Mean 5.0 4.3 –0.77 (–2.26 to 0.71); 0.306 –0.98 (–2.27 to 0.31); 0.137
n 290 288
SD 8.68 9.46
Median 5 5
Missing 15 15
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TABLE 50 Range of injured ankle motion at the 6-week and 6-month follow-up (ITT) (continued )
Range of ankle motion
Treatment group
Unadjusted statistics
(95% CI); p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
6 months
Mean 11.9 11.9 0.04 (–1.76 to 1.83); 0.968 0.28 (–1.39 to 1.94); 0.745
n 289 282
SD 10.31 11.49
Median 10 10
Missing 9 13
Angle of injured ankle plantar flexion (°)
6 weeks
Mean 24.5 22.5 –2.05 (–4.18 to 0.08); 0.059 –1.95 (–4.01 to 0.11); 0.064
n 290 288
SD 12.94 13.11
Median 24 20
Missing 15 15
6 months
Mean 33.7 31.3 –2.46 (–4.65 to –0.27); 0.028 –2.23 (–4.25 to –0.21); 0.030
n 289 282
SD 13.68 12.99
Median 35 30
Missing 9 13
Eversion of injured ankle (%)
6 weeks
Mean 49.4 50.2 0.82 (–7.26 to 8.89); 0.842 –0.15 (–8.26 to 7.95); 0.971
n 284 278
SD 40.56 55.84
Median 50 50
Missing 21 25
6 months
Mean 87.6 86.8 –0.79 (–12.30 to 10.71); 0.892 –0.70 (–12.10 to 10.70); 0.904
n 289 277
SD 82.40 53.22
Median 80 80
Missing 9 18
Inversion of injured ankle (%)
6 weeks
Mean 47.9 56.0 8.05 (0.51 to 15.59); 0.036 7.82 (0.16 to 15.47); 0.045
n 288 284
SD 36.21 54.00
Median 45.7 50
Missing 17 19
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TABLE 50 Range of injured ankle motion at the 6-week and 6-month follow-up (ITT) (continued )
Range of ankle motion
Treatment group
Unadjusted statistics
(95% CI); p-value
Adjusted statistics (95% CI);
p-valueORIF CCC
6 months
Mean 83.3 83.6 0.21 (–8.74 to 9.15); 0.964 0.42 (–8.53 to 9.37); 0.927
n 289 282
SD 64.06 42.29
Median 75 80
Missing 9 13
Started partial weight-bearing
6 weeks
Yes, n (%) 110 (36.1) 119 (39.3) 0.414
No, n (%) 195 (63.9) 184 (60.7)
Missing, n (%) 0 0
Note: a negative value implies that the treatment effect is in favour of ORIF.
TABLE 51 Summary of the EQ-5D pain item and OMAS pain item at the 6-week and 6-month follow-up (ITT)
Pain outcomes
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio (95% CI);
p-valueORIF, n (%) CCC, n (%)
EQ-5D pain/discomfort item
6 weeks
No pain/discomfort 132 (43.3) 137 (45.2) 0.90 (0.65 to 1.26); 0.555 0.92 (0.65 to 1.29); 0.622
Moderate pain/discomfort 137 (44.9) 136 (44.9)
Extreme pain/discomfort 6 (2.0) 2 (0.7)
Missing 30 (9.8) 28 (9.2)
6 months
No pain/discomfort 120 (40.3) 115 (39.0) 1.03 (0.73 to 1.44); 0.878 1.05 (0.74 to 1.49); 0.772
Moderate pain/discomfort 140 (47.0) 147 (49.8)
Extreme pain/discomfort 9 (3.0) 5 (1.7)
Missing 29 (9.7) 28 (9.5)
OMAS pain item
6 weeks
None 221 (72.5) 217 (71.6) 1.06 (0.75 to 1.50); 0.746 1.13 (0.78 to 1.62); 0.519
While walking on
uneven surface
28 (9.2) 20 (6.6)
While walking on even
surface outdoors
9 (2.9) 12 (3.9)
While walking indoors 37 (12.1) 37 (12.2)
Constant and severe 10 (3.3) 15 (5.0)
Missing 0 2 (0.7)
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
TABLE 51 Summary of the EQ-5D pain item and OMAS pain item at the 6-week and 6-month follow-up (ITT)
(continued )
Pain outcomes
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio (95% CI);
p-valueORIF, n (%) CCC, n (%)
6 months
None 130 (43.6) 137 (46.4) 0.86 (0.64 to 1.16); 0.326 0.90 (0.66 to 1.22); 0.483
While walking on
uneven surface
90 (30.2) 91 (30.9)
While walking on even
surface outdoors
38 (12.8) 35 (11.9)
While walking indoors 31 (10.4) 20 (6.8)
Constant and severe 9 (3.0) 11 (3.7)
Missing 0 1 (0.3)
TABLE 52 Patient satisfaction at the 6-week and 6-month follow-up (ITT)
Patient satisfaction
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio (95% CI);
p-valueORIF, n (%) CCC, n (%)
6 weeks
Very dissatisfied 16 (5.2) 14 (4.6) 1.01 (0.68 to 1.49); 0.976 1.01 (0.68 to 1.50); 0.961
Somewhat dissatisfied 6 (2.0) 9 (3.0)
Neither satisfied
nor dissatisfied
8 (2.6) 11 (3.6)
Somewhat satisfied 37 (12.1) 32 (10.6)
Very satisfied 192 (63.0) 193 (63.7)
Missing 46 (15.1) 44 (14.5)
6 months
Very dissatisfied 11 (3.7) 15 (5.1) 1.06 (0.71 to 1.57); 0.790 1.05 (0.69 to 1.59); 0.814
Somewhat dissatisfied 6 (2.0) 6 (2.0)
Neither satisfied
nor dissatisfied
13 (4.4) 8 (2.7)
Somewhat satisfied 36 (12.1) 33 (11.2)
Very satisfied 186 (62.4) 188 (63.7)
Missing 46 (15.4) 45 (15.3)
TABLE 53 Summary of radiological malunion at the 6-month follow-up (ITT)
Malunion typea
Treatment group
Total (N= 556),
n (%)ORIF (N= 281), n (%) CCC (N= 275), n (%)
No malunion 270 (96.1) 233 (84.7) 503 (90.5)
Talar shift 4 (1.4) 21 (7.6) 25 (4.5)
Talar tilt 1 (0.4) 0 1 (0.2)
Diastasis 0 0 0
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TABLE 53 Summary of radiological malunion at the 6-month follow-up (ITT) (continued )
Malunion typea
Treatment group
Total (N= 556),
n (%)ORIF (N= 281), n (%) CCC (N= 275), n (%)
Talar shift and talar tilt 3 (1.0) 15 (5.5) 18 (3.2)
Talar shift and diastasis 1 (0.4) 3 (1.1) 4 (0.7)
Talar tilt and diastasis 0 1 (0.4) 1 (0.2)
Talar shift, talar tilt and diastasis 2 (0.7) 2 (0.7) 4 (0.7)
Missing 28 36 64
a Talar shift (talar subluxation > 2mm); talar tilt of > 2°; and diastasis (tibiofibular clear space of ≥ 5mm).
TABLE 54 Summary of radiological malunion and no malunion at the 6-month follow-up (ITT)
Radiological assessment
Treatment group
p-valueORIF (N= 281), n (%) CCC (N= 275), n (%)
No malunion 270 (96.1) 233 (84.7) < 0.001
Malunion 11 (3.9) 42 (15.3)
Missing 28 36
TABLE 55 Summary of radiological non-union at the 6-month follow-up (ITT)
Radiological assessment
Treatment group
p-valueORIF (N= 281), n (%) CCC (N= 274), n (%)
Lateral malleolus
Radiologically fracture not united 0 8 (2.9) 0.003
Not injured/no issues with union identified 281 (100) 266 (97.1)
Missing 28 37
Medial malleolus
Radiologically fracture not united 3 (1.1) 20 (7.3) < 0.001
Not injured/no issues with union identified 278 (98.9) 254 (92.7)
Missing 28 37
TABLE 56 Olerud–Molander Ankle Scores analysed as an ordinal outcome at 6 weeks and 6 months (ITT)
OMAS
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio
(95% CI); p-valueaORIF, n (%) CCC, n (%)
6 weeks
Poor (0–30%) 98 (32.1) 105 (34.6) 0.94 (0.68 to 1.29); 0.686 0.91 (0.65 to 1.27); 0.561
Fair (31–60%) 193 (63.4) 179 (59.1)
Good (61–90%) 12 (3.9) 17 (5.6)
Excellent (91–100%) 1 (0.3) 0
Missing 1 (0.3) 2 (0.7)
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TABLE 56 Olerud–Molander Ankle Scores analysed as an ordinal outcome at 6 weeks and 6 months (ITT)
(continued )
OMAS
Treatment group
Unadjusted odds ratio
(95% CI); p-value
Adjusted odds ratio
(95% CI); p-valueaORIF, n (%) CCC, n (%)
6 months
Poor (0–30%) 19 (6.4) 25 (8.5) 0.90 (0.67 to 1.23); 0.520 0.97 (0.70 to 1.34); 0.854
Fair (31–60%) 95 (31.9) 101 (34.2)
Good (61–90%) 160 (53.7) 135 (45.8)
Excellent (91–100%) 24 (8.0) 33 (11.2)
Missing 0 1 (0.3)
a Treatment effect estimate using ordinal logistic regression model adjusting for age, sex, hospital, baseline OMAS and
AO classification.
TABLE 57 Assessment of the blinding strategy at the 6-month follow-up (ITT)
Treatment received
Blinded assessors guess
Total James’ Blinding Index (95% CI)CCC ORIF Don’t know
CCC 38 24 174 236 0.82 (0.79 to 0.84)
ORIF 11 50 180 241
Total 49 74 354 477
TABLE 58 Summary of unadjusted and adjusted time-to-event analyses looking at time to discharge and time to
first readmission (ITT)
Event
Number of participants
experiencing an event,
n (%)
Unadjusted analysis Adjusted analysis
Hazard ratio
(95% CI) p-value
Hazard ratio
(95% CI) p-value
Time to discharge (days) 613 (98.9) 0.97 (0.83 to 1.14) 0.726 1.11 (0.94 to 1.31) 0.230
Time to readmission (days) 89 (14.4) 1.32 (0.82 to 2.11) 0.249 2.05 (1.14 to 3.72) 0.017
TABLE 59 Process variables summarised by treatment group (ITT)
Process variable
Treatment group
Total p-valueORIF CCC
Randomisation
Time from injury to randomisation (days)
Mean 2.8 2.8 2.8 0.804
n 309 311 620
SD 2.66 2.97 2.82
Median 2 2 2
IQR 1–4 1–3.4 1–3.7
Minimum 0 0 0
Maximum 15 28 28
Missing 0 0 0
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TABLE 59 Process variables summarised by treatment group (ITT) (continued )
Process variable
Treatment group
Total p-valueORIF CCC
Randomisation/theatre
Time from randomisation to theatre procedure (days)
Mean 2.2 2.1 2.2 0.789
n 309 306 615
SD 2.55 2.24 2.40
Median 1.0 2.0 1.4
IQR 0–3.4 0–3 0–3
Minimum 0 0 0
Maximum 17 14.4 17
Missing 0 5 5
Treatment
Time from injury to primary treatment (days)
Mean 5.0 4.9 5.0 0.519
n 309 306 615
SD 3.49 3.30 3.39
Median 5.0 4.4 4.4
IQR 2–7 2–7 2–7
Minimum 0 0 0
Maximum 19 18 19
Missing 0 5 5
Theatre
Time from entry into anaesthetic room to start time in theatre (minutes)
Mean 29.2 18.0 23.6 < 0.001
n 306 306 612
SD 14.78 10.74 14.06
Median 27.0 16.0 21.0
IQR 18–37 10–24 14–30
Minimum 0 0 0
Maximum 90 100 100
Missing 3 5 8
Time from start to end of procedure in theatre (minutes)
Mean 78.9 30.3 54.7 < 0.001
n 307 305 612
SD 29.88 24.18 36.49
Median 78 25.0 45.0
IQR 60–96 20–32 24–80.5
Minimum 0 0 0
Maximum 211 216 216
Missing 2 6 8
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TABLE 59 Process variables summarised by treatment group (ITT) (continued )
Process variable
Treatment group
Total p-valueORIF CCC
Additional theatrea procedure
Time from primary procedure to additional procedure in theatre (days)
Mean 4.9 10.4 8.2 0.009
n 15 23 38
SD 1.99 11.11 9.08
Median 5.0 7.0 6.0
IQR 3–6 5–12.4 4–9
Minimum 2 1 1
Maximum 8.4 56.9 56.9
Missing 0 0 0
Time from entry into anaesthetic room to start time in theatre (minutes)
Mean 33.3 29.0 30.7 0.419
n 15 23 38
SD 12.27 17.83 15.83
Median 33 22.0 27.5
IQR 20–45 15–42 19–43
Minimum 15 4 4
Maximum 50 62 62
Missing 0 0 0
Time from start to end of procedure in theatre (minutes)
Mean 79.7 76.3 77.6 0.530
n 15 23 38
SD 36.42 46.83 42.52
Median 80.0 70.0 77.5
IQR 56–94 44–90 50–90
Minimum 21 18 18
Maximum 180 225 225
Missing 0 0 0
Theatre/hospital discharge
Time from theatre to hospital discharge
Mean 5.3 5.9 5.6 0.021
n 309 304 613
SD 5.84 9.17 7.68
Median 3.0 2.5 3.0
IQR 2–6.4 1–7 1–7
Minimum 0 0 0
Maximum 39.9 74.3 74.3
Missing 0 7 7
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TABLE 59 Process variables summarised by treatment group (ITT) (continued )
Process variable
Treatment group
Total p-valueORIF CCC
Hospital discharge/hospital readmission
Time from hospital discharge to readmission (days)
Mean 62.4 46.8 51.7 0.054
n 32 70 102
SD 54.22 51.36 52.51
Median 44.7 14.7 26.2
IQR 17.2–101 9–75.9 10–95.3
Minimum 1 4 1
Maximum 161.2 174.6 174.6
Missing 0 0 0
IQR, interquartile range.
a Here ‘n’ is the number of additional theatre procedures/readmissions where a patient can have more than one additional
procedure/readmission.
TABLE 60 Summary of the duration from randomisation and injury to the date allocated treatment received (ITT)
Time between events
Treatment group
p-valueORIF CCC
Time from injury to allocated treatment received (days)
Mean 5.2 4.8 0.186
n 302 277
SD 3.73 3.26
Median 5 4
IQR 2–7 2–7
Minimum 0 0
Maximum 27 18
Missing 7 34
Time from randomisation to allocated treatment received (days)
Mean 2.4 2.0 0.326
n 302 277
SD 2.97 2.10
Median 1 2
IQR 0–4 0–3
Minimum 0 0
Maximum 26 10
Missing 7 34
IQR, interquartile range.
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TABLE 61 Summary of reported adverse events (ITT)
Complication type
Treatment group
ORIF (n= 309) CCC (n= 311)
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Interoperative fracture 1 (0.3) 0 1 0 0 0
Imperfect reduction
reported
0 0 0 4 (1.3) 0 4
Compartment syndrome 0 0 0 0 0 0
Vascular injury 1 (0.3) 0 1 1 (0.3) 0 1
Nerve palsy 2 (0.6) 0 2 2 (0.6) 0 2
Wound breakdown 20 (6.5) 1 (0.3) 22 5 (1.6) 0 5
Infection 7 (2.3) 1 (0.3) 9 2 (0.6) 0 2
Septicaemia 0 0 0 0 0 0
Other clinical issue with
wound (not breakdown
or infection)
6 (1.9) 0 6 1 (0.3) 0 1
Clinical issue with
metalwork
4 (1.3) 0 4 0 0 0
Implant failure 5 (1.6) 0 5 0 0 0
Non-wound skin problem 13 (4.2) 0 13 12 (3.9) 0 12
Pain from cast 12 (3.9) 0 12 16 (5.1) 0 16
Plaster sore 15 (4.9) 0 15 22 (7.1) 0 22
Plaster saw laceration 1 (0.3) 0 1 5 (1.6) 0 5
DVT 3 (1.0) 0 3 6 (1.9) 0 6
PE 1 (0.3) 0 1 6 (1.9) 0 6
Refracture of ankle 0 0 0 0 0 0
Fall postoperatively 3 (1.0) 0 3 4 (1.3) 0 4
Other fracture sustained 1 (0.3) 0 1 0 0 0
Poor bone quality
encountered
4 (1.3) 0 4 0 0 0
Poor skin condition
encountered
3 (1.0) 0 3 6 (1.9) 0 6
Non-union 0 0 0 2 (0.6) 0 2
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TABLE 62 Summary of the additional procedures in theatre (ITT)
Complication type
Treatment group
ORIF (n= 309) CCC (n= 311)
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Number of
participants
experiencing
an event
once (%)
Number of
participants
experiencing
an event
twice (%)
Absolute
number
of events
Remanipulation and
traditional cast
1 (0.3) 0 1 0 0 0
Convert to external fixation 0 0 0 0 0 0
Convert to retrograde nail 0 0 0 0 0 0
Revision of ORIF 3 (1.0) 0 3 1 (0.3) 0 1
Wound washout 2 (0.7) 0 2 1 (0.3) 0 1
Delayed wound closure 0 0 0 0 0 0
Wound debridement 1 (0.3) 0 1 0 0 0
Incision and drainage of
haematoma
1 (0.3) 0 1 0 0 0
Amputation 0 0 0 0 0 0
Removal of syndesmotic
screws
6 (1.9) 0 6 1 (0.3) 0 1
Removal of other metalwork
Because of infection 1 (0.3) 1 (0.3) 3 0 0 0
With washout 0 0 0 2 (0.6) 0 2
Because of pain 0 0 0 0 0 0
Because of poor position
of implant
1 (0.3) 0 1 0 0 0
Other reason 1 (0.3) 0 1 0 0 0
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Appendix 3 Health economic evaluation
Per protocol
With completely missing cases via imputation (per protocol)
We repeated the economic evaluation including patients with completely missing information.
These patients were included by imputing their missing information. Results with imputed data included
were comparable to the results with those data removed.
The full per-protocol population included 573 patients: 275 and 298 in the CCC and ORIF groups,
respectively. Using the best-fit models, compared with ORIF, CCC had a mean cost savings to the NHS
and society of £648 and £557, respectively, and comparable QALYs (difference = +0.01) (Table 63).
Cost-effectiveness planes displayed the majority of incremental costs as negative while incremental QALYs
were largely positive, but with a modest number of estimates being negative (Figures 27 and 28). The
probability that CCC is cost-effective was very high over the range of willingness to pay for both the NHS
(> 94%) and societal perspectives (> 84%) (Figures 29 and 30).
TABLE 64 Baseline characteristics of per-protocol participants with complete 6-week and 6-month utility
information vs. those missing either utility. Counts and percentages are shown unless otherwise indicated
Variable Complete, n (%) Missing, n (%) p-value
n 520 (91) 53 (9) –
Age, years [mean (SD)] 71 (7.13) 68 (7.66) 0.01
OMAS [mean (SD)] 88.5 (17.5) 94.6 (9.9) 0.01
Female 385 (74) 43 (81) 0.33
Heart disease 68 (13) 8 (15) 0.84
Hypertension 223 (43) 21 (40) 0.76
Asthma 72 (14) 9 (17) 0.68
Diabetes mellitus 50 (10) 6 (11) 0.88
Epilepsy 9 (2) 53 (100) 1.00
Renal disease 8 (2) 3 (6) 0.07
Liver disease 5 (1) 1 (2) 0.44
CVA/TIA 29 (6) 2 (4) 0.76
Peptic ulcer 14 (3) 2 (4) 0.65
Malignancy 62 (12) 8 (15) 0.65
TABLE 63 Sensitivity: with completely missing cases via imputation. Cost-effectiveness results using the best-fit and
OLS models. Per-protocol population
Outcome
Treatment group
Difference, mean (95% CI)ORIF, mean (95% CI) CCC, mean (95% CI)
NHS costs (£) 6777 (5367 to 8522) 6129 (4796 to 7822) –648 (–1402 to 66)
Societal costs (£) 7969 (6448 to 9789) 7412 (5935 to 9204) –557 (–1673 to 620)
QALYs 0.2949 (0.2746 to 0.3132) 0.3037 (0.2865 to 0.3196) 0.0088 (–0.0163 to 0.0350)
continued
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TABLE 64 Baseline characteristics of per-protocol participants with complete 6-week and 6-month utility
information vs. those missing either utility. Counts and percentages are shown unless otherwise indicated
(continued )
Variable Complete, n (%) Missing, n (%) p-value
DVT/PE 23 (4) 4 (8) 0.30
Osteoarthritis 154 (30) 19 (36) 0.43
Rheumatoid arthritis 22 (4) 1 (2) 0.71
Smoking status – – 0.49
Never 258 (50) 31 (58)
Ex-smoker 212 (41) 18 (34)
Yes 50 (10) 4 (8)
Home care support – – 0.74
Lives alone 161 (31) 19 (36)
Lives with someone 353 (68) 34 (64)
Lives with carers 1 (0) 0 (0)
Home care package 5 (1) 0 (0)
Institution care 0 (0) 0 (0)
Walking aids – – 0.38
None 446 (86) 48 (91)
One stick 53 (10) 4 (8)
Two sticks 5 (1) 0 (0)
Frame/rollator 14 (3) 0 (0)
Wheelchair 2 (0) 1 (2)
Bed-bound 0 (0) 0 (0)
Walking distance – – 0.11
About house 15 (3) 2 (4)
< 100m 34 (7) 0 (0)
< 0.5 mile 53 (10) 3 (6)
> 0.5 mile 418 (80) 48 (91)
Missing 0 (0) 0 (0)
CVA, cerebrovascular accident; TIA, transient ischaemic attack.
TABLE 65 Mean values of complete information as well as magnitude of incomplete information for relevant
outcomes and resource use items for per-protocol patients
Outcome/resource Meana Missing (%)
Utilityb
Prior to injury 0.84 0
At presentation 0.06 7
6 weeks 0.36 0
6 months 0.49 3
Casts
Casts in plaster room 0.18 5
Casts in theatre room 0.07 6
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TABLE 65 Mean values of complete information as well as magnitude of incomplete information for relevant
outcomes and resource use items for per-protocol patients (continued )
Outcome/resource Meana Missing (%)
Sick days
Sick days 4.78 6
Care homes
Friend/family at home days 8.28 7
Community hospital days 1.43 7
Intermediate care days 0.30 7
Nursing home (NHS) days 0.53 7
Nursing home (private) days 0.22 7
Friend/family stay days 1.41 7
Work days off by friend/family 2.00 7
Health professional visits
GP 0.29 7
Nurse 2.43 9
Physiotherapy inpatient 0.31 5
Physiotherapy outpatient 0.74 7
Physiotherapy home 0.16 7
Hospital A&E 0.07 7
Hospital specialist 0.75 7
Psychologist 0.01 7
Trauma outpatient 1.59 0
Hospital transports 1.09 7
Community care 3.18 7
Private physiotherapy 0.05 0
Private consultant 0.00 0
Private osteopath 0.00 0
Private transports 0.26 0
Prescriptions
Painkillers 1.53 7
Anti-inflammatory 0.22 6
Gel 0.02 6
Sleeping pills 0.07 6
Antidepressants 0.10 6
Painkillers (self-buy) 0.87 7
Anti-inflammatory (self-buy) 0.14 7
Gel (self-buy) 0.05 7
Sleeping pills (self-buy) 0.00 7
Antidepressants (self-buy) 0.00 7
A&E, accident and emergency.
a Mean of per-protocol population complete responses.
b Health utility score derived from EQ-5D.
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FIGURE 27 Sensitivity: with completely missing cases via imputation. Per-protocol cost-effectiveness plane showing
incremental total NHS costs along y-space and incremental QALYs along x-space for 10,000 bootstrap replicates.
Origin is ORIF.
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FIGURE 28 Sensitivity: with completely missing cases via imputation. Per-protocol cost-effectiveness plane showing
incremental total societal costs along y-space and incremental QALYs along x-space for 10,000 bootstrap replicates.
Origin is ORIF.
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Intention to treat
Cases included in the economic evaluation
The ITT population included 618 participants. The number of participants’ completely missing information
invalid for an economic evaluation was 67 out of 618 (11%). Complete missingness was not statistically
associated with intervention (odds ratio 1.03; 95% CI 0.62 to 1.78; p = 1.0; Fisher’s exact test). Baseline
characteristics between complete cases and missing cases are presented in Table 74. Missing cases showed
comparable baseline characteristics to the complete cases.
Missingness was more likely in pilot patients (odds ratio 156; p < 0.001). However, as pilot patients were
not associated with intervention (odds ratio 1.03; 95% CI 0.60 to 1.78; p = 1.0; Fisher’s exact test);
baseline characteristics were balanced between complete and missing cases; and missingness was not
associated with intervention, we treated any remaining missingness as missing at random.
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FIGURE 29 Sensitivity: with completely missing cases via imputation. Per-protocol cost-effectiveness acceptability
curve displaying the probability of cost-effectiveness (y-axis) as a function of the willingness-to-pay threshold
(x-axis) under the NHS perspective. The dotted line presents the asymptote where the willingness to pay is infinite.
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FIGURE 30 Sensitivity: with completely missing cases via imputation. Per-protocol cost-effectiveness acceptability
curve displaying the probability of cost-effectiveness (y-axis) as a function of the willingness-to-pay threshold
(x-axis) under the societal perspective. The dotted line presents the asymptote where the willingness to pay
is infinite.
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The 67 cases of completely missing information were removed and the economic evaluation continued
with the 551 patients with sufficient valid information. Of the remaining participants, incomplete data
remained at around 7% across most variables (see Table 75). Exceptions included lower missingness of
utility prior to injury (0%), 6 weeks (0%) and 6 months (3%). Having concluded missingness was missing
at random, we continued with multiple imputation with chained equations. Multiple imputation showed
healthy convergence and the density plots of imputed values followed closely to the observed values
(see Figures 41–44).
Baseline characteristics (intention to treat)
Baseline characteristics have previously been presented in Chapter 3. The CCC group showed lower
baseline utility compared with the ORIF group (0.83 vs. 0.85; p = 0.03; Wilcoxon rank-sum test).
Otherwise, the CCC group showed comparable baseline characteristics across age, sex, OMASs and a
range of health conditions.
Resource use (intention to treat)
Mean resource use following ORIF and CCC is presented in Table 66. Patterns of resource use between
CCC and ORIF remained similar to the per-protocol population. The CCC group showed lower theatre
time during the index procedure (–49 minutes), slightly higher rate of additional procedures (+1.5%),
higher rate of readmission (+13.5%) and greater cast use (+1.39). Overall length of stay was comparable
(–0.25 days).
TABLE 66 Intention-to-treat average resource use over the index procedure, readmission and the 6-month
follow-up period. Means and SDs are shown except where indicated
Resource
Treatment group
Difference, meanORIF, mean (SD) CCC, mean (SD)
Index procedure
Theatre time (hours) 1.31 (0.50) 0.49 (0.40) –0.81
Screws 6.56 (2.99) 0.43 (1.83) –6.13
Antigliding plates 0.10 (0.34) 0.01 (0.09) –0.09
Tubular plates 0.73 (0.60) 0.06 (0.46) –0.67
Dynamic compression plates 0.01 (0.10) 0.00 (0.00) –0.01
Reconstruction plates 0.01 (0.10) 0.00 (0.00) –0.01
Locking plates 0.12 (0.51) 0.01 (0.09) –0.11
Other plates 0.04 (0.20) 0.00 (0.06) –0.04
Tightropes 0.00 (0.00) 0.00 (0.00) 0.00
Wirings 0.08 (0.33) 0.01 (0.12) –0.08
Other implants 0.08 (0.35) 0.00 (0.00) –0.08
Additional procedure [n (%)] 15 (5.4) 19 (6.9) 1.5
Theatre time (hours)a 1.33 (0.61) 1.37 (0.79) 0.04
Anaesthesia [n (%)]a 15 (100) 19 (100) 0.0
Screwsa 6.07 (3.10) 4.58 (3.76) –1.49
Antigliding platesa 0.27 (0.46) 0.11 (0.32) –0.16
Tubular platesa 0.53 (0.52) 0.42 (0.51) –0.11
Dynamic compression platesa 0.07 (0.26) 0.05 (0.23) –0.01
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TABLE 66 Intention-to-treat average resource use over the index procedure, readmission and the 6-month
follow-up period. Means and SDs are shown except where indicated (continued )
Resource
Treatment group
Difference, meanORIF, mean (SD) CCC, mean (SD)
Reconstruction platesa 0.00 (0.00) 0.00 (0.00) 0.00
Locking platesa 0.13 (0.35) 0.11 (0.32) –0.03
Other platesa 0.00 (0.00) 0.05 (0.23) 0.05
Tightropesa 0.00 (0.00) 0.00 (0.00) 0.00
Wiringsa 0.07 (0.26) 0.05 (0.23) –0.01
Other implantsa 0.13 (0.52) 0.00 (0.00) –0.13
Casts in plaster room 0.00 (0.06) 0.09 (0.34) 0.08
Casts in theatre room 0.01 (0.08) 0.91 (0.35) 0.90
LOS (days) 9.78 (23.07) 9.25 (10.50) –0.53
Readmission [n (%)] 23 (8.3) 60 (21.8) 13.5
Theatre time (hours)a 0.30 (0.48) 0.97 (0.88) 0.66
Anaesthesia [n (%)]a 9 (39.1) 42 (70.0) 30.9
Screwsa 0.35 (1.30) 4.28 (4.06) 3.94
Antigliding platesa 0.00 (0.00) 0.07 (0.31) 0.07
Tubular platesa 0.04 (0.21) 0.35 (0.48) 0.31
Dynamic compression platesa 0.00 (0.00) 0.05 (0.22) 0.05
Reconstruction platesa 0.00 (0.00) 0.00 (0.00) 0.00
Locking platesa 0.00 (0.00) 0.15 (0.58) 0.15
Other platesa 0.00 (0.00) 0.03 (0.18) 0.03
Tightropesa 0.00 (0.00) 0.03 (0.26) 0.03
Wiringsa 0.00 (0.00) 0.03 (0.18) 0.03
Other implantsa 0.00 (0.00) 0.05 (0.29) 0.05
LOSa (days) 5.14 (7.77) 5.57 (10.69) 0.43
Total inclusive of 6 months
Theatre time (hours) 1.40 (0.57) 0.80 (0.82) –0.61
Casts 0.07 (0.35) 1.46 (0.96) 1.39
Hospital LOS (days) 10.21 (23.33) 10.47 (12.25) 0.25
Follow-up inclusive of 6 months
Care homes
Friend/family at home days 11.81 (21.30) 11.85 (27.00) 0.04
Community hospital days 2.70 (13.98) 2.95 (15.00) 0.25
Intermediate care days 0.84 (9.44) 1.35 (10.46) 0.50
Nursing home (NHS) days 0.93 (7.12) 0.51 (4.23) –0.42
Nursing home (private) days 0.61 (6.10) 0.61 (6.50) 0.00
continued
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
141
TABLE 66 Intention-to-treat average resource use over the index procedure, readmission and the 6-month
follow-up period. Means and SDs are shown except where indicated (continued )
Resource
Treatment group
Difference, meanORIF, mean (SD) CCC, mean (SD)
Productivity
Sick days 8.13 (24.74) 8.20 (30.06) 0.07
Friend/family stay days 2.61 (13.20) 1.60 (11.31) –1.01
Work days off by friend/family 2.99 (9.33) 2.53 (11.88) –0.46
Health services
GP 0.68 (1.66) 0.60 (1.25) –0.08
Nurse 3.86 (11.60) 3.36 (15.09) –0.50
Physiotherapist inpatient 0.90 (4.04) 1.58 (7.95) 0.68
Physiotherapist outpatient 3.33 (4.13) 3.19 (3.98) –0.14
Physiotherapist home 0.65 (1.92) 0.92 (4.50) 0.28
Hospital A&E 0.09 (0.33) 0.11 (0.33) 0.01
Hospital specialist 0.92 (2.86) 1.07 (1.92) 0.15
Psychologist 0.01 (0.12) 0.02 (0.22) 0.01
Trauma outpatient 1.83 (2.08) 2.48 (2.47) 0.65
Hospital transports 1.29 (2.28) 1.89 (2.86) 0.60
Community care 6.14 (30.71) 8.85 (39.15) 2.71
Private physiotherapist 0.46 (2.32) 0.20 (1.30) –0.25
Private consultant 0.00 (0.06) 0.00 (0.06) 0.00
Private osteopath 0.04 (0.42) 0.08 (0.93) 0.03
Private transports 0.37 (2.11) 0.27 (1.01) –0.10
Prescriptions
Painkillers 2.29 (3.49) 2.33 (3.97) 0.04
Anti-inflammatory 0.44 (1.31) 0.33 (0.83) –0.11
Gel 0.13 (0.61) 0.12 (0.55) –0.01
Sleeping pills 0.05 (0.32) 0.14 (1.33) 0.09
Antidepressants 0.10 (0.63) 0.23 (2.22) 0.13
Painkillers (self-buy) 2.18 (6.65) 2.10 (8.60) –0.08
Anti-inflammatory (self-buy) 0.47 (1.83) 0.37 (1.55) –0.10
Gel (self-buy) 0.15 (0.67) 0.13 (0.51) –0.02
Sleeping pills (self-buy) 0.00 (0.06) 0.00 (0.00) 0.00
Antidepressants (self-buy) 0.00 (0.00) 0.00 (0.00) 0.00
A&E, accident and emergency; LOS, length of stay.
a Estimates use denominator restricted to those who had relevant event.
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Patterns of care time between the ORIF and CCC groups were also comparable to the per-protocol
population. Most of the care time was spent at homes with friends/family (≈12 days). Both groups spent
around 1 or fewer days in the intermediate care home and nursing home. However, time spent in the
community hospital was modestly longer at 2–3 days for each group. In addition, the CCC group spent
0.41 fewer days over the ORIF group in NHS nursing homes.
Patterns of mean health service use between the ORIF and CCC groups were also comparable to the
per-protocol populations with modest nurse (≥ 3 visits), physiotherapy (≥ 3 visits), trauma outpatient
(≈2 visits) and community care visits (6 to 9 visits). However, the CCC group had more visits to a
community care centre compared with ORIF (9.26 vs. 6.20 days; p = 0.06). Medication use between the
two groups was low to negligible.
Private health resource use was low to negligible and mean levels were comparable between ORIF and CCC.
Patients in both groups took around 8 days off work, while their friends and families took just under 3 days.
Health outcomes (intention to treat)
The raw, unadjusted utilities at presentation and at 6 weeks and 6 months after randomisation are
presented in Table 67. At presentation, the utility in the CCC group trended higher than the ORIF group
(0.07 vs. 0.04), although this difference was not statistically significant (p = 0.10). Compared with the ORIF
group, utility in the CCC group was comparable at 6 weeks (0.36 vs. 0.37; p = 0.13) and 6 months
(0.48 vs. 0.49; p = 0.50). Total QALYs over the trial period were also comparable between the CCC and
the ORIF groups (0.30 vs. 0.30; p = 0.88). Figure 31 shows the mean utility scores; the QALYs are indicated
by the area under the curve. QALYs were estimated from presentation time to 6 months.
Costs (intention to treat)
The mean raw, unadjusted costs of the resource uses for each group using mean unit cost parameters are
presented in Table 68. Compared with the ORIF group, the CCC group had a large initial cost savings
(–£1008), driven by savings in theatre time use ( –£798), which was eroded with increased readmissions
(+£450) and health services (+£471). Mean cost differences were negligible for additional procedures
(+£27), casts (+£41) and medications (+£2).
Societal cost differences between the CCC and ORIF groups were negligible across private nursing homes
(£0), private health services (–£29), out-of-pocket medications (–£1) and work days (–£40).
Over the 6-month trial period, the CCC group had a slight mean cost increase to the NHS of £22 and a
slight mean cost savings to society of £48. Figure 32 presents the cost burden for the CCC and ORIF
groups for the cost categories. The cost burdens, from largest to least, were the primary procedure, health
services/medications, care homes, readmission, additional procedure and casts. The figure represents the
total cost burden; 360° represents ≈£6600. ORIF displays cost savings represented by the white space
where a full circle fails to fill.
TABLE 67 Intention-to-treat raw, unadjusted utility and QALYs over the 6-month follow-up. 95% CIs obtained
using the bootstrap method
Health outcomes
Treatment group
Difference, mean (95% CI) p-valueORIF, mean (95% CI) CCC, mean (95% CI)
Utility (baseline) 0.04 (0.01 to 0.07) 0.07 (0.04 to 0.10) 0.03 (–0.02 to 0.07) 0.10
Utility (6 weeks) 0.37 (0.35 to 0.39) 0.36 (0.34 to 0.37) –0.02 (–0.04 to 0.01) 0.12
Utility (6 months) 0.49 (0.47 to 0.51) 0.48 (0.47 to 0.50) 0.00 (–0.03 to 0.03) 0.50
QALYs 0.30 (0.28 to 0.31) 0.30 (0.29 to 0.31) 0.00 (–0.01 to 0.02) 0.88
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TABLE 68 Intention-to-treat raw, unadjusted costs using mean unit costs over the 6-month trial period. 95% CIs
obtained using the bootstrap method
Resource
Treatment group
Difference, mean, £ (95% CI)ORIF, mean, £ (95% CI) CCC, mean, £ (95% CI)
Index procedure
Theatre time 1584 (1526 to 1642) 786 (741 to 837) –798 (–872 to –722)
Implant 77 (71 to 86) 5 (3 to 8) –72 (–81 to –65)
LOS 2690 (2157 to 3549) 2552 (2234 to 2919) –138 (–1078 to 552)
Total 4351 (3817 to 5218) 3343 (3011 to 3725) –1008 (–1963 to –304)
Additional procedure
Theatre time 87 (45 to 136) 114 (63 to 173) 27 (–45 to 100)
Implant 4 (2 to 6) 4 (2 to 7) 0 (–3 to 3)
Total 91 (47 to 143) 118 (65 to 179) 27 (–48 to 103)
Readmission
Theatre time 35 (13 to 60) 254 (178 to 332) 219 (140 to 301)
Implant 0 (0 to 1) 13 (8 to 18) 13 (8 to 18)
LOS 118 (43 to 211) 336 (185 to 541) 218 (40 to 437)
Total 153 (66 to 263) 603 (405 to 845) 450 (226 to 709)
Casts
Number 2 (1 to 3) 43 (40 to 47) 41 (38 to 45)
Care homes
Community hospital days 523 (234 to 877) 571 (284 to 958) 49 (–418 to 537)
Intermediate care days 54 (2 to 136) 86 (20 to 175) 32 (–73 to 137)
Nursing home (NHS) days 92 (21 to 187) 51 (11 to 105) –41 (–146 to 48)
Nursing home (private) days 59 (0 to 140) 59 (0 to 146) 0 (–101 to 106)
Total 727 (384 to 1145) 767 (443 to 1202) 40 (–497 to 602)
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FIGURE 31 Graph showing ITT utility (quality of life) over time (length of life). Area is the QALYs.
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TABLE 68 Intention-to-treat raw, unadjusted costs using mean unit costs over the 6-month trial period. 95% CIs
obtained using the bootstrap method (continued )
Resource
Treatment group
Difference, mean, £ (95% CI)ORIF, mean, £ (95% CI) CCC, mean, £ (95% CI)
Health services 1360 (1088 to 1676) 1830 (1413 to 2350) 471 (–55 to 1068)
Health services (private) 93 (50 to 147) 64 (42 to 89) –29 (–87 to 21)
Medications 5 (4 to 6) 7 (4 to 11) 2 (–1 to 6)
Medications (private) 4 (3 to 6) 4 (3 to 5) –1 (–2 to 1)
Workdays 1097 (802 to 1,424) 1057 (701 to 1476) –40 (–520 to 463)
Total societal cost 7885 (6933 to 8994) 7837 (6787 to 9151) –48 (–1599 to 1610)
Total NHS cost 6631 (5720 to 7718) 6652 (5689 to 7906) 22 (–1460 to 1598)
LOS, length of stay.
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FIGURE 32 Pie chart of ITT NHS costs for (a) ORIF and (b) CCC, grouped by primary procedure, health services/
medications, care homes, readmission, additional procedure and casts.
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Regression models (intention to treat)
Total societal and NHS costs, as well as QALYs, were obtained by fitting a GLM and adjusting for baseline
characteristics. We used the same regression models as those used for the NHS perspective.
Regression coefficients for total NHS and societal costs are presented in Tables 69 and 70. Regression
coefficients for total QALYs are presented in Table 71.
TABLE 69 Regression coefficients for ITT total NHS costs
Variable
GLM
Estimate Standard error p-value
Intercept 6936 3695 0.06
CCC –689 378 0.07
Age 83 34 0.01
Female 507 417 0.22
Baseline utility –2205 2492 0.38
Baseline OMAS –53 23 0.02
Hypertension 423 411 0.30
Asthma –783 537 0.15
Diabetes mellitus 1121 931 0.23
Ex-smoker –313 416 0.45
Smoker –617 369 0.10
Home support: does not live alone –1702 523 0.001
Walking aids: one or more 3471 1412 0.01
Walking distance: < 0.5 mile or worse 2719 992 0.01
TABLE 70 Regression coefficients for ITT total societal costs
Variable
GLM
Estimate Standard error p-value
Intercept 18,847 4385 < 0.001
CCC –721 461 0.12
Age –18 39 0.64
Female 441 518 0.40
Baseline utility –2538 2908 0.38
Baseline OMAS –81 28 0.004
Hypertension 94 487 0.85
Asthma –1345 654 0.04
Diabetes mellitus 1673 1135 0.14
Ex-smoker –392 527 0.46
Smoker –1005 464 0.03
Home support: does not live alone –2423 633 < 0.001
Walking aids: one or more 2988 1477 0.04
Walking distance: < 0.5 mile or worse 3190 1105 0.004
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Cost-effectiveness: 6 months (intention to treat)
NHS perspective
Results of the cost-effectiveness outcomes are presented in Table 72. The mean total QALYs for CCC and
ORIF were 0.30 and 0.29, respectively, while the mean total NHS costs were £6191 and £6883, respectively.
The incremental differences favoured the CCC group. The CCC group had higher mean total QALYs
(+0.01) and lower mean total NHS cost (–£692). At the mean for an ICER of £25,000/QALY, as CCC was
both more effective and less costly, it dominated ORIF.
To assess the variability of the estimates, we plotted the incremental costs and incremental QALYs on
the cost-effectiveness plane (Figure 33). The cost-effectiveness plane summarises all 10,000 bootstrap
estimates. The cost-effectiveness plane shows that the large majority of incremental costs are negative;
the incremental QALYs, however, show more uncertainty with a modest proportion being negative.
The majority, however, show both negative incremental costs and positive incremental QALYs.
TABLE 71 Regression coefficients for ITT total QALYs
Variable Estimate Standard error p-value
Intercept 0.765 0.060 < 0.001
CCC –0.010 0.009 0.23
Age 0.001 0.001 0.44
Female 0.026 0.010 0.01
Baseline utility –0.089 0.037 0.02
Baseline OMAS –0.001 0.000 0.16
Hypertension –0.022 0.009 0.02
Asthma 0.003 0.013 0.80
Diabetes mellitus –0.005 0.015 0.72
Ex-smoker 0.019 0.011 0.09
Smoker –0.009 0.009 0.31
Home support: does not live alone 0.005 0.009 0.63
Walking aids: one or more 0.035 0.016 0.03
Walking distance: < 0.5 mile or worse 0.046 0.013 0.001
TABLE 72 Cost-effectiveness results of the ITT population
Outcome
Treatment group
Difference, mean (95% CI)ORIF, mean (95% CI) CCC, mean (95% CI)
NHS costs (£) 6883 (5400 to 8812) 6191 (4804 to 8029) –692 (–1438 to 24)
Societal costs (£) 8233 (6645 to 10,245) 7460 (5940 to 9382) –773 (–1904 to 410)
QALYs 0.2925 (0.2705 to 0.3120) 0.3026 (0.2851 to 0.3195) 0.0101 (–0.0156 to 0.0379)
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The variability across the range of willingness-to-pay thresholds was summarised with a cost-effectiveness
acceptability curve (Figure 34). Over a common willingness to pay, CCC displayed a high probability of
cost-effectiveness (> 96%).
Societal perspective
The mean total QALYs remained the same for both the NHS and societal perspectives. Costs, however,
differed. After resampling the trial population and unit costs, refitting the GLMs and using marginal
estimation, mean total societal costs for the CCC and ORIF groups were £7460 and £8233, respectively
(see Table 72).
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FIGURE 33 Intention-to-treat cost-effectiveness plane showing incremental total NHS costs along y-space and
incremental QALYs along x-space for 10,000 bootstrap replicates. Origin is ORIF.
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FIGURE 34 Intention-to-treat cost-effectiveness acceptability curve displaying the probability of cost-effectiveness
(y-axis) as a function of the willingness-to-pay threshold (x-axis) under the NHS perspective. The dotted line
presents the asymptote where the willingness to pay is infinite.
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The incremental differences favoured the CCC group. The CCC group had lower mean total societal cost
(–£773) and unchanged higher mean total QALYs (+0.01). At the mean incremental cost and QALYs for
an ICER of £25,000/QALY, CCC dominated ORIF, as it was both more effective and less costly.
The cost-effectiveness plane displayed modest variability in incremental costs (Figure 35). However, the
large majority of incremental costs were negative. The incremental QALYs also displayed a modest
proportion of negative estimates.
Over a common willingness to pay, CCC displayed a high probability of cost-effectiveness (> 90%) (Figure 36).
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FIGURE 35 Intention-to-treat cost-effectiveness plane showing incremental total societal costs along y-space and
incremental QALYs along x-space for 10,000 bootstrap replicates. Origin is ORIF.
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FIGURE 36 Intention-to-treat cost-effectiveness acceptability curve displaying the probability of cost-effectiveness
(y-axis) as a function of the willingness-to-pay threshold (x-axis) under the societal perspective. The dotted line
presents the asymptote where the willingness to pay is infinite.
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Lifetime (intention to treat)
There was no evidence to support modelling differences in the long term. Reasons were presented in the
main body of the report.
Sensitivity: with completely missing cases via imputation (intention to treat)
We repeated the economic evaluation including patients with completely missing information. These
patients were included by imputing their missing information. Results were comparable with the results
with those patients removed. All tables and figures for the full population are provided in Tables 73–75
and Figures 37–40.
TABLE 73 Sensitivity: with completely missing cases via imputation. Cost-effectiveness results using the best-fit and
OLS models. ITT population
Outcome
Treatment group
Difference, mean (95% CI)ORIF, mean (95% CI) CCC, mean (95% CI)
NHS costs (£) 6991 (5519 to 8844) 6285 (4922 to 8009) –707 (–1454 to 13)
Societal costs (£) 8191 (6615 to 10,106) 7517 (6034 to 9343) –674 (–1762 to 433)
QALYs 0.2938 (0.2736 to 0.3115) 0.3027 (0.2862 to 0.3183) 0.0089 (–0.0152 to 0.0344)
TABLE 74 Baseline characteristics of ITT participants with complete 6-week and 6-month utility information vs.
those missing either utility. Counts and percentages are shown unless otherwise indicated
Variable Complete, n (%) Missing, n (%) p-value
n 551 (89) 67 (11) –
Age (years), mean (SD) 71 (7.24) 69 (7.82) 0.04
OMAS, mean (SD) 88.3 (17.6) 92.7 (14.4) 0.01
Female 405 (74) 54 (81) 0.27
Heart disease 74 (13) 8 (12) 0.88
Hypertension 235 (43) 31 (46) 0.66
Asthma 75 (14) 10 (15) 0.91
Diabetes mellitus 51 (9) 6 (9) 1.00
Epilepsy 9 (2) 67 (100) 0.61
Renal disease 8 (1) 4 (6) 0.03
Liver disease 5 (1) 1 (1) 0.50
CVA/TIA 31 (6) 4 (6) 0.78
Peptic ulcer 15 (3) 3 (4) 0.43
Malignancy 65 (12) 8 (12) 1.00
DVT/PE 24 (4) 5 (7) 0.23
Osteoarthritis 163 (30) 21 (31) 0.88
Rheumatoid arthritis 24 (4) 2 (3) 1.00
Smoking status – – 0.31
Never 273 (50) 40 (60)
Ex-smoker 226 (41) 22 (33)
Yes 52 (9) 5 (7)
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TABLE 74 Baseline characteristics of ITT participants with complete 6-week and 6-month utility information vs.
those missing either utility. Counts and percentages are shown unless otherwise indicated (continued )
Variable Complete, n (%) Missing, n (%) p-value
Home care support – – 0.75
Lives alone 173 (31) 24 (36)
Lives with someone 372 (68) 43 (64)
Lives with carers 1 (0) 0 (0)
Home care package 5 (1) 0 (0)
Institution care 0 (0) 0 (0)
Walking aids – – 0.36
None 471 (85) 58 (87)
One stick 57 (10) 7 (10)
Two sticks 6 (1) 1 (1)
Frame/rollator 15 (3) 0 (0)
Wheelchair 2 (0) 1 (1)
Bed-bound 0 (0) 0 (0)
Walking distance – – 0.31
> 0.5 mile 441 (80) 57 (85)
< 0.5 mile 56 (10) 6 (9)
< 100m 37 (7) 1 (1)
About house 17 (3) 3 (4)
Nil 0 (0) 0 (0)
CVA, cerebrovascular accident; TIA, transient ischaemic attack.
TABLE 75 Mean values of complete information as well as magnitude of incomplete information for relevant
outcomes and resource use items for ITT patients
Outcome/resource Meana Missing (%)
Utilityb
Prior to injury 0.84 0
At presentation 0.06 6
6 weeks 0.36 0
6 months 0.49 3
Casts
Casts in plaster room 0.18 5
Casts in theatre room 0.07 6
Sick days
Sick days 4.78 6
continued
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TABLE 75 Mean values of complete information as well as magnitude of incomplete information for relevant
outcomes and resource use items for ITT patients (continued )
Outcome/resource Meana Missing (%)
Care homes
Friend/family at home days 8.05 7
Community hospital days 1.38 7
Intermediate care days 0.33 7
Nursing home (NHS) days 0.50 6
Nursing home (private) days 0.26 7
Friend/family stay days 1.32 7
Work days off by friend/family 1.96 7
Health professional visits
GP 0.27 7
Nurse 2.34 9
Physiotherapy inpatient 0.30 5
Physiotherapy outpatient 0.72 7
Physiotherapy home 0.17 7
Hospital A&E 0.07 7
Hospital specialist 0.73 7
Psychologist 0.01 7
Trauma outpatient 1.56 1
Hospital transports 1.07 7
Community care 3.15 7
Private physiotherapy 0.05 1
Private consultant 0.00 1
Private osteopath 0.00 1
Private transports 0.25 1
Prescriptions
Painkillers 1.53 6
Anti-inflammatory 0.22 6
Gel 0.02 6
Sleeping pills 0.07 6
Antidepressants 0.10 6
Painkillers (self-buy) 0.87 7
Anti-inflammatory (self-buy) 0.16 7
Gel (self-buy) 0.05 7
Sleeping pills (self-buy) 0.00 7
Antidepressants (self-buy) 0.00 7
A&E, accident and emergency.
a Mean of ITT population complete responses.
b Health utility score derived from EQ-5D.
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FIGURE 37 Sensitivity with completely missing cases via imputation. ITT cost-effectiveness plane showing
incremental total NHS costs along y-space and incremental QALYs along x-space for 10,000 bootstrap replicates.
Origin is ORIF.
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FIGURE 38 Sensitivity with completely missing cases via imputation. ITT cost-effectiveness plane showing
incremental total societal costs along y-space and incremental QALYs along x-space for 10,000 bootstrap replicates.
Origin is ORIF.
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The full ITT population included 618 patients: 309 and 309 in the CCC and ORIF groups, respectively.
Using the best-fit models, compared with ORIF, CCC had a mean cost savings to the NHS and to society of
£707 and £674, respectively, and a mean QALY increase of 0.01 (see Table 73). Cost-effectiveness planes
displayed the majority of incremental costs as negative while incremental QALYs were largely positive, but
with a modest number of estimates that were negative (see Figures 37 and 38). Decision uncertainty was
very high over the range of willingness to pay for both the NHS (> 95%) and societal perspectives (> 95%)
(see Figures 39 and 40).
Multiple imputation with chained equations
Missing data were imputed using multiple imputation with chained equations, when appropriate, using R
version 3.1.2 and the package ‘MICE’. Potential predictors included baseline characteristics as well as all
resource use and health outcome items. Downstream variables were removed as predictors of upstream
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FIGURE 39 Sensitivity with completely missing cases via imputation. ITT cost-effectiveness acceptability curve
displaying the probability of cost-effectiveness (y-axis) as a function of the willingness-to-pay threshold (x-axis)
under the NHS perspective. The dotted line presents the asymptote where the willingness to pay is infinite.
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FIGURE 40 Sensitivity with completely missing cases via imputation. ITT cost-effectiveness acceptability curve
displaying the probability of cost-effectiveness (y-axis) as a function of the willingness-to-pay threshold (x-axis)
under the societal perspective. The dotted line presents the asymptote where the willingness to pay is infinite.
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variables. Multiple imputation was conducted using 40 iterations and five imputations. The imputations
showed healthy convergence and imputed values followed comparable distribution shapes to the observed
data as displayed below for the per-protocol and ITT populations (Figures 41–44).
Bootstrapped statistical models
Total costs and total QALYs were adjusted using statistical modelling and predicted using marginal
estimation. The entire process was bootstrapped 10,000 times to generate a distribution of adjusted,
marginally estimated cost and effect pairs for ORIF and CCC.
Relevant covariates for the statistical models included age, sex, baseline utility and other baseline covariates
identified by independent statistical association with the dependent variable at a p-level less than 25%.
Final statistical models used a GLM framework. The appropriate family and link function were identified
using the Modified Park’s Test and Pregibon Link Test, respectively (URL for the code: www.uphs.upenn.
edu/dgimhsr/stat-cstanal.htm).
For costs, the gamma family was found to show the most likely fit (least likely was Gaussian) to the variance
structure, while the link function was found to be the log-link. Instead of QALYs, the QALY decrement was
used in order to achieve convergence. For QALYs, the Gaussian was found to show the most likely fit (least
likely was inverse Gaussian), while the link function was found to be the identity link.
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FIGURE 41 Healthy convergence of the Gibbs sampler for the major health economic variables of per-protocol
utilities. (a) Mean utility at presentation; (b) SD of utility at presentation; (c) mean utility at 6 months; and
(d) standard utility at 6 months.
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FIGURE 42 Density plots for selected variables showing comparable distributions for the observed data and
imputed data sets. (a) Utility at presentation; (b) utility at 6 months; (c) home care days; (d) community hospital
days; (e) intermediate care days; (f) NHS nursing home days; (g) private nursing home days; and (h) sick days.
(continued )
DOI: 10.3310/hta20750 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 75
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Keene et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
D
en
si
ty Observed
Imputed
(c)
0.0
0.1
0.2
0.3
0.4
0 50 100
D
en
si
ty Observed
Imputed
(d)
0.00
0.10
0.20
0 4020 60
D
en
si
ty Observed
Imputed
(e)
0.0
0.1
0.2
0.3
0.4
0.5
0 20 40
D
en
si
ty Observed
Imputed
(f)
0.0
0.8
0.6
0.4
0.2
503010– 100
D
en
si
ty Observed
Imputed
(g)
0.0
0.8
0.6
0.4
0.2
0 20 40 60
D
en
si
ty Observed
Imputed
(h)
0.00
0.06
0.04
0.02
0 50 150
FIGURE 42 Density plots for selected variables showing comparable distributions for the observed data and
imputed data sets. (a) Utility at presentation; (b) utility at 6 months; (c) home care days; (d) community hospital
days; (e) intermediate care days; (f) NHS nursing home days; (g) private nursing home days; and (h) sick days.
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FIGURE 43 Healthy convergence of the Gibbs sampler for the major health economic variables of ITT utilities.
(a) Mean utility at presentation; (b) SD of utility at presentation; (c) mean utility at 6 months; and (d) standard
utility at 6 months.
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FIGURE 44 Density plots for selected variables showing comparable distributions for the observed data and
imputed data sets for the ITT population. (a) utility at presentation; (b) utility at 6 months; (c) home care days;
(d) community hospital days; (e) intermediate care days; (f) NHS nursing home days; (g) private nursing home days;
and (h) sick days.
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